The role of selective decontamination of the digestive tract as an antimicrobial prophylaxis strategy in paediatric intensive care by Petros, Andranick Joseph
THE ROLE OF SELECTIVE DECONTAMINATION OF THE DIGESTIVE
TRACT AS AN ANTIMICROBIAL PROPHYLAXIS STRATEGY IN 
PAEDIATRIC INTENSIVE CARE
Thesis submitted in accordance with the requirements of the 
University of Liverpool for the degree of Doctor of Medicine
by
Andranick Joseph Petros
December 2011
Table of Contents
Acknowledgements iii
Glossary iv
Summary 1
Chapter 1 Basics of antimicrobial prophylaxis of Selective 3
Decontamination of the Digestive Tract
Chapter 2 Evidence-based medicine in Intensive Care 26
Chapter 3 The application of the adult evidence for Selective 49
Digestive Decontamination (SDD) to the paediatric 
population.
Chapter 4 Meta-analysis of randomized controlled trials in 78
paediatric patients
Chapter 5 Mortality rates and admission diagnoses for children 98
admitted to paediatric intensive care: a 5 year dataset 
Chapter 6 PICANet mortality in Alder Hey vs. UK Paediatric Intensive 109
Care Unit
Chapter? Conclusions 117
List of Tables 119
List of Figures 123
Bibliography 124
APPENDIX 162
ii
ACKNOWLEDGMENTS
The author wishes to thank Dr H K F van Saene most sincerely for his loyalty and 
friendship for almost 20 years and for his invaluable supervision of this thesis. 
Without his support and inspiration this thesis would not have happened.
GLOSSARY
AH Alder Hey
AB Antibiotic
AGNB Aerobic Gram-negative bacilli
AML Acute myeloid leukaemia
APACHE Acute physiology and chronic health evaluation
BMT Bone marrow transplant
Cl Confidence Interval
Diag Diagnostic Samples
ESBL Extended Spectrum Beta-Lactamases
GCS Glasgow Coma Score
GOSH Great Ormond Street Hospital
ICP Intra-cranial pressure
ICU Intensive Care Unit
IPI Intrinsic Patogenicity Index
1L Interleukin
IQR Interquartile range
MRSA Methicillin-resistant Staphylococcus aureus
OR Odds Ratio
IV
PICANet
PICU
PIM
PPM
PTA
QDS
RCT
RR
SAP
SDD
SMR
SOD
Surv
TDS
TNF
VAP
VISA
VRE
Paediatric Intensive Care Audit Network 
Paediatric Intensive Care Unit 
Paediatric Index of Mortality 
Potential Pathogenic Micro-organisms 
Polymyxin/Tobramycin/Amphotericin 
Four times daily 
Randomised controlled trial 
Relative Risk
Single-drug antifungal prophylaxis 
Selective Decontamination of the Digestive Tract 
Standardised Mortality Rate 
Selective Decontamination of the Oropharynx 
Surveillance Samples 
Three times daily 
Tumour necrosis factor 
Ventilator associated pneumonia
Staphylococcus aureus with intermediate sensitivity to vancomycin 
Vancomycin-resistant enterococci
v
Summary
THE ROLE OF SELECTIVE DECONTAMINATION OF THE 
DIGESTIVE TRACT AS AN ANTIMICROBIAL PROPHYLAXIS 
STRATEGY IN PAEDIATRIC INTENSIVE CARE
A. J. Petros
The object of this thesis is to explore whether there may be any benefit in using 
selective decontamination of the digestive tract (SDD) in critically ill children who 
require treatment in an intensive care unit (ICU).
There is a significant body of work that confirms unequivocally that SDD reduces 
morbidity and mortality in adults. This comprises of 64 RCT and 11 meta analyses, 
which demonstrate significant reductions in morbidity and mortality without 
resistance emerging.
Chapter 1 describes and defines the components and application of SDD. Chapter 2 
puts SDD into context with other therapies used in ICU to reduce mortality. The 
evidence supporting SDD is categorised in terms of GRADE scoring and compares 
other interventions on the same scale. SDD is the only manoeuvre that has the 
highest recommendation. Chapter 3 describes the 11 meta analyses of the 64 RCTs 
in detail. Chapter 4 describes a meta analysis of the four paediatric RCTs available 
in the literature. The results demonstrate that mortality is not affected by SDD. 
However, there is a reduction in pneumonia rates in children even with the small 
numbers available to analyse.
Chapter 5 looks at the national database for children admitted to PICUs for the 5 
year period 2004-2008 and describes demographics for the group and looks in detail 
at the causes of admission at Alder Hey (AH) children’s hospital and Great Ormond 
Street Hospital and nationally. AH was reviewed as this centre practiced SDD during 
the entire period and for a number of years prior to 2004. Great Ormond Street
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Hospital is the largest PICU in the country and both are compared to the national 
database. Finally, Chapter 6 compares the mortality rates between the three groups 
and looks in more depth at the severity of illness of the various groups to see if SDD 
has any effect on different subsets of patients.
From the data available no real differences were found between the hospitals. It is 
perhaps not surprising that there is no significant difference between the groups as a 
result of one unit using SDD. It is difficult to imagine that one manoeuvre can impact 
on such a heterogeneous yet small group. To provide randomized controlled trial 
(RCT) evidence that SDD is superior sample size is very important in these 
circumstances. A sample size of 30,000 children would be needed. This would 
require 100% recruitment for two years from every PICU in the UK. Hence, 
surrogate measures and inferences have to be relied upon.
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Chapter 1
BASICS OF ANTIMICROBIAL PROPHYLAXIS OF SELECTIVE 
DECONTAMINATION OF THE DIGESTIVE TRACT
In 1975 Frantz et al reported the clinical course of 54 neonates with necrotizing 
enterocolitis (NEC) compared to a matched group of 98 control patients. On the day 
of life that NEC occurred, all 54 NEC patients and 63% of controls were receiving 
standard formula feedings, both at 80cal/kg/day. Stool cultures at the time revealed a 
significantly increased growth of Klebsiella species in NEC neonates compared to 
control patients. The authors suggested that the combined presence of certain 
intestinal bacteria and enteric feedings, perhaps requiring a background of mucosal 
ischemia, may be of aetiologic significance in the development of NEC and its 
radiologic hallmark, pneumatosis intestinalis.
The concept of intestinal translocation of enteric bacteria and its association with 
Gram-negative sepsis was established in animal models in 1979 by Berg. The term 
translocation was originally used by Berg and Owens to refer to the passage of 
viable bacteria from the gut through the epithelium to the lamina propria and thence 
to mesenteric lymph nodes and possibly other organs (Berg RD) and subsequently 
modified by Alexander to refer to the movement of viable and nonviable microbes or 
their toxic products across an intact intestinal barrier (Alexander JW).
One fundamental premise of SDD is that gut bacterial overgrowth is harmful to the 
critically ill patient (Figure 1.1).
1. Overgrowth in the oropharynx causes lower airway infections as potential 
pathogens spill over into the lungs and in the gut bacteria migrate and translocate 
across the permeable gut wall.
2. Overgrowth also induces immunosuppression.
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Figure 1.1
Diagram depicting the normal and abnormal carrier state within the lumen of the gut 
and the mechanisms by which normal flora compete with gut pathogens. In illness, 
bacterial overgrowth occurs and bacteria translocate through the mucosal 
membranes.
Protection Disease
The intestinal normal flora can enhance host defense by occupying the gut in large 
numbers and diversity, thereby 1) preventing colonisation of the host by pathogens 
by more successfully competing for essential nutrients or for epithelial attachment 
sites; 2) producing antimicrobial compounds, volatile fatty acids, and modified bile 
acids that in turn create a luminal microenvironment unfavorable for the growth of 
pathogens; and 3) inducing recruitment of immune cells and activation of appropriate 
immune and inflammatory responses. Bacterial overgrowth overcomes these micro­
environmental and immunologic responses and disrupts the integrity of the epithelial 
defense by normal flora. Adapted from Davis CP (Lei L).
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3. Aerobic Gram-negative bacilli (AGNB) carried in the gut translocate from the 
lumen of the gut into the Peyers patches where their endotoxin component 
stimulates macrophages to produce cytokines such as tumour necrosis factor 
(TNF). Cytokinaemia results in a down regulation of macrophage activity in the 
gut, liver, abdomen and lungs (Deitch EA) and is almost certainly responsible for 
the inflammation of organs resulting in multiple organ failure (Waydhas C).
4, Finally, gut overgrowth guarantees increased spontaneous mutation, polyclonality 
and subsequent antimicrobial resistance (van Saene HKF (2008 CDT)).
These four harmful consequences of gut overgrowth can be reduced by SDD (de la 
Cal MA 2005; van Saene JJM; Horton JW; Conraads VM) as it controls overgrowth 
and thereby reduces the faecal endotoxin pool (van Saene JJM).
The Philosophy of SDD: Control of Overgrowth
The major hazard for any intensive care patient is the development of infection. 
Prevention of such a complication is the absolute essential of intensive care. 
Selective decontamination of the digestive tract is a strategy aimed at preventing 
infection using prophylactic parenteral and enteral antimicrobials. It is a prophylactic 
antimicrobial regimen specifically designed to prevent severe endogenous and 
exogenous infections of lower airways and blood in the critically ill patients requiring 
treatment on the intensive care unit and produces a significant reduction in mortality 
in this vulnerable group (Silvestri L (2009)). It is based upon two fundamental 
principles (van Saene HKF (1996 JHI)):
Firstly, that pathogenesis of infection is due to a limited range of potential pathogens. 
There are six normal potential pathogens: Streptococcus pneumoniae, Haemophilus 
influenzae, Moraxella catarrhalis, Staphylococcus aureus, Escherichia coli and 
Candida albicans. Abnormal flora consists of nine abnormal potential pathogens, 
eight aerobic Gram-negative bacilli and methicillin-resistant Staphylococcus aureus 
(MRSA). The eight AGNB are Klebsiella, Proteus, Morganella, Citrobacter, 
Enterobacter, Serratia, Acinetobacter and Pseudomonas species. (Figure 1.2)
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Secondly, the three types of pathogenic pathways each require a different 
intervention. The SDD concept defines three different types of infection (Table 1.1).
Table 1.1
Philosophy of SDD - Carriage classification of infections. PPM - potential pathogenic 
micro-organisms,
Infection PPM Timing Frequency Manoeuvre
Primary
endogenous
6 ‘normal’
9’ abnormal’
<1 week 55% Parenteral
antimicrobials
Secondary
endogenous
9 ‘abnormal’ >1 week 30% Hygiene and enteral
antimicrobials
Exogenous 9 ‘abnormal’ Anytime during
ICU treatment
15% Hygiene and topical
antimicrobials
1) Primary endogenous - which generally develops within a week and is the most 
frequent type of infection responsible for approximately 55% of infections. This 
type of infection is caused by potential pathogens, which are present in the 
admission (oropharynx or gut) flora and may be either normal or abnormal flora.
2) Secondary endogenous infection - which is invariably caused by abnormal 
bacteria not present in the admission flora but acquired during treatment on the 
ICU. This type of infection generally occurs after one week and represents 30% 
of infections.
3) Exogenous infection is caused by abnormal potential pathogens never carried in 
the digestive tract but introduced directly in the patient from an external source. 
Exogenous infection may occur at any time, during ICU treatment, and accounts 
for 15% of infections (Silvestri L (2009)).
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Figure 1.2
Pathogenesis of infection is due to a limited range of potential pathogens. The figure 
describes the potential routes of entry of these pathogens.
Wound
Line
Skin
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Prevention of the primary endogenous route requires an initial course of parenteral 
antimicrobials which will eradicate carriage of normal flora and should the patient 
already be infected, also treat that infection. Cefotaxime was originally chosen for 
two reasons: its spectrum of activity against normal flora and the majority of the 
AGNB (Stoutenbeek CP (1987)), secondly, it is highly effective in eradicating 
oropharyngeal and gut carriage of normal flora due to high salivary and biliary 
concentrations (Stoutenbeek CP (1989)). Yeast carriage cannot be eradicated using 
parenteral antifungals, only enteral polyenes, including amphotericin B and nystatin, 
have been shown to achieve this (van Saene HKF ICM 2003).
To prevent secondary endogenous infection enteral antimicrobials polymyxin and 
tobramycin are administered to prevent the acquisition of abnormal flora in the 
carrier state and eradicate it should the patient be carrying abnormal flora. 
Secondary endogenous infection may occur if enteral antimicrobials are 
administered too late and should be treated via the parenteral route.
The combination of enteral polymyxin (Hoeprich PD) and tobramycin (Neu HC) was 
chosen because it covers all abnormal AGNB, including Pseudomonas species. 
Additionally, there is a synergistic combination between the two (Kuipers JS). Only in 
the case of MRSA endemicity is enteral vancomycin added to polymyxin/tobramycin 
to eradicate and clear the MRSA carrier state (Silvestri L (2002)).
Standard hygiene measures and scrupulous attention to sterile technique are crucial 
in preventing the introduction of potential pathogens from external sources directly 
into sterile organs, bypassing the carrier state. Identical antimicrobials polymyxin, 
tobramycin and vancomycin are indicated for topical use, e.g. in a paste on a 
tracheostomy site to control exogenous lower airway infections. These three 
interventions were first combined by Stoutenbeek in 1984 (Stoutenbeek CP (1984)). 
Stoutenbeek developed the prophylactic strategy further to include surveillance 
cultures thus creating the full four component SDD prophylaxis (Figure 1.2).
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Mechanisms of action in controlling overgrowth
The acceptance of the classification of the carrier state is crucial in explaining the 
efficacy of SDD in order to select the correct antimicrobials (Silvestri L (2009) Chest). 
Carriage may be either high grade (defined as >105 potential pathogens per ml or 
gram of digestive tract secretions) or low grade (defined as <105 potential pathogens 
per mL or gram of digestive tract secretions) (van Saene HKF (1996 JHI)). The 
continuing success of SDD is based on the chosen antimicrobials ability to clear 
carriage, in particular high grade carriage also known as gut overgrowth(Husebye H).
In order for the target micro-organisms to be completely eradicated, the 
concentrations of the selected antimicrobials in saliva, bile and faeces must be 
effective (Novick WJ Jr; Maier H; Gotoff SR; Bodey GP; Tedesco F; Geraci JE; Currie 
BP; Hofstra W; Hofstra W 1982). These concentrations are shown in Table 1.2 and 
are deemed to be of greater importance than sparing the colonisation resistance flora 
(van der Waaij D).
Table 1.2
Effective concentrations against prevailing micro-organisms achieved in saliva, bile 
and faeces with antimicrobials used in SDD regimen given enterally. These 
concentrations are more important than sparing of the colonisation resistance flora 
(van der Waaij D; Vollaard EJ).
Antimicrobials selected for SDD
Concentrations (mg/L) in
Saliva Bile Faeces
Cefotaxime 6 20
Polymyxin E 16-1,000
Tobramycin 100
Amphotericin B 60
or Nystatin <100
Vancomycin 3,000-24,000
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Practical guidelines on how to use SDD
All patients who require treatment on the 1CU for minimally two days require the 
immediate administration of parenteral cefotaxime in high doses for four days, to 
control mortality due to ‘early’ primary endogenous infections caused by the ‘normal’ 
potential pathogens such as S.pneumoniae and S.aureus (Table 1.3). Additionally, 
high doses of parenteral cefotaxime eradicate oropharyngeal and gut carriage of 
normal potential pathogens such as S.aureus and E.coli. The enteral antimicrobials 
are given throughout the treatment on ICU to control mortality associated with ‘late’ 
secondary endogenous infections. A paste or gel is applied into the lower cheeks to 
prevent and, if already present, eradicate oral carriage of ‘abnormal’ PPM, i.e. to 
decontaminate the oropharynx. A suspension is administered via the nasogastric 
tube to decontaminate stomach and gut. Polymyxin and tobramycin with or without 
vancomycin are used to control ‘abnormal’ carriage of AGNB, in particular 
Pseudomonas aeruginosa. In case of MRSA endemicity, enteral vancomycin is 
added to polymyxin/tobramycin. Tobramycin is replaced by paromomycin in case of 
endemicity of AGNB producing extended spectrum beta-lactamase (ESBL) resistant 
to tobramycin. In case of Serratla endemicity, both polymyxin and tobramycin are 
replaced by paromomycin. Enteral amphotericin B or nystatin is used to control yeast 
overgrowth. The third component is topical antimicrobials to control exogenous 
infections. Finally, regular surveillance samples of throat and rectum are obtained to 
monitor efficacy and safety of SDD.
Efficacy of the SDD regimen
There are now 64 RCTs (Abdel-Razek SM; Abele-Horn M; Aerdts SJ; Arnow PM; 
Barret JP; Bergmans DC; Bion JF; Blair P; Boland JP; Bouter H; Brun-Buisson C ; 
Camus C; Cerra FB; Cockerill FR 3rd; de Jonge E; de la Cal MA (2005); de Smet 
AM; Diephenhrst GM; Farran L ; Ferrer M; Finch RG; Flaherty J; Gastinne H; 
Gaussorgues PH ; Georges B ; Gosney M; Hammond JM; Hellinger WC; Jacobs S; 
Kerver AJ; Korinek AM; Krueger WA; Laggner AN; Lingnau W; Luiten EJ; Martinez- 
Peilus AE; Martinez-Pellus AE (1997); Oudhuis GJ; Palomar M; Pneumatikos l; Pugin 
J; Quinio B; Rayes N; Rios F; Rocha LA; Rodrlguez-Roldan JM; Rolando N; Rolando 
N (1996); Ruza F; Sanchez Garcia M; Schardey HM; Smith SD; Stoutenbeek CP 
(1996); Stoutenbeek CP (2007); Tetteroo GW; Ulrich C; Unertl K; Verwaest C; 
Wiener J; Winter R; Yilmazlar A; Yu J; Zobel G; Zwaveling JH) using SDD.
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There are eleven meta-analyses examining only RCTs assessing the efficacy of SDD 
(Vandenbroucke-Grauls CMJ; D’Amico R; Safdar N; Liberati A; Silvestri L (2005 
ICM)\ Silvestri L (2007 JH/); Silvestri L (2008 AIC); Silvestri L ( 2009 JCC); Liberati A 
(2009 Cochrane)] Silvestri L (2010); Silvestri L (2010 Resp Med)) (Table 1.4). Five 
meta-analyses have the endpoint of lower airway infection (Vandenbroucke-Grauls 
CMJ; D’Amico R; Liberati A; Silvestri L (2008); Liberati A (2009)) and all show a 
significant reduction of lower airway infections due to both Gram-negative and Gram­
positive bacteria (OR 0.28, 90%CI 0.22-0.38).
The most recent meta-analysis also demonstrates that SDD using parenteral and 
enteral antimicrobials reduces multiple organ failure dysfunction syndrome (MODS) 
(Silvestri L (2010)). In that study the sample size of 1270 patients was too small to 
show a survival benefit.
Mortality was the endpoint in eight meta-analyses (Vandenbroucke-Grauls CMJ; 
D’Amico R; Safdar N; Liberati A; Silvestri L (2007 JCI); Silvestri L (JCC); Liberati A 
(2009 Cochrane); Silvestri L (2010)), five had sample sizes between 4,902 and 8,065 
where a survival benefit is consistently shown (D’Amico R; Liberati A (2004); Silvestri 
L (2007 JCI); Silvestri L (2009 JCC); Silvestri L (2010 CCM)). Mortality reduction was 
not significant in the remaining three meta analyses due to the small sample size 
(259, 491 and 1270 patients). Survival benefit is almost certainly due to the control of 
severe infections of both lower airways and blood. Bloodstream infections due to 
AGNB were significantly reduced (OR 0.36; Cl 95% 0.22 -.0.60) (Silvestri L (2007 
JHI)), fungaemia was also reduced (OR 0.89; Cl 95% 0.16-4.95) but this did not 
achieve significance (Silvestri L (2005 ICM)). Although Gram-positive blood stream 
infections increased, this was not significant (OR 1.03; Cl 95% 0.75-1.41) (Silvestri 
L (2008 AIC)). Figure 1.3 demonstrates the incidence of publications of RCTs and 
meta-analyses over the last 24 years. There was a flurry of RCTs in the 1990s and 
then the number of meta-analyses increased being able to draw upon data from the 
RCTs.
11
Ta
bl
e 1
.3
 Full fou
r c
om
po
ne
nt
-s
tra
te
gy
 o
f S
D
D
.
I o
o o o o
O CM O O
00 lO CM CO
Q) 0)
O) O)
O O
Q. CL
ro c
CM CM
O OO O O
C o CL O
O D)
XI ^o o o o o'' 0)
t— 00 CM LO CM CM CD
>- CD
Q . . •
Ta
bl
e 1
.4
 The 11 me
ta
-a
na
ly
se
s 
of
 th
e 
64
 R
C
Ts
 lo
ok
 a
t t
he
 e
ffi
ca
cy
 o
f S
D
D
.
M
or
ta
lit
y
O
R
 (9
5%
C
I)
0.
92
,
0.
45
 to
 1.
84
0.
80
,
0.
69
 to
 0
.9
3
0.
82
,
0.
22
 to
 2
.4
5
0.
78
0.
68
 to
 0
.9
6
N
R
0.
74
,
0.
61
 to
 0.
91
N
R
N
R
0.
71
,
0.
61
 to
 0
.8
2
0.
75
,
0.
65
 to
 0
.8
7
0.
82
0.
51
 to
 1.
32
N
R
co
t3cD
</)/!% --- M"l^-
Q £ >p O o' O °c c: in in o03 "O CDD) C ° M">« (VOcog
<u
co
d
Q.
«4-»
13
E - io D- O T“03 C o CD 00 CO M-
S? o ^ - M" - d , - d - ■»-
to o ^ 
T3 03 N
R
N
R
N
R
N
R CDCO o COco £ CO _ COCO O O O N
R
N
R
N
R
N
R
O ‘t: d co d co d CM 't_ IDo .£ cr M" CM h-
m O d d d d
>% ^ CD CO 00 00 CD| c o T_; ■M- T- h- CO CO
.t- o ^5 - o , d in O ^ - d r d - d d
^ o 10 /•> ro O cr CO o a: CMo O Co O Dd 00fM o Cd LO O
i— (T> 03 • -♦—* z z z z z • 'Q) Or ^ ° 00 d CD ° CD O O o o ° CM$ .e q: o CM CM O CO CM M"
^ o d d d d d d d
0)
Ql <D h- O) CM ID ID co CM M" o CMC N CM CM CO r- O ■X— h- inc •— h- CD o o M" CD CD CM CMCO W
CO
ID CO CD 00 CD M" CO CM
(/)
° h; CO CO CM X— M" T— CO CMz o CO CO M- in uo CM COa:
10)
i.o o
x: 3
o3 &_
< oc o k- k_ L. k-(D JD 03 03 to w 00 00 n. to 03 to toT3 3 E ~o 0) CD CD CD CD ^ CD (D <DE ro03 »- < l*—03 -Q > 03 “ tn _> ^ > ? _> -Q _> _>
> O b CO CO 5k CO co O 0 co _i (O CO
Figure 1.3
Incidence of publications of randomized controlled trials and meta-analyses on SDD.
64 randomized controlled trials (RCT) on SDD over 24 years (1987-2011)
i.illlllilli iiL EjxO
11 Meta-analyses of SDD over 21 years (1991-2011)
10
9
8
7
6
5
4
3
2
1
0 I“i i i i i i i i i r E xxH
14
Safety profile of the SDD regimen
Concerns about resistance are legitimate for any antimicrobial prophylaxis (Kaiser 
AB; Petros A) and the safety of SDD relies on resistance not emerging against the 
SDD antimicrobials (Baxby D). A recent meta-analysis of the 64 SDD RCTs does not 
show any increase in resistance to the SDD antimicrobials but a significant reduction 
in resistance.
The main resistance problems in ICU come under four categories
1. AGNB: in particular Klebsiella species, can produce extend ESBL. Acinetobacter 
and Pseudomonas species are often multi-resistant to different classes of 
antimicrobials, principally due to reduced permeability of these two bacteria 
(Jarlier V).
2. MRSA: which differs from country to country and can be endemic in the ICU and 
eradication poses serious problems for the intensivist (Bronzwaer SL).
3. Azole-resistant Candida species: is an increasing problem on the ICU since the 
introduction of fluconazole (Lyon GM).
4. Vancomycin-resistant enterococci (VRE): is a greater problem in North America 
than in Europe (Zhanel GG).
The SDD regimen and resistant organisms
Resistant Aerobic Gram Negative Bacilli
There are 3 RCTs with the endpoint of antimicrobial resistance amongst AGNB 
(Brun-Buisson C; de Jonge E; de Smet AM). In a Parisian hospital there was 
endemicity of an ESBL producing Klebsiella. The carriage and infection rates in the 
control group were 19.6% and 9%, respectively; enteral antimicrobials were added 
and the rates were reduced to 1% and 0% (Brun-Buisson C). A Dutch study 
demonstrated that carriage of AGNB resistant to imipenem, ceftazidime, 
ciprofloxacin, tobramycin and polymyxins occurred in 16% of SDD patients 
compared to 26% of control patients with a relative risk (RR) of 0.6 (95% Cl 0.5 - 
0.8) (de Jonge E). The most extensive RCT (6,000 patients) was also undertaken in 
The Netherlands. This study demonstrated that the percentage of patients carrying 
AGNB resistant to ceftazidime was significantly less in those receiving enteral 
polymyxin/tobramycin compared to standard care (de Smet AM) (Table 1.5).
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Table 1.5
ICU Patients carrying aerobic Gram-negative bacilli (AGNB) resistant to ceftazidime 
receiving selective decontamination of the digestive tract (SDD) versus standard 
care (de Smet AM ). Figures are percentages of patients
AGNB SDD Standard Care
E.coli 1.3 3.3 p<0.05
K.pneumoniae 0.4 2.2 p<0.05
E.cloacae 1.7 4.7 p<0.05
P.aeruginosa 0.7 2.6 p<0.05
The Gut Concept
The gut concept may explain the findings of these three RCTs in that there is 
significantly less resistance when enteral antimicrobials are added. Parenteral 
antimicrobials alone do not reach lethal concentrations within the gut when excreted 
via bile, resulting in faecal overgrowth of AGNB which in turn promotes resistant 
mutant strains. The addition of enteral antimicrobials clears overgrowth (high grade 
carriage) including resistant mutants.
Approximately 30% of patients either import, acquire or develop de novo 
antimicrobial resistance (Viviani M; Garrouste-Orgeas M). The common denominator 
for these three mechanisms is the gut. ICU patients are susceptible to gut 
overgrowth due to impaired gut motility and they have a high risk for de novo 
development (van Saene HKF (2008 CD7)). The polymyxin/tobramycin combination 
creates a unique environment. This mixture is synergistic and results in very high 
bactericidal levels in both saliva and faeces which maintains colonisation resistance 
(Mulder JG; van Saene HKF(1998)). These three features of SDD when combined 
eradicate overgrowth and profoundly influence the balance of forces associated with 
resistance (Silvestri L(2001)).
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Practically all ESBL-producing AGNB are sensitive to the enteral combination of 
polymyxin/tobramycin (Taylor ME). Although rare, some ESBL-producing AGNB 
such as Klebsiella species may be resistant to tobramycin (Al Naiemi N). Under 
these circumstances, the eradication of this type of abnormal carriage has been 
unsuccessful using polymyxin/tobramycin. The reason for this being that a 
combination of two enteral agents active against the abnormal ESBL-producing 
AGNB is required for successful SDD (Brun-Buisson C (1991)). Tobramycin needs 
to be replaced by an active aminoglycoside, e.g. neomycin (Brun-Buisson C (1989)) 
or paromomycin (Abecasis F, Bodey GP). Parenteral antimicrobials that disregard 
the patient’s gut ecology may promote acquisition, carriage and subsequent 
overgrowth of ESBL-producing AGNB (Hoyen CK; Pultz NJ; Martins IS). Therefore 
blind administration of SDD is not advocated and surveillance of faecal flora is 
required with modification of the enteral component of SDD as necessary.
There are four long-term studies (>2 years) evaluating the impact of 
polymyxin/tobramcyin on resistance amongst AGNB (Stoutenbeek CP (1987 JAC); 
Leone M; Sarginson RE; Heininger A) (Table 1.6). The resistance data of the long 
term studies confirm the RCT findings that rates of carriage and infection due to 
resistant AGNB in patients receiving parenteral and enteral antimicrobials are not 
increased but are actually lower compared with patients receiving solely parenteral 
antimicrobials.
Resistant MRSA
SDD was not originally designed to cover MRSA, as it was not a significant problem 
in the early 1980’s. During 7 of the 64 SDD RCTs MRSA was endemic in study 
units, resulting in a trend towards higher infection rates in those 7 RCTs (de la Cal 
MA 2004; Ferrer M; Gastinne H; Hammond JM; Lingnau W; Verwaest C; Wiener J). 
In order to combat endemic MRSA enteral vancomycin needs to be added to SDD 
(Silvestri L (2002)).
Three studies using long term SDD with enteral vancomycin (>2 years) did not report 
any emergence of Staphylococcus aureus with intermediate sensitivity to 
vancomycin (VISA) or vancomycin-resistant enterococci (VRE) (de la Cal MA (2004
17
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JHiy, Cerda E; Viviani M) (Table 1.7). Similarly, MRSA overgrowth is invariably 
present in the critically ill when MRSA is endemic and guarantees the presence of 
VISA strains following the parenteral use of vancomycin (Guerin F). The addition of 
enteral vancomycin produces faecal vancomycin levels of up to 3,000mg/L 
preventing or eradicating, if already present, the VISA mutants. A similar scenario 
applies to carriage and overgrowth of abnormal VRE and the intravenous 
administration of antimicrobials such as linezolid, resulting in the emergence of 
linezolid-resistant VRE mutants (Verma N). As far as we are aware, there are no 
studies that assessed the efficacy of enteral vancomycin in preventing and 
eradicating carriage and overgrowth of VRE (Stiefel U; Salgado CD).
Azole-resistant Candida species
The use of azoles, in particular, fluconazole, has been reported to increase Candida 
krusei, Candida glabrata and Candida albicans resistance (Lyon GM). Surveillance 
cultures of throat and rectum are essential in detecting carriers of Candida species 
resistant to fluconazole. Knowledge of carriage of resistant strains allows the enteral 
administration of polyenes such as amphotericin B or nystatin to eradicate the 
carrier state, preserving the value of fluconazole as a useful antifungal agent (van 
Saene HKF (1999 JHI)).
Vancomycin-resistant enterococci
VRE was endemic in the units where 2 of the 64 RCTs were performed (Arnow PM; 
Flellinger WC). Carriage and infection rates of VRE were similar in both test and 
control groups. Six RCTs added enteral vancomycin to the classical SDD regimen 
and screened for VRE (Bergmans DC; Gaussorgues PH; Korinek AM; Krueger WA; 
Pugin J; Schardey HM). VRE was not isolated from any samples either diagnostic or 
surveillance. Enteral vancomycin in high doses does not promote VRE rather, 
parenteral antimicrobials which disregard gut ecology are responsible for the 
promotion of VRE (Stiefel U; Salgado CD).
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Table 1.7
Long term studies of enteral vancomycin on staphylococcal and enterococcal 
resistance.
Author Study Patients % patients with carriage (surv)
and/or infection (diagn) due to
VISA and/or VREType Period Type Number
de la Cal Prospective
observational
4 years Med/Surg
>3 days of MV
799 13/799 (5%) carried VRE
Cerda Prospective
observational
4 years Burns 375 No emergence of VRE or VISA
in either surv or diag
Viviani Prospective
observational
2 years MV >3days 265 No emergence of VRE or VISA
in either surv or diag
Surv = Surveillance samples;
Diag = diagnostic samples;
VISA = vancomycin-intermediate Staphylococcus aureus\ 
VRE = vancomycin-resistant enterococci 
MV = mechanical ventilation
SDD was introduced into AH paediatric intensive care unit in 1999 (Sarginson RE) and 
a database developed to record the relevant data on both carriage and infection (van 
Saene HKF (2005 2nd ed)). The density of patients carrying and infected with resistant 
bacteria did not increase over the 5 years use of SDD (Figures 1.4 and 1.5). Density of 
patients was defined as the number of patients carrying or infected with resistant 
bacteria per month of 100 days, i.e. number of patients per month divided by number 
of patient days per month multiplied by 100.
The over-riding message from RCTs, meta-analyses and long-term studies is that 
the addition of enteral to parenteral antimicrobials does not promotes resistance but 
contributes to its control (van Saene HKF (2003 ICM)).
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Benchmarking SDD against other manoeuvres which reduce mortality on ICU
It is only now after 60 years of intensive care medicine that ICU manoeuvres are 
being properly assessed against the rigorous endpoint of reduction in mortality. This 
is perhaps not surprising, as the methods of grading success have only recently 
been described and evidence based medicine driven clinical practice established.
In recent years, there are five manoeuvres that have been shown to reduce mortality 
in RCTs: ventilation with low tidal volumes for acute lung injury and respiratory 
distress syndrome (ARDS Network 2000); recombinant human activated protein C 
for severe sepsis (Bernard GR); intensive insulin therapy (Van den Berghe G); low 
doses of steroids in patients with septic shock (Annane D) and SDD (de Jonge E, de 
Smet AM, Krueger WA) (Table 1.8). Table 1.8 reports the levels of evidence 
obtained using the Grade system (Atkins D; Dellinger R), which classifies the quality 
of evidence as high grade (Grade A), moderate (Grade B), low (Grade C) or very 
low (Grade D) (see Chapter 2). RCTs begin as high quality evidence but may be 
downgraded due to limitations in implementation, inconsistency or imprecision of the 
results, indirectness of the evidence, and possible reporting bias. An example of this 
is high glucose control (A down to C): the success of the original Belgian RCT (van 
den Berge G) in reducing mortality has not to date been reproduced (NICE-SUGAR, 
Beardsall K). Additionally, a recent tight glucose control meta-analysis produced 
negative and contradictory results (Wiener RS).
The Grade system also classifies recommendations as strong (Grade 1) or weak 
(Grade 2). The grade of strong or weak is considered of greater clinical importance 
than a difference in letter level of quality of evidence. A strong recommendation in 
favour of an intervention reflects that the desirable effects of adherence to a 
recommendation (beneficial health outcomes, less burden on staff and patients and 
cost savings) will clearly outweigh the undesirable effects (harms, more burdens, 
greater costs).
SDD is the only evidence based manoeuvre with a Grade 1A recommendation.
All RCTs of SDD, whether mono (de Jonge E) or multicentre (de Smet AM; Krueger 
WA), that assessed the full four component SDD protocol consistently demonstrated 
a significant survival benefit, provided the sample size was large enough. Similarly,
21
all meta-analyses that assessed the full SDD protocol with a large enough sample 
size showed a consistent survival benefit (D’Amico R; Liberati A; Silvestri L (2007 
JHI)] Silvestri L (2009 (JCC); Liberati A (Cochrane)). The mortality data show an 
intriguing observation that trial design determines the magnitude of the survival 
benefit (Silvestri L (2009 (JCC)). The relative reduction in the odds ratio for mortality 
was 41% when all patients receive the full SDD protocol (de Jonge E), 29% when 
half the patients receive the antimicrobial prophylaxis (Silvestri L (2009 (JCC)) and 
17% when one third of the population are treated with SDD (de Smet AM; Oostdijk 
EA). In the trial of the unit-wide application of SDD (de Jonge E), the SDD protocol 
virtually eliminated transmission of potential pathogens via the hands of care-givers 
and hence exogenous infection in decontaminated patients. Mixing decontaminated 
and non-decontaminated patients in the same unit dilutes the survival benefit. This 
is the case in the RCT design, wherein the patients receiving and not receiving SDD 
are treated within the same unit (de Jonge E). Patients who are decontaminated 
protect control patients from transmission, acquisition, carriage and subsequent 
infection, whereas the patients not receiving SDD remain at risk of acquiring 
potential pathogens and subsequent exogenous infections, resulting in a reduction 
in the true effect of SDD. The most recent multicentre RCT in 6,000 patients with a 
17% relative reduction - albeit statistically significant - clearly underlines the issue 
of diluting the SDD effect by increasing the number of non-decontaminated patients 
treated in the same unit with patients receiving SDD (de Smet AM; Oostdijk EA).
Costs implication for using SDD
Although the cost effectiveness of SDD has not yet been formally calculated the 
daily costs of 6-12 Euros (de Smet AM; Quinio B; Collard HR) can hardly be an 
issue for an ICU intervention that reduces pneumonia, septicaemia and mortality by 
72%, 37% and 29% respectively (Table 1.4).
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Chapter 2
EVIDENCE-BASED MEDICINE IN INTENSIVE CARE
Introduction
In intensive care there have been many clinical trials evaluating numerous new 
therapies and much data generated. How is all this data to be evaluated and which 
specific treatment options should be chosen? This is where evidenced based 
medicine comes to the fore. It involves integrating clinical expertise, best research 
evidence and patient values. Clinical expertise involves the ability to use clinical 
skills and past experience to identify risks and benefits of potential interventions. 
Best research evidence includes relevant clinical research into accuracy and 
specificity of diagnostic tests and the power of the prediction of these tests, either 
science based or patient-centred.
Evidence based medicine (EMB) was extolled by David Seckett who described two 
processes, one for assessing the quality of a therapy on a scale of l to IV and a 
second for making recommendations for usage of that therapy on a scale of A-D. 
However, more recently a newer method of grading the quality of evidence and 
strength of recommendation for a new therapy has been developed. The Grading of 
Recommendations Assessment, Development and Evaluation (GRADE) is being 
increasingly used as the structure on which to develop guidelines (Jaeschke R). The 
GRADE Working Group reported its suggestions in 2004 with further refinement in 
2008 (Atkins D; Schunemann HJ). The use of a structured approach to collect, 
analyse and summarise all the relevant evidence allows the production of grades of 
recommendations.
The GRADE system is used widely by the World Health Organization, the American 
College of Physicians, the American Thoracic Society, the Cochrane Collaboration 
and many other organizations, up to 25 different groups demonstrating GRADE’S 
success as a methodology (Guyatt GH).
GRADE guides the assessment of the quality of evidence for a particular treatment
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or therapy. The study design, study quality, consistency, and directness are all 
assessed. The GRADE system classifies the quality of evidence in one of four 
levels—high (A), moderate (B), low (C) and very low (D). The factors influencing the 
decision on quality are described in Table 2.1. Evidence from randomized controlled 
trials (RCTs) contributes to high quality evidence, but confidence in the evidence 
may be decreased for several reasons; study limitations; inconsistency of results; 
indirectness of evidence; imprecision and reporting bias (Table 2.1).
Observational studies such as cohort and case-control studies start with a “low 
quality” rating. However, grading upwards may be possible if for example the size of 
the treatment effect is very large, if there is a strong causal relationship.
GRADE also makes recommendations from strong (1) to weak (2). The former is 
where the intervention clearly outweighs its undesirable effects and the latter where 
the trade-off between desirable and undesirable effects is less clear. As to making 
recommendations for a specific therapy this involves a balance between benefits and 
harms. Making a recommendation inevitably involves placing a relative value on 
each outcome though it is difficult to judge how much weight to give to different 
outcomes (Atkins D).
In making a recommendation four main factors should be considered (Table 2.2).
• The trade-offs -this should consider the estimated size of the effect for the 
main outcomes, the confidence limits around those estimates, and the relative 
values placed on each outcome,
• The quality of the evidence
• Translation of the evidence into specific practice, allowing for factors that 
could qualify the expected effect, such as proximity to a hospital or availability 
of necessary expertise
• Uncertainty about the baseline risk for the population of interest.
The strong or weak grading is felt to be of greater clinical important than classifying 
the quality of the intervention. Using GRADE provides a framework for structured 
assessment and can help to ensure that appropriate judgments are made about a 
new therapy or manoeuver.
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Table 2.1
Descriptions of Levels and Quality used in the GRADE system.
Quality Level Description
High quality A Further research is very unlikely to change our confidence in
the estimate of effect. Randomised control trials.
Moderate quality
B Further research is likely to have an important impact on our
confidence in the estimate of effect and may change the
estimate.
Low quality
C Further research is very likely to have an important impact on
our confidence in the estimate of effect and is likely to
change the estimate. Observational studies.
Very low quality D Any estimate of effect is very uncertain. Any other evidence.
Confidence in the quality of evidence used in GRADE
Decreases if:
Serious (-1) or very serious (- 2) limitation to study quality
Important inconsistency (-1)
Some (-1) or major (- 2) uncertainty about directness
Imprecise or sparse data (-1)
High probability of reporting bias (-1)
Increases grade if:
Strong evidence of association—significant relative risk of > 2 (< 0.5) based
on consistent evidence from two or more observational studies, with no
plausible confounders (+1)
Very strong evidence of association—significant relative risk of > 5 (< 0.2)
based on direct evidence with no major threats to validity (+2)
Evidence of a dose response gradient (+1)
All plausible confounders would have reduced the effect (+1)
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Table 2.2
Factors influencing recommendations by GRADE.
Net benefits the intervention clearly does more good than harm.
Trade-offs there are important trade-offs between the benefits and harms.
Uncertain trade-offs it is not clear whether the intervention does more good than harm.
No net benefits the intervention clearly does not do more good than harm.
The ICU literature was searched using these GRADE rules for manoeuvres that may 
impact on infectious morbidity and mortality. We have classified the most common 
manoeuvres according to levels of evidence and grades of recommendations (Table 
2.3).
Infection control manoeuvres
Hand washing, isolation, protective clothing, care of equipment and environment
It has never been shown in a RCT that hand hygiene prevents pneumonia and 
reduces mortality in ventilated patients. The efficacy of hand hygiene on the 
incidence of infection has been studied in 8 non-randomized studies (Casewell M; 
Massanari RM; Maki DG; Simmons B; Doebbeling RN; Webster J; Koss WG; Slota 
M) (Table 2.4). Data about the incidence of pneumonia are not presented in these 
studies. The only study that demonstrated an impact on mortality due to hand 
hygiene is the cohort study of Semmelweis in 1861 in post-partum women reducing 
mortality due to puerperal sepsis from 11 % down to 3% (Silvestri L JHI2005).
There are no data available on the effect of isolation, protective clothing, care of 
equipment and environment on the pneumonia rate and mortality in ventilated 
patients (Cepeda JA).
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Table 2.3
Analysis of the literature and grading of evidence, and recommendations for the 
control of morbidity and mortality due to infection in ventilated patients on ICU.
Reduced infection Reduced Mortality
Level of Grade of Level of Grade of
evidence recommendation evidence recommendation
Non antibiotic interventions
Hand washing/isolation/
protective clothing/
care of equipment and
environment
D 2 D 2
Positioning
Rotation therapy None None None None
Semi-recumbent position None None None None
Subglottic secretion drainage None None None None
Oral antiseptic
decontamination None None None None
Immunomodulation
• Immunonutrition A 1 None None
• Steroids None None B 1
• Immunoglobulins None None C 2
• Activated protein-C None None B 1
• Anti-inflammatory None None A 1
modulators
Antibiotic interventions
Selective Decontamination of
the Digestive tract (SDD) (4
component)
A 1 A 1
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These five traditional infection control measures target the control of transmission of 
micro-organism via hands of carriers. They are important but the impact should not 
be overestimated. An optimal infection control policy can only reduce infections due 
to micro-organisms acquired on the unit i.e. secondary endogenous and exogenous 
infections. They fail to influence primary endogenous infections due to micro­
organism present in the admission flora. This type of infection is the major infection 
problem on the ICU varying between 60-85%.
Non antibiotic interventions
Positional Therapy
Severely ill patients who require ventilation are almost always treated in the supine 
position. This leads to collapse of the lower parts of the lung and reduced clearance 
of lower airway secretions. These two factors increase the risk of pneumonia. 
Treating a patient in a specialised rotating bed in which the patient is continuously 
rotated from -40° to +40° around their longitudinal axis could theoretically help in the 
prevention of pneumonia.
There is one meta-analysis available of 6 RCTs and also a further two RCTs (Choi 
SC; Summer WR; Traver GA). A significant reduction in pneumonia was found in 
patients who received rotational therapy. Of the 6 studies, 5 were performed in 
surgical or neurological patients. The sixth trial in which there was no reduction in 
pneumonia was performed in non-surgical ICU patients and a more recent RCT in a 
mixed ICU population does not support the meta-analysis. Rotation therapy requires 
special beds, is associated with considerable costs and is unpleasant for the 
patients. A cost effective analysis is not available.
Semi-recumbent position
Although in general the throat has been considered as the internal source of 
potential pathogenic micro-organisms (PPM) causing pneumonia, it is suggested that 
aspiration of PPM carried in the stomach may play a role in the pathogenesis of 
pneumonia, the so called stomach-lung route (Craven DE). Based upon this concept, 
ventilating patients in a semi-recumbent position is thought to have a beneficial effect 
on reducing the incidence of reflux and aspiration from the stomach whereby
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pneumonia in ventilated patients could be prevented. This manoeuvre has been 
investigated in three randomized control trials (Drakulovic MB; van Nieuwenhoven 
CA; Keeley L) (Table 2.5). The first study shows that ventilating patients in a semi- 
recumbent position leads to a significant reduction in pneumonia. Mortality rates 
however, were identical in both test and control group. Patients who underwent 
abdominal or neurosurgery and patients with refractory shock and patients who were 
readmitted to ICU within one month were excluded. The second RCT failed to 
confirm these results; there was no difference in pneumonia rate or mortality. The 
treatment of ventilated ICU patients in semi-recumbent position at an angle of 45° is 
difficult in practice and is often associated with frequent changes in patient position. 
Recently, Keeley was also unable to demonstrate any reduction in ventilator 
associated pneumonia in patients nursed at 450 (p<0.176). Meta analysis of these 
studies reveals no significant impact on VAP by this manoeuver. Cost is not reported 
as an issue for this intervention (Silvestri L JCC 2010; Alexion 2009).
Continuous aspiration of sub- glottic secretions
Stasis of saliva contaminated with potential pathogens above the cuff on the 
endotracheal tube increases the risk of aspiration pneumonia. The removal and 
prevention of this salivary stasis using continuous aspiration via a specially designed 
endotracheal tube is thought to prevent pneumonia. The intervention of subglottic 
secretion drainage (SSD) has been evaluated in 10 RCTs (Mahul P; Valles J; Kollef 
MH; Smulders K; Metz C; Bo H; Liu SH; Lorente L; Zheng RQ; Bouza E). Three 
studies were performed in a mixed ICU population requiring ventilation for >72hr and 
a fourth study in cardiac surgery patients. The results of these trials are not 
consistent. Two studies showed a significant reduction in pneumonia the other two 
failed to show any impact on pneumonia during ventilation. There was no difference 
in mortality in test and control group in any of the studies; although the specially 
designed tubes and suction equipment are expensive this technique has been 
suggested to be cost effective on theoretical grounds only. There were no harmful 
side effects associated with this manoeuvre in any of the studies. Bo et al found that 
the presence of subglottic secretion may be an origin of the pathogenetic organisms 
of ventilator associated pneumonias (VAP) (Bo H). The morbidity of VAP in 
mechanically ventilated patients can be reduced by SSD. Liu et al confirmed that
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migration of the dominant bacteria of the subglottic secretion was one of the 
important factors for ventilator associated lower airway infection. The concentration 
of bacteria in the subglottic secretion was significantly reduced by subglottic 
secretion drainage when SSD was used and that SSD reduced the incidence of 
ventilator associated airway infection and VAP in patients ventilated of <5d (Liu SH). 
Zheng supported these conclusions (Zheng RQ). However, Lorente et al found that 
the use of an endotracheal tube with polyurethane cuff and subglottic secretion 
drainage helps prevent early- and late-onset VAP (Lorente L). Bouza et al 
demonstrated that continuous aspiration of subglottic secretions reduces the 
incidence of VAP in patients who are at risk (Bouza E).
There are two meta analyses. Dezfulian reported on 5 RCTs involving 896 patients. 
They found that SSD reduced the incidence of ventilator-associated pneumonia by 
nearly 50% (RR=0.51; 0.37-0.71), by reducing early-onset pneumonia occurring 
within 5-7 days after intubation. SSD also shortened the duration of mechanical 
ventilation by 2 days and the length of stay in the ICU by 3 days and delayed the 
onset of pneumonia by 6.8 days. Dezfulian et al concluded that SSD appears 
effective in preventing early-onset ventilator-associated pneumonia among patients 
expected to require >72 hours of mechanical ventilation (Dezfulian C). Siivestri et al 
(the 21st Anesthesia and ICU Symposium 2008) reported on 10 RCTs of SSD (Table 
2.5), 9 of which reported results on pneumonia rates. In 1953 patients studied, there 
was a 57% reduction in VAP (OR 0.43, 95% Cl 0.32-0.58; p<0.001) and in 1846 
patients in 7 of the 9 RCTs who reported, there was no effect on mortality. So 
subglottic drainage is effective in preventing VAP; though sub group analysis 
revealed it was not effective in cardiac surgery patients.
Oropharyngeal Decontamination using Antiseptics
There are now 16 RCTs, which report varying degrees of success of oropharyngeal 
decontamination using antiseptics (De Riso AJII; Fourrier F; Houston S; 
MacNaughton PD; Grap MJ; Fourrier F; Segers P; Koeman M; Bopp M; Tad YD; 
Tantipong H; Panchabhai TS; Scannapieco FA; Munro CL; Bellissimo-Rodrigues F; 
Cabov T). However, the outcome of six meta-analyses confirms that antiseptic usage
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has no benefit in reducing pneumonia or mortality (Pineda LA; Chlebicki MR; Chan 
BY; Kola A; van Saene HKF JCC 2009; Carvajal C) (Table 2.5). In 1202 patients 
Pineda et al reported that use of oral decontamination with chlorhexidine did not 
result in significant reduction in the incidence of nosocomial pneumonia in patients 
who received mechanical ventilation, nor altered the mortality rate. Chlebicki et al 
demonstrated no mortality benefit with chlorhexidine, though in seven small RCTs 
there was a reduction in VAP most marked in cardiac surgery patients. Neither 
antiseptic nor antibiotic oral decontamination reduced mortality or duration of 
mechanical ventilation or stay in the intensive care unit in a meta-analysis of 11 
studies by Chan et al. Kola et al found in seven RCTs a reduction in the relative risk 
(RR) of lower respiratory tract infections in those receiving chlorhexidine (RR 
(random): 0.58). However, these results only applied to patients ventilated for up to 
48h. From 10 studies but not all RCT Carvajal et al report a reduction in the risk of 
VAP with chlorhexidine (OR: 0.56, 95% Cl: 0.44-0.73). However, neither a reduction 
in mortality, nor lengths of MV nor ICU length of stay were seen.
Immunomodulation
Enteral feeding
Total parenteral nutrition (TPN) has been shown to be harmful in terms of infection 
rates and liver impairments. This prompted the desire to enterally feed the ICU 
patient as quickly as possible because it is thought to be essential for the gut 
anatomy and physiology in order to prevent loss of mucosa integrity and subsequent 
translocation. In addition several nutrients added to the enteral feed have been 
shown to influence immunologic and inflammatory responses in humans. There are 
two meta-analyses available on immunonutrition in the critically ill (Beale RJ; 
Heyland DK) (Table 2.6). Both meta analyses demonstrated a significant reduction in 
overall infection rate, though they do not specifically say pneumonia, there was no 
reduction in mortality in either of the meta-analyses. Surgical patients seemed to 
benefit more than medical patients. In two large RCTs mortality rate was significantly 
higher in the subgroup who received immunonutrition. Some have speculated that 
added arginine may have been detrimental to the immune system.
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Steroids
High doses of steroids given to septic patients are thought to be beneficial for three 
reasons. Steroids effectively suppress generalised inflammation due to micro­
organisms and their toxins. Steroids have been shown to significantly reduce septic 
shock and early mortality within 72hrs. Steroids have been shown to significantly 
reduce mortality due to particular severe invasive infections including meningitis, 
typhoid and pneumocystes pneumonia (PCP). There have been a number of meta 
analyses and RCTs on the use of steroids in sepsis (Cronin L; Lefering R; Bollaert 
PE; Briegel J; Annane D 2002) (Table 2.6). The major perceived side effects of high- 
dose steroids are the associated immune suppression and subsequent risk of super­
infections. Indeed the two meta-analyses show a trend towards increased mortality 
from secondary infection in patients receiving steroids. A recent systematic review by 
Annane in 2009 (Annane D 2009) examining the benefits and risks of steroids in 
sepsis reviewed 17 RCTs encompassing 2138 patients and 3 quasi-RCTs of 246 
patients. Sub group analysis of prolonged low-dose corticosteroid therapy, suggests 
a beneficial drug effect on short-term mortality (Annane D 2009).
The COIITSS study (COIITSS Study) demonstrated that intensive insulin therapy 
together with hydrocortisone for septic shock did not improve in-hospital mortality. 
The addition of oral fludrocortisone did not result in a statistically significant 
improvement in in-hospital mortality (COIITSS Study).
It would appear that superinfections abolish the beneficial effects of steroids. A 
recent European study entitled ‘Use of early corticosteroid therapy on ICU admission 
in patients affected by severe pandemic (H1N1) influenza A infection’ (Martin- 
Loeches I) was unable to demonstrates a benefit form using steroids in patients with 
H1N1 respiratory infections. However, it was unclear what the purpose of the 
corticosteroid therapy use was; whether it was for replacement therapy as advocated 
by (Annane D 2009) or for the control of inflammation (Sprung C).
Steroids are used in septic patients requiring treatment on the intensive care unit 
(ICU) for two reasons;
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[i] at low doses (1mg/kg/day methylprednisone) for long periods as replacement 
therapy in patients with presumed relative adrenal insufficiency (Annane D 
2009).
[ii] at high doses (5mg/kg/day) for four days in an attempt to block pro- 
inflammatory cytokine burst (Sprung C).
In the European H1N1 study low doses of methylprednisone (24mg/day) or 
prednisone (30mg/day) for two weeks were evaluated suggesting replacement 
therapy was used. Hence the results of this study seem to demonstrate that adrenal 
failure is not an important problem in H1N1 pneumonia as could be expected in a 
mono-organ disease. Consequently what this study does demonstrate and confirms 
is that prolonged steroid use is a risk factor for superinfections and that if patients 
with H1N1 pneumonia die, they die due to superinfections.
The major problem in H1N1 pneumonia is severely inflamed lungs. Modulation of 
this excessive inflammatory response provoked by the viral infection is an attractive 
pathophysiological concept. Short courses of high doses corticosteroids can down- 
regulate this inflammatory cytokine response.
The use of high dose steroids in severe sepsis and septic shock was abandoned in 
the 1980s as a result of the Sprung and Bone studies. However in the Sprung study 
a significant reduction of mortality was found during the first ten days in the treatment 
group (Sprung C). This early survival benefit disappeared due to the subsequent 
development of superinfections, generally occurring after one week. The Bone study 
(Bone RC), unfortunately providing only data on mortality at day 14, also 
demonstrated a high incidence of superinfection. Bone was the first to link 
superinfection with a high mortality.
Can the use of corticosteroids ever produce survival benefit if the importance of 
concurrent bacterial and/or fungal superinfections is not recognised? For example, in 
the Annane meta-analysis (Annane D, 2009) there were no superinfections and a
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survival benefit was obtained. In contrast, in this European study superinfections 
were reported, and, hence no survival benefit.
Selective decontamination of the digestive tract has been acknowledged to be an 
effective and safe manoeuvre for the control of severe superinfections of lower 
airways and blood in the critically ill on the ICU (Liberati A 2009). SDD can prevent 
these lethal superinfections.
The question still remains, if in patients with severe inflammation such as H1N1 
induced pneumonitis who remain clear of superinfection by applying SDD, is giving 
high dose steroids beneficial?
The next logical step would be to combine steroids with SDD whereby the perceived 
harmful effects of steroids could be abolished in that the early survival benefit from 
steroids can be preserved in keeping the patient free from secondary infections 
using SDD. The time has come to perform a randomized trial of SDD and steroids 
versus only SDD with the endpoint of mortality (Petros A).
Anti-inflammatory mediators
Almost 60 RCTs have been undertaken testing the hypothesis that modulation of the 
endogenous host inflammatory response can improve survival for patients with a 
clinical diagnosis of sepsis. The results have been frustrating and no new agent has 
been introduced into clinical practice (Marshall J).
Pooled data from studies using a monoclonal antibody to neutralise tumour necrosis 
factor demonstrate a statistically significant, 3.5% reduction in mortality. In 
aggregate, the three completed studies using recombinant intereleukin-1 (IL-1) 
receptor antagonists to neutralise IL-1 also showed an absolute mortality reduction 
of 5%. Natanson and colleagues (Zeni F) have shown that the combined results of 
all completed trials, independent of the therapeutic agents employed demonstrate a 
statistically significant 3% overall reduction in 28 day all cause mortality. It is 
debateable whether this small clinical benefit is sufficiently important to justify clinical 
use of these therapies, given the costs and potential toxicity of the agent involved.
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Immunoglobulins
Polyclonal intravenous immunoglobulins significantly reduce mortality and can be 
used as an extra treatment option for sepsis and septic shock (Alejandria MM). 
Overall mortality was reduced in patients who received polyclonal intra-venous 
immunoglobulin (n=492; RR=0.64; 95% Cl 0.51 to 0.80). For the two high-quality 
trials on polyclonal intra-venous immunoglobulin, the RR for overall mortality was 
0.30, but the confidence interval was wide (95% Cl 0.09 to 0.99, n=91). However, all 
the trials were small and the totality of the evidence is insufficient to support a robust 
conclusion of benefit. Adjunctive therapy with monoclonal intravenous 
immunoglobulins (MGs) remains experimental.
Activated protein-C
Drotrecogin alfa (activated), or recombinant human activated protein C, is thought to 
have anti-inflammatory, anti-thrombotic and profibrinolytic properties. In a 
randomized trial of 1690 patients the mortally rate was 30.8% in the placebo group 
and 24.7% in the drotrecogin alpha group, which translates into an absolute 
reduction in risk of death of 6.2% (p=0.05). The incidence of serious bleeding was 
higher in the drotrecogin alfa (activated) group that the placebo group (Bernard GR). 
This is level 1 evidence and grade B recommendation.
Tight Glucose Control
Van den Berghe et al demonstrated that intensive insulin therapy reduces morbidity 
and mortality in patients in cardiac surgical intensive care units (ICUs) (van den 
Berghe G 2001). However, intensive insulin therapy significantly reduced morbidity 
but not mortality among all patients in a medical ICU (Van den Berghe G 2006).
The American Diabetes Association and Surviving Sepsis Campaign recommend 
tight glucose control in critically ill patients based largely upon one trial that shows 
decreased mortality in a surgical intensive care unit. Because similar studies report 
conflicting results and tight glucose control can cause dangerous hypoglycemia, the 
data underlying this recommendation should be critically evaluated (Wiener RS).
41
In paediatric patients intensive insulin therapy to achieve age-adjusted normal 
fasting glucose concentrations improves short-term outcome of patients in PICU, in 
an RCT performed by Vlasselaers D et al in 2009. However, the NIRTURE study of 
tight glucose control in neonates and infants did not conclusively demonstrate the 
value of insulin therapy in preterm infants (Beardsall K).
The practice of tight glucose control is accompanied by an increased incidence of 
hypoglycaemia. Hermanides and colleagues (Hermanides J) demonstrated that 
hypoglycaemia increased the rate of death to 40/1000 in those who have 
experienced hypoglycaemia and 17/1000 who were not hypoglycaemic.
Antibiotic interventions
Selective Decontamination of the Digestive tract
SDD is based on the observation that critical illness changes body flora, promoting a 
shift from:
(i) Normal {Streptococcus pneumoniae in the throat and Escherichia coli in the 
gut) towards abnormal carriage (aerobic Gram-negative bacilli and methicillin- 
resistant Staphylococcus aureus in throat and gut) (Table 2.7).
(ii) Low to high grade carriage (gut overgrowth) of both normal and abnormal 
flora.
Parenteral cefotaxime controls gut overgrowth due to ‘normal’ bacteria, enteral 
polyenes control gut overgrowth due to ‘normal' Candida species. Enteral 
polymyxin/tobramycin (without or with vancomycin) eradicate, if already present, and 
prevent overgrowth with ‘abnormal’ bacteria.
Gut overgrowth is the crucial event preceding endogenous infections (Table 2.8). 
Primary endogenous infection is caused by ‘normal’ and ‘abnormal’ potential 
pathogens, present in the patient’s admission flora. This infection generally develops 
within a week and is the most frequent type of infection (55%). Secondary 
endogenous infection is invariably caused by ‘abnormal’ bacteria not present in the 
admission flora but acquired during treatment on the intensive care unit (ICU). This 
infection generally occurs after one week on ICU (30%). Exogenous infection is
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caused by ‘abnormal’ bacteria never carried in the patient’s oropharynx and/or gut. 
This type of infection may occur anytime during ICU-treatment (15%).
These three types of ICU-infection each require different prophylaxis. Primary 
endogenous can only be controlled by parenteral antimicrobials, secondary 
endogenous are prevented by enteral antimicrobials and high hygiene standards, 
exogenous are controlled by topical antimicrobials and hygiene.
These three interventions were first combined by Stoutenbeek who expanded the 
prophylaxis to include surveillance cultures creating the full four component SDD 
protocol, the main mechanism of action being gut overgrowth control (Figure 2.1) 
(Stoutenbeek CP 75 /CM 1984).
There are 64 randomized controlled trials evaluating SDD and 11 meta-analyses, 
confirming SDD reduces pneumonia (72%), septicaemia (37%) and mortality (29%) 
without resistance emerging (Table 2.9).
Bloodstream infection was the endpoint in 3 meta-analyses (Silvestri L 2005; 
Silvestri L 2007; Silvestri L AIC 2008), and was significantly reduced (OR 0.63, 
95%C! 0.46-0.87). AGNB septicaemias were significantly reduced whereas Gram­
positive ones were increased but not significantly due to the low incidence in the 
control group (Table 2.6). Multi-organ dysfunction syndrome was the endpoint in one 
of the most recent meta-analyses (Silvestri L 2010) and the relative reduction of 50% 
seen was significant. Mortality was the endpoint in 8 meta-analyses 
(Vandenbroucke-Grauls CMJ; D’Amico R; Safdar N; Liberati A 2004; Silvestri L JCI 
2007; Silvestri L JCC 2009; Liberati A 2009; Silvestri L CCM 2010). SDD consistently 
reduced mortality as long as the sample size was large enough. The sample size 
was too small in 3 meta-analyses (Vandenbroucke-Grauls CMJ; Safdar N; Silvestri L 
CCM 2010).
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Figure 2.1
The full four component protocol of SDD, that aims to control the three different 
types of infection that occur on ICU. PTA - poylmyxin/tobamycin/amphotericin.
control the 
ficacy of 
PTA
To classify infections 
according to the carrier 
state
Parenteral
antibiotic
Hygiene
Surveillance
cultures
Primary
endogenous
Exogenous
Secondary
endogenous
The four 
components of 
SDD
Types of 
infection 
prevented 
by SDD
Definitions of infection 
according to the criterion of 
carriage
Caused by ‘normal’ and 
‘abnormal’ PPMs carried by 
the patients in throat and/or 
gut on admission to the ICU
The causative ‘abnormal’ PPM 
is not carried in the patient’s 
digestive tract and is 
introduced directly into the 
sterile organ
Caused by ‘abnormal’ PPMs 
not carried by the patients in 
throat and/or gut on admission 
to the ICU. The PPM is 
acquired during ICU stay 
causing secondary carriage
To identify a 
resistance problem
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Table 2.7
Classification of micro-organisms based upon their intrinsic pathogenicity. The 
intrinsic pathogenicity index (IPI) is the ratio between the number of ICU patients 
with an infection due to a particular micro-organism and the number of ICU patients 
who carry the same particular micro-organism. Normal PPM are carried by healthy 
individuals in throat and gut. Individuals with an underlying condition carry both 
normal and abnormal PPM in throat and gut.
Intrinsic
Pathogenicity
Site Micro-organism Flora
Low level
IPI = 0.01
Indigenous
flora
Throat Peptostreptococci, Veillonella spp, 
Streptococcus viridans
Normal
Gut Bacteroides spp, Clostridium spp, 
enterococci, E. coli
Vagina Peptostreptococci, Bacteroides spp, 
lactobacilli
Skin Propionibacterium acnes, coagulase 
negative staphylococci
Potential
IPI = 0.3-0.6
Normal
PPM
Throat S. pneumoniae, H influenzae,
Moraxella catarrhalis, S. aureus,
Candida spp
Normal
Gut E. coli, S. aureus, Candida spp
Abnormal
PPM
Throat 
& Gut
Klebsiella, Enterobacter, Citrobacter, 
Proteus, Morganella, Serratia, 
Pseudomonas, Acinetobacter spp,
MRSA
Abnormal
High level
IPI = 0.9-1.0
Epidemic
Micro­
organisms
Throat
Gut
Neisseria meningitidis
Salmonella spp
Abnormal
MRSA = methicillin-resistant Staphylococcus aureus
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Morbidity vs. mortality as the important endpoint ?
SDD is an antimicrobial strategy aimed at preventing severe infections of lower 
airways and blood. It has been demonstrated to work successfully in adults but 
evidence for its success in children is less clear. Adults on ICU die of infections. The 
question is whether children die of infection. The clinical evidence supports the 
assumption that they do. Causes of infectious mortality include septicaemia, 
pneumonia, and meningitis. If there are a substantial proportion of children who die 
from infection then using SDD would make sense. The incidence of infection in a 
four-year prospective study in a large tertiary paediatric intensive care unit was 
41.9% of all admissions (Sarginson R).
In adults, the pneumonia rate is 30% in children it is nearer 15% (Ruza F). In adults 
the septicaemia rate is 25% whereas in children it is 10% (Zobel G). So the morbidity 
due to infection is about third less in children compared to adults. The mortality is 
again about 30% in adults and in children it is about 5%. In the subgroup that 
requires ventilation for a minimum of four days it rises to 10% (Sarginson R).
So determining whether SDD can impact upon mortality in children is going to be 
difficult and is discussed further in Chapter 5.
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Table 2.8
Carriage classification of severe infections of lower airways and blood.
Infection PPM Timing Frequency Manoeuvre
1. Primary
endogenous
6 ‘normal’
9’ abnormal’
<1 week 55% Parenteral
antimicrobials
2. Secondary
endogenous
9 ‘abnormal’ >1 week 30% Hygiene and enteral
antimicrobials
3. Exogenous 9 ‘abnormal’ Anytime
during ICU
treatment
15% Hygiene and topical
antimicrobials
PPM = potentially pathogenic micro-organism;
6 ‘normal’ PPM : Streptococcus pneumoniae, Haemophilus influenzae, Moraxella 
catarrhalis, Candida albicans, Staphylococcus aureus, Escherichia coli;
9 ‘abnormal’ PPM: Klebsiella, Enterobacter, Citrobacter, Proteus, Morganella, 
Serratia, Acinetobacter, Pseudomonas species and methicillin-resistant 
Staphylococcus aureus (MRSA)
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Chapter 3
THE APPLICATION OF THE ADULT EVIDENCE FOR SELECTIVE 
DECONTAMINATION OF THE DIGESTIVE TRACT TO THE PAEDIATRIC 
POPULATION
The purpose of this chapter is to evaluate the adult experience with selective 
digestive decontamination and its effect on mortality and severe respiratory and 
bloodstream infections in order to determine whether this may be extrapolated to the 
paediatric population. A literature search of the following databases was undertaken: 
Medline (1980-2010), Embase (1980-2010), CINAHL (1981-2010) and the Cochrane 
Central Register of Controlled Trials and Cochrane Database of Systematic Reviews 
(1989-2010). Keywords used were, paediatrics, children, infants, neonates, selective 
digestive decontamination, selective gut decontamination, selective oral 
decontamination, SDD, SGD, ventilator associated pneumonia, VAP prevention. 
Limits of English language were applied. Reference lists of retrieved articles were 
also reviewed. All articles in English identified from the literature search were 
evaluated.
All randomized controlled studies of SDD undertaken in adults or paediatrics were 
included in the review. 64 randomized controlled trials (RCTs) and 11 meta-analyses 
were identified of which 4 RCTs were conducted in paediatrics. Five of the 9 meta­
analyses with the endpoint of mortality showed a significant survival benefit with the 
full SDD regimen. The six meta-analyses with the endpoint of lower airway infection 
showed a significant reduction. Three meta-analyses showed that the incidence of 
AGNB blood stream infections was significantly reduced. A meta-analysis of the 4 
paediatric trials showed an effect on paediatric morbidity but not mortality. SDD 
reduces mortality and severe respiratory and systemic infections in adults. There is 
limited evidence for the use of SDD in paediatrics. Paediatric patients have been 
shown to follow the same pattern of primary endogenous, secondary endogenous 
and exogenous infection as adults; the adult information is likely to be generalisable
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to the paediatric population. To achieve a significant survival benefit in paediatrics a 
much larger number of children would need to be studied.
Background
Selective Digestive Decontamination has been advocated as a prophylactic 
antimicrobial manoever for patients requiring intensive care (Almuslim O). Since its 
introduction 25 years ago Level 1 evidence has accrued to unequivocally support the 
effectiveness of SDD at reducing severe lower airway and blood stream infections in 
patients in adult intensive care units (van Saene HK JCC 2009).
The oropharyngeal cavity and gastrointestinal tract play an important role in the 
pathogenesis of pneumonia and septicemia in critically ill patients. Migration and 
translocation of aerobic gram-negative bacilli (AGNB) and methicillin-resistant 
staphylococcus aureus (MRSA) may occur and result in respiratory tract and blood 
stream infections (Baxby D). Primary carriage is where the patient is admitted with 
flora in the digestive tract, and secondary carriage occurs when the patient acquires 
flora in the digestive tract whilst having treatment on the intensive care unit. SDD 
aims to prevent secondary carriage of hospital acquired or “abnormal" flora, including 
AGNB and MRSA and yeasts by the enteral application of antibiotics and antifungals 
to the oropharynx and gastro-intestinal system. Many advocates of SDD also 
recommend the use of a parenteral cephalosporin, usually cefotaxime, as an 
essential component of the SDD regimen for the first three to four days, in order to 
treat any primary endogenous infection and to clear carriage of community acquired 
or "normal” flora such as S.aureus and E.coli (Stoutenbeek CP JoT 1987).
Gut overgrowth (van Saene HKF JHI 1996) may harm the critically ill in four main 
ways:
(i) Inflammation - overgrowth of abnormal AGNB and production of endotoxin 
has been shown to lead to cytokinaemia and inflammation of major organ 
systems (Baue AE).
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(ii) Immunosuppression - overgrowth of abnormal AGNB (and associated 
endotoxin production) has been shown to impair immunity due to generalised 
inflammation following absorption of AGNB and/or endotoxin (Deitch EA).
(iii) infection - there is a quantitative relationship between surveillance and 
diagnostic samples. When there is overgrowth in surveillance samples the 
diagnostic samples become positive which is the first stage in the 
development of infection (Van Uffelen R).
(iv) Resistance - the abnormal carrier state in overgrowth concentrations 
guarantees increased spontaneous mutation leading to polyclonality and 
antibiotic resistance (van Saene HKF CD72008).
SDD is a prophylactic measure using selected antimicrobials to control overgrowth of 
both “normal” and “abnormal” flora, thereby reducing the four harmful side-effects of 
overgrowth i.e. control of inflammation (Conraads VM) restoration of suppressed 
systemic immunity (Horton JW); infection prevention (de la Cal MA JHI 1994) and 
resistance control (van Saene HKF D 2004).
There have been three recent reports describing the efficacy of SDD in children 
(Sarginson RE CCM 2004; (Paulus S EJC 2005); Thorburn K CM! 2006. However, 
these are observational single-centre studies. Therefore the aim was to assess the 
efficacy and adverse effects of SDD in the paediatric population from the available 
evidence, and contrast this with adult evidence.
What is selective decontamination of the digestive tract?
SDD is an antimicrobial strategy aimed at preventing infection using prophylactic 
parenteral and enteral antimicrobials. It is based upon two fundamental principles; 
pathogenesis of infection is due to a limited range of potential pathogens, and the 
three types of pathogenic pathway each require a different intervention.
SDD defines 15 potential pathogens (van Saene HKF ICM 2003). There are six 
“normal" potential pathogens {Streptococcus pneumoniae, Haemophilus influenzae,
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Moraxella catarrhalis, Staphylococcus aureus, Escherichia coli and Candida 
albicans) as well as nine “abnormal” pathogens (van Saene HKF ICM 2003). The 
abnormal pathogens consist of eight AGNBs (Klebsiella, Citrobacter, Enterobacter, 
Proteus, Morganella, Serratia, Acinetobacter and Pseudomonas species) and MRSA 
(van Saene HKF /CM 2003).
The three pathogenic pathways for infection defined by the criterion of carriage are 
primary endogenous, secondary endogenous and exogenous infection. Primary 
endogenous infection generally develops within a week and is the most frequent type 
of infection, responsible for approximately 55% of infections (Sarginson RE CCM 
2004; Silvestri L JHI 1999; de la Cal MA Chest 2001). This type of infection is 
caused by potential pathogens which are present in the admission (oropharynx or 
gut) flora and may be either normal or abnormal flora. Secondary endogenous 
infection is generally caused by abnormal bacteria not present in the admission flora 
but acquired during treatment on the ICU. This type of infection generally occurs 
after one week and represents approximately 30% of infections (Sarginson RE CCM 
2004; Silvestri L JH1 1999; de la Cal MA Chest 2001). Finally, exogenous infection is 
caused by abnormal potential pathogens never carried in the digestive tract but 
introduced directly into the patient from an external source. Exogenous infection may 
occur at any time during ICU treatment, and accounts for approximately 15% of 
infections (Silvestri L JHI 2005).
Table 3.1 and 3.2 describe the full four component SDD regimen and the rationale 
for its use. Elimination of the primary endogenous route requires an initial course of 
parenteral antimicrobials in order to eradicate carriage of normal flora and to treat 
any pre-existing infection (Baxby D; Stoutenbeek CP ICM 1984). Cefotaxime was 
originally chosen because of its broad spectrum of activity against normal flora and 
the majority of the AGNB (Baxby D) and because of it’s high salivary and biliary 
concentrations render it a highly effective antimicrobial for eradication of 
oropharyngeal and gut carriage of normal flora (Stoutenbeek CP JoT 1987).
To prevent secondary endogenous infection, the antimicrobials polymyxin, 
tobramycin and amphotericin B are administered enterally to prevent the acquisition 
of abnormal flora and to eradicate any abnormal flora the patient may already be
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carrying. If there is a delay in administering the enteral antibiotics, secondary 
endogenous infection may occur, this should be treated via the parenteral route. The 
combination of enteral polymyxin and tobramycin (Kucers1) was chosen because it 
covers all abnormal AGNB including Pseudomonas species, in addition to being 
synergistic (Kuipers JS). There are five different polymyxin preparations, A-E, 
however only two are clinically available, B and E (colistin). Colistin is the only 
enteral polymyxin available in the United Kingdom (Martin J). Enteral polyenes such 
as amphotericin B and nystatin are used to clear ‘normal’ fungal carriage, (Hofstra W 
1979; Hofstra W 1982). Enteral vancomycin is only added to the polymyxin 
/tobramycin/amphotericin B combination in cases of MRSA endemicity in order to 
eradicate and clear the MRSA carrier state (Silvestri L AJIC 2002).
Standard hygiene measures and scrupulous attention to sterile technique is crucial in 
order to prevent the introduction of potential pathogens from external sources 
directly into sterile organs, bypassing the carrier state. Again, polymyxin E (or 
colistin), tobramycin, amphotericin B and vancomycin (if MRSA is endemic) are used 
topically, e.g. in a paste on a tracheostomy site, to prevent exogenous lower airway 
infections (Veelo DP).
The fourth component of the SDD regimen is the use of surveillance cultures in order 
to monitor the efficacy of the SDD protocol and the development of antimicrobial 
resistance. These three interventions were first combined by Stoutenbeek in 1984 
(Stoutenbeek CP ICM 1984), who then went on to further develop the SDD regimen 
by adding this final component of surveillance cultures.
Efficacy
There are 64 randomized controlled trials (RCTs) (Abdel-Razek SM; Abele-Horn M; 
Aerdts SJ; Arnow PM; Barret J; Bergmans DC; Bion JF; Blair P; Boland JP; Bouter 
H; Brun-Buisson C; Camus C; Cerra FB; Cockerill FR 3rd; de Jonge E; de La Cal MA 
AS 2005; de Smet AM; Diepenhorst GM; Farran L ; Ferrer M; Finch RG; Flaherty J; 
Gastinne H; Gaussorgues PH ; Georges B ; Gosney M; Hammond JM; Hellinger 
WC; Jacobs S; Kerver AJ; KorinekAM; Krueger WA; Laggner AN; Lingnau W; Luiten 
EJ; Martinez-Pellus AE CCM 1993; Martinez-Pellus AEICM 1997; Oudhuis GJ;
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Palomar M; Pneumatikos I; Pugin J; Quinio B; Rayes N; Rios F; Rocha LA; 
Rodriguez-Roldan JM; Rolando N Hep 1993; Rolando N LTS 1996; Ruza F; 
Snachez Garcia M; Schardey HM; Smith SD; Stoutenbeek CP 1996; Stoutenbeek 
CP /CM 2007; Tetteroo GW; Ulrich C; Unertl K; Verwaest C; Wiener J; Winter R; 
Yilmazlar A; Yu J; Zobel G; Zwaveling JH) and eleven meta-analyses of only RCTs 
(Vandenbroucke-Grauls CMJ; D’Amico R; Safdar N; Liberati A; Silvestri L ICM 2005; 
Silvestri L JHI 2007; Silvestri L AIC 2008; Silvestri L JCC 2009; Liberati A Cochrane 
2009; Silvestri L CCM 2010) that assess the efficacy of SDD in reducing mortality 
and respiratory and bloodstream infections (Tables 3.3, 3.4). All but four of these 
RCTs were conducted in adults.
Six meta-analyses have the endpoint of lower airway infection (Vandenbroucke- 
Grauls CMJ; D’Amico R; Liberati A 2004; Silvestri L AIC 2008; Liberati A). All 
invariably show a significant reduction of lower airway infections due to both Gram- 
negative and Gram-positive bacteria.
There are nine meta-analyses with the endpoint of mortality (Vandenbroucke-Grauls 
CMJ; D’Amico R; Safdar N; Liberati A 2004; Silvestri L JHI 2007; Silvestri L JCC 
2009; Liberati A 2009; Silvestri L CCM 2010; Petros A). Five of the nine, with sample 
sizes between 4,902 and 8,065 patients, consistently show a significant survival 
benefit with the full SDD regimen (D’Amico R MJ 1998; Liberati A 2004; Silvestri L 
JHI 2007; Silvestri L JCC 2009; Liberati A 2009). In the other four meta-analyses the 
mortality reduction was not significant, due to the small sample size (259, 335, 491 
and 1270 patients) (Vandenbroucke-Grauls CMJ; Safdar N; Silvestri L CCM 2010; 
Petros A).
The significant survival benefit seen is in all likelihood due to the control of severe 
infections of not just lower airways but also the bloodstream. Three of the meta­
analyses have the endpoint of septicemia/bloodstream infections, (Silvestri ICM 
2005; Silvestri L JHI 2007; Silvestri L AIC 2008). If classified by causal 
microorganism, the incidence of AGNB, a major cause of mortality, was significantly 
reduced, (Silvestri L HI 2007; Silvestri L AIC 2008). However, bloodstream infections 
caused by Gram-positive organisms did not increase but not significantly (Silvestri L 
JHI 2007; Silvestri L AIC 2008), refuting concerns that SDD promotes Gram-positive
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infections (Kallet R). Blood stream infections due to fungi were non-significantly 
reduced (OR 0.89, 95%CI 0.16-4.95) due to the low event rate in the control group 
(Silvestri L ICM 2005). Finally, one of the most recent meta-analyses demonstrates 
that SDD using the full SDD regimen of both parenteral and enteral antimicrobials 
reduces multiple organ failure dysfunction syndrome (MODS) by 50% (Silvestri L 
CCM 2010).
SDD in Paediatrics
Paediatric patients follow the adult model of primary endogenous, secondary 
endogenous and exogenous infections (Stoutenbeek CP JoT 1987) therefore the 
results of the adult studies and meta-analyses are likely to be generalisable to the 
paediatric population.
The mortality rate in children is between 5-10% depending on their severity of illness, 
as assessed by the PIM score and type of injury or underlying illness. The mortality 
rate in UK PICUs between 1998 and 2006 was 4.9% (Smit M). So any manoeuvre, 
which attempts to prove a reduction in mortality, will have to have a very large 
sample size to prove statistical significance. For example, to demonstrate a 
significant reduction in any adult study which has a 30% incidence of an event, then 
5000 patients need to be included in the study. For children, using a mortality rate of 
5%, approximately 10,000 children would need to be enrolled in any RCT to 
demonstrate a significant difference clearly not a realistic option. It is thus easier to 
demonstrate a reduction in morbidity rather than mortality in children.
Four RCTs of SDD have been performed in children between 1991 and 2001 and 
include a total of 335 patients (Barret JP; Ruza F; Smith SD; Zobel G) (Table 3.5). 
Zobel G et al were the first to undertake a prospective randomized controlled trial of 
SDD in paediatrics in 1991. The primary endpoint of their study was the effect on 
colonisation and infection rates of AGNB and yeasts in the oropharynx, gut and 
respiratory tracts of critically ill children on the paediatric intensive care unit. 25 
children were randomized to receive the full 4-component SDD regimen, and 25 
were randomized to the control group and received either perioperative antibiotic 
prophylaxis or antibiotic therapy if indicated by clinical or microbiological evidence of
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infection. Both groups were comparable in terms of baseline age, weight, sex and 
severity of illness. The investigators found that colonisation with Gram-negative 
micro-organisms and yeasts in the oropharynx and digestive and respiratory tracts 
increased rapidly in up to 52% of patients in the control group versus no colonisation 
in the treatment group (p<0.01), and the rate of acquired secondary infections was 
36% in the control group and 8% in the treatment group (p<0.025). There was no 
significant difference between the groups in the duration of intensive care, 
mechanical ventilation or mortality rate. This study used gentamicin as the enteral 
aminoglycoside component and found detectable serum gentamicin levels of 1.5 ± 
0.18mg/L. No adverse effects were attributed to SDD.
In 1993 Smith et al undertook a prospective RCT of SDD in 36 paediatric orthotopic 
liver transplant patients, in order to determine whether SDD influenced the rate of 
post-operative infections (Smith SD). Patient groups were well matched in terms of 
baseline characteristics. While the difference in effect between the treatment and 
control groups may have been attenuated as both groups received intravenous 
cefotaxime, and SDD treatment was only continued until feeding resumed, this study 
still found significantly fewer patients with acquired secondary Gram-negative 
infections in the treatment group (8% vs 36%, p<0.001), as well as a significant 
reduction in AGNB in the stool (p<0.05) which returned to baseline by 3 weeks. 
Gram-positive and anaerobic organisms were unaffected and there was no 
significant difference in the incidence of fungal infections. ICU length of stay, total 
hospital length of stay and mortality were not significantly different between the two 
groups. Mild diarrhoea occurred in 6 of the 18 patients in the treatment group, but did 
not require early discontinuation of SDD and resolved when SDD treatment was 
terminated.
Ruza et al undertook a prospective RCT of the enteral components in 244 PICU 
patients aged 1 month to 14 years old with neurological coma, in order to determine 
the incidence of nosocomial infection. 100 patients were randomized to receive SDD 
treatment, 116 patients to control, 18 patients were withdrawn due to protocol 
violation. Both groups were well matched in terms of age, sex, diagnosis on 
admission, and multi-organ system failure (MOSF) scores. However, therapeutic 
intervention scoring system (TISS) scores, number of organ systems affected, and
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number of patients who were mechanically ventilated were significantly higher at 
baseline in the SDD group. No significant reduction in antibiotic use, length of stay or 
mortality was seen with SDD, which was in all likelihood due to the small sample 
size. Univariant analysis found no significant reduction in incidence of nosocomial 
infections with SDD, but multivariant analysis found that SDD acted as a protective 
factor for >90% of the sample with respect to respiratory and urinary tract infections, 
reducing the risk to 1 in 5 (odds ratio: 0.21) and 1 in 3 (odds ratio: 0.33), 
respectively. Analysis using the intention to treat model, incorporating the withdrawn 
patients, would have strengthened the reliability of the conclusions. The full four- 
component regimen has been seen to provide the greatest efficacy in adults, as 
discussed above, therefore results may have been improved had oropharyngeal 
component and the intravenous component also been utilised in the treatment 
group. No adverse effects were attributed to SDD in the 116 patients in the treatment 
group.
The last paediatric RCT reported in the literature was conducted in 2001 by Barret et 
al. (Barret JR) who investigated the use of the enteral SDD components in paediatric 
patients with severe burns, in order to determine bacterial colonisation of the 
digestive tract and burn wounds and the incidence of nosocomial infections and 
septic complications. 11 patients were randomized to the treatment group and 12 
randomized to placebo. No significant differences were seen in the colonisation rates 
of burn wounds, sputum, nasogastric aspirates or faeces. Similar incidences of 
pneumonia, sepsis and other complications had similar incidences in both groups, 
but patients in the SDD group had a significantly higher incidence of diarrhoea 
(p=0.003). This study only utilised the enteral component of SDD; combined with the 
very small subject numbers this may have accounted for the non-significant results, 
as the oropharyngeal component is essential for the control of respiratory tract 
infections (Stoutenbeek CP JoT 1987).
The results from the four paediatric RCTs have been analysed in a meta-analysis 
(Petros A). Overall mortality for SDD vs. control children was 13 of 170 (6.7%) and 
11 of 163 (7.6%), respectively, demonstrating a non-significant reduction in the odds 
of death (odds ratio, 1.18; 95% confidence interval, 0.50-2.76; p = 0.70). In three 
studies including 109 children, infection was demonstrated in 10 of 54 (13%) patients
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in the SDD group and 24 of 55 (15.9%) in the controls (odds ratio, 0.34; 95% 
confidence interval, 0.05-2.18; p = 0.25). Pneumonia was diagnosed in 5 of 170 
patients (2.9%) in the SDD group and in 16 of 163 patients (9.8%) in the control 
group (odds ratio, 0.31; 95%CI, 0.11-0.87; p=0.027). Therefore even with these 
small patient numbers, there was a significant reduction in infectious morbidity in the 
paediatric population.
No further RCTs of SDD in paediatrics have been reported in the literature in the last 
decade. Paulus et al. undertook an observational study of SDD in the setting of a 
children’s haematology/oncology unit, and concluded that addition of SDD to 
systemic antibiotics maintained a low level of resistance and mortality (Paulus, S). 
The lack of any randomisation or control group in this study renders it as high risk for 
internal selection and investigator bias, and further verification of these results in the 
form of a randomized controlled trial is necessary. However, this study is useful due 
to the encouraging lack of microbiological resistance seen with SDD over the three 
year duration of the study and the extremely low incidence of secondary endogenous 
infection seen with SDD. No specific adverse effects were attributed to the use of 
SDD in this paediatric study.
Table 3.6 describes a paediatric dosage regimen (Kucers JS) for SDD and Table 3.7 
the UK licensing status, presentation & cost for the individual components.
Adverse Effects
Absorption of the enteral products from the gastrointestinal tract appears negligible; 
therefore systemic adverse effects are likely to be minima! unless the integrity of the 
gut wall is breached. Adverse effects include the risk of antibiotic resistance 
(Almuslim O), possibility of blockage of nasogastric tubes by the enteral medication 
(Smit M) and diarrhoea in paediatric patients (Barret JP; Smith SD). Diarrhoea has 
not been associated with SDD in adult critically ill patients (van der Spoel Jl). The 
diarrhoea in paediatric patients may be due to the high osmolality of the suspension 
pulling in fluid into the gut. Total obstruction of the oesophagus and jejunum due to 
accumulation of oral paste has been described in three adult patients (Smit M,) but 
not in paediatrics to date.
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Antimicrobial resistance
There is an anecdotal report of one centre involved in the de Smet et al. national 
RCT of SDD (de Smet AM) that has since experienced the first serious vancomycin 
resistant enterococcus (VRE) epidemic in their hospital, resulting in temporary 
closure of four ICUs (Meessen N). At Alder Hey the isolation of four plasmid- 
mediated extended-spectrum p-lactamase positive multi-drug resistant (MDR) 
strains was reported from four patients receiving SDD who were not previously 
carriers of these MDR strains prior to their admission to the ICU, which was felt to be 
associated with use of the intravenous cefotaxime component of SDD (Abecasis F).
Adverse effects of the individual components of SDD
Colistin (colistimethate sodium, polymyxin E) oral liquid: No specific adverse effects 
have been documented with enteral colistin. Colistin is not absorbed via the enteral 
route in paediatrics (Martin J). However, it may be absorbed from the gastro­
intestinal tract in infants less than six months old (Kucers'; Martin J). Adverse effects, 
particularly neurotoxicity are more likely with excessive intravenous doses. These 
effects would be unlikely with enteral administration.
Tobramycin base oral liquid: Aminoglycosides are not absorbed from the gut, 
although there is a risk of absorption in patients with inflammatory bowel disease and 
liver impairment (Martin J). High (toxic) serum levels of tobramycin have been 
observed in adult patients receiving SDD who have severe renal impairment 
requiring continuous veno-venous haemofiltration (CWH) (Mol M). Detectable 
serum levels of tobramycin have also been seen in a patient with normal renal 
function with bowel perforation receiving SDD (Posthouwer D). Intravenous 
tobramycin, like any aminoglycoside may cause ototoxicity and nephrotoxicity, and 
may impair neuromuscular transmission, therefore are contraindicated in children 
with myasthenia gravis (Martin J). While no specific adverse effects have been 
attributed to enteral tobramycin in paediatric patients receiving SDD, it would seem 
prudent, in light of enteral absorption seen with gentamicin use in earlier SDD 
paediatric trials (Zobel G) that serum tobramycin levels are monitored particularly if 
renal or liver function is impaired, the patient is on any form of renal replacement
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therapy or if there is any suspicion that the patient may be at risk of increased 
absorption due to gastrointestinal disease. SDD should be avoided in paediatric 
patients with myasthenia gravis.
Amphotericin B oral liquid: Enteral absorption is minimal. Adverse effects include 
rash, glossitis, nausea, vomiting, diarrhoea, irritation of skin and mucous membranes 
and rarely hypersensitivity (Dermapharm AG). Amphotericin B liquid also contains 
parabens, sodium benzoate and sodium metabisulphite, which may cause allergic 
reactions including anaphylaxis and bronchospasm particularly in patients with a 
history of asthma (Dermapharm AG).
Summary
SDD is a well studied prophylactic regimen for preventing nosocomial infections in 
intensive care patients. Evidence from randomized controlled trials and meta­
analyses in critically ill adult patients demonstrates a significant benefit in terms of 
reduction in respiratory tract and blood stream infections and mortality with the use 
of SDD as antibiotic prophylaxis in the setting of intensive care units with a low level 
of endemic antibiotic resistance. SDD is a safe intervention with minimal adverse 
effects. The assertion that development of antimicrobial resistance is a risk with SDD 
is not supported by the current available literature and is thus far limited to anecdotal 
reports and opinion.
Information from studies in adults may be applicable to the paediatric 1CU 
population, which has been shown to follow the same pattern of primary 
endogenous, secondary endogenous and exogenous infection. To achieve a 
significant survival benefit in paediatrics a much larger number of children would 
have to be studied. Despite the small number of paediatric patients in a limited 
number of RCTs there is still a demonstrable reduction in morbidity in children.
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Chapter 4
META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS IN PAEDIATRIC 
PATIENTS
Introduction
There is level 1A evidence that SDD reduces severe infections of lower airways and 
blood and mortality in critically ill adults. However, there are very few randomized 
control trials (RCTs) in critically ill children requiring treatment on a paediatric 
intensive care unit (PICU) and the sample size of the studies are relatively small. 
There are no meta-analyses of SDD in paediatrics.
Since the recent Dutch RCT on selective decontamination of the digestive tract 
(SDD) demonstrated a significant reduction in mortality in critically ill adults in 
intensive care (de Smet AM NEJM 2009) there has been a resurgence of 
interest in the value of SDD. There are now 64 RCTs and 11 meta-analyses 
demonstrating significant reduction in morbidity and more importantly mortality 
in ventilated patients in intensive care.
The use of SDD in paediatrics has been very limited in contrast to the adult 
experience. This is in partly due to the low rates of infection and mortality in the 
general paediatric population. The overall mortality rate in paediatric intensive 
care varies (Sands R) between 5-10% compared to 20-30% in adults. There 
are of course subgroups of children who are at greater risk of infections and 
also death that could benefit from the use of SDD.
A meta analysis was undertaken with the aim of examining the impact of 
selective decontamination of the digestive tract (SDD) on morbidity and 
mortality in critically ill children. MEDLINE, EMBASE, the Cochrane Register of 
Controlled Trials, were searched for previous RCTs and then a meta analysis 
was undertaken comparing administration of enteral antimicrobials in SDD with 
or without a parenteral component, with placebo or standard therapy used in the
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controls. Primary end point was the number of children who acquired 
pneumonia. Secondary end points were number of children with infections and 
overall mortality. Odds ratios were pooled with the random effect model.
Four RCTs including 335 patients were identified. Pneumonia was diagnosed in 
5 of 170 patients (2.9%) for SDD and 16 of 165 patients (9.7%) for controls 
(odds ratio, 0.31; 95% confidence interval, 0.11-0.87; p=0.027). Overall 
mortality for SDD was 13 of 170 (6.7%) vs. control, 11 of 163 (7.6%) 
demonstrating a non-significant reduction in the odds ratio for death (OR 1.18; 
95% confidence interval, 0.50-2.76; p = 0.70). In three studies (n=109), infection 
occurred in 10 of 54 (13%) patients on SDD and 24 of 55 (15.9%) in the 
controls (OR, 0.34; 95% confidence interval, 0.05-2.18; p=0.25). SDD 
significantly reduces the number of children who develop pneumonia.
The participants in this systematic review and meta-analysis include children up 
to the age of sixteen who receive selective decontamination of the digestive 
tract. The reason for undertaking the meta-analysis is to assess the four 
paediatric RCTs with respect to the primary endpoint of pneumonia, the 
secondary endpoint of overall infection and finally overall mortality from in 
RCTs.
Search Strategy
RCTs were obtained by searching Electronic databases EMBASE, MEDLINE, 
with no restriction on language, or gender. Search key words were SDD, 
selective decontamination of the digestive tract, selective bowel 
decontamination, gut decontamination. In addition the authors searched their 
personal archives and published meta-analyses on SDD.
Inclusion and exclusion criteria
Inclusion and exclusion criteria were established before reviewing abstracts and 
articles. All randomized trials comparing enteral administration of the SDD 
antibiotics (oropharyngeal, intestinal, or both), with or without a parenteral 
component, with no treatment or placebo in the controls were included. RCTs 
with usable information by outcome were finally included in the meta-analysis.
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Studies were excluded for the following reasons: (1) non-randomized studies or 
studies with inappropriate design; (2) double publications or studies including 
data extracted from main publication; (3) both study arms received SDD; (4) 
studies including neutropenic, stem cell and bone marrow transplant patients.
Extraction of outcome measures
Three investigators independently retrieved the published findings from each 
study and compared the sets of data. Any disagreement was resolved by 
discussion. The following data were sought for each study and recorded on 
standard collection sheets: specific antimicrobials used and routes; number of 
patients in each arm; number of patients with pneumonia, and infection; number 
of deaths.
Quality Assessment
The quality of each study was assessed with reference to a predefined list of 
seven criteria in a scoring system of 0-14, reported originally by Heyland et al 
(Heyland DK) and modified by Brazzi et at and Silvestri et al (Brazzi L). The 
criteria included randomization, study blinding, patient selection, population 
description, reproducibility, definitions of infection and carriage (Silvestri L JHI 
2007). The assessment was made by three investigators.
Definitions
Pneumonia was defined based on the individual clinical and laboratory criteria 
employed by the authors of the selected RCTs, i.e. fever, increased volume and 
purulence of lower airway secretions, a culture positive for potential pathogens 
in high concentrations (>105 quantitatively or >2+ semi-quantitatively) and the 
presence of a new or evolving pulmonary infiltrate on the chest x-ray (Ruiz M). 
All other infections were defined according to Center Disease Control (CDC) 
criteria (Garner JS).
Mortality was evaluated at hospital discharge if this information was provided, 
otherwise mortality in PiCU was used (Liberati A Cochrane Database 2009).
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Statistical Analysis
The primary endpoint was the number of children developing pneumonia during 
treatment with SDD. Secondary end points were overall infection and mortality. 
We planned a priori the following subgroup analysis of the three endpoints: (a) 
type of regimen used (parenteral plus enteral or enteral only); (b) randomization 
procedures (adequate or inadequate); (c) blinding of patients and caregivers to 
allocated treatment (blinded or unblinded). We hypothesised that the treatment 
effect would be lower with enteral only regimen, in adequate randomisation, and 
in blinded studies. Randomisation was adequate when patients were 
randomized by telephone or a central office. A study was blinded when both 
caregivers and outcome assessors were blinded.
Results are presented as odds ratio (OR) with 95% confidence intervals (Cl) 
using the random effects model. The Cochran Q statistic for heterogeneity was 
used both for the outcome measures and through subgroup analyses. We 
considered heterogeneity to be significant if the P value was <0.10. /2 was also 
evaluated using the formula 100% x (Q-df)/Q where Q is Cochran Q, and df the 
degree of freedom (number of studies -1). Negative values of I2 are equal to 
0%, /2<30% indicates mild heterogeneity and 30-50% moderate and >50% 
severe heterogeneity. Computations were performed using the EasyMA 
software (Cucherat M).
Results
Search findings and characteristics of the studies
The preliminary search identified 152 potentially relevant studies (Figure 4.1). Of 
these studies, 88 were excluded: 64 studies were not randomized, 21 RCTs were 
double publications, and 3 RCTs used SDD in both arms. We identified 64 
potentially appropriate RCTs of whom 60 were excluded because there were not 
performed in children (supplementary material). A final sample of 4 RCTs, which 
enrolled a total of 335 patients (170 SDD, 165 controls), was the basis for the 
systematic review and meta-analysis.
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The four RCTs are described in detail in Table 4.1 (Zobel G; Smith SD; Ruza F; 
Barret JP). The trials include a varied population ranging from severely burned 
paediatric patients, to children in paediatric intensive care units, to children 
undergoing liver transplantation. Quality assessment for all trials resulted in a 
median score of 9.2 (range 8.4 -9.9). Zobel G et al achieved a score 10.3, Smith et 
al 9.7, Ruza et al 7.3 and Barret et al of 8.7. This compares well with previous quality 
assessment of all the SDD meta analyses of adult and paediatric data which 
resulted in a median score of 9.0 (IQR 8-11) (Silvestri L JHI 2007). Leclerc & Noizet 
undertook a systematic review of the four paediatric studies (Leclerc F).
Zobel and colleagues studied 50 children in a cardiac paediatric intensive care unit. 
SDD was given to 25 children in a prospective RCT following surgery in addition to 
the routine antibiotic regimen and 25 children were controls. During the study 
colonisation with Gram-negative microorganisms and yeasts in the oropharynx, and 
digestive and respiratory tracts increased up to 52% in the control group. There was 
no colonisation with these microorganisms in the treatment group. The rates of 
acquired secondary infections in the control and treatment groups were 36% and 
8%, respectively (p<0.025). There were no differences in length of intensive care or
82
Ta
bl
e 
4.
1 Gener
al
 ch
ar
ac
te
ris
tic
s o
f r
an
do
m
iz
ed
 co
nt
ro
lle
d 
tri
al
s o
f s
el
ec
tiv
e 
de
co
nt
am
in
at
io
n u
nd
er
ta
ke
n i
n c
hi
ld
re
n. c0)
E
O)0)
O' o e>
0)> =
(0 o 
D) (0 
O CDz
co
TO
3
Q.
O
Q_
O O
O O Q
Q
0)
c
oa
T3c
HI
O)c
s
c
m
c
3
o
o
T3 p)
CM CO 
IT) CO
CO
c 
o
o 
c
0)
TO3cr
0)
T3<
CM
C
o
Q.
ETO
CTO
CL(/>
CTO
OCO
CO CO
COo TO■c
o
0 -*—* TO O cr 
0 ■a 
<
U (/)
0 0•4-> ■*->
c 2
D CO
3
O
c
o
V) V) V)
COo TOtr
o
0 -*—> TO O cr 
0 ■aTOc
c
TO
CL
CO
c
o>>
E
O
cTO>
c
oTO
ETO
CO CO
□
CO
0
TO
0
TOocr
0■oTOc
oTO
0
Q.
CL
CO
0C
o
■5;
O
T3 CO 
0 0
C iS 
3 CO
SD
D
, e
le
ct
iv
e 
de
co
nt
am
in
at
io
n o
f t
he
 d
ig
es
tiv
e 
tra
ct
; C
, c
on
tro
l; L
O
S,
 le
ng
th
 o
f s
ta
y;
 N
S,
 no
t s
ig
ni
fic
an
t; I
C
U
, in
te
ns
iv
e 
ca
re
 un
it;
 P,
 po
ly
m
yx
in
; C
ol
, 
co
lis
tin
; T
, T
ob
ra
m
yc
in
; A
, A
m
ph
ot
er
ic
in
; N
y,
 N
ys
ta
tin
;0
, o
ro
ph
ar
yn
x;
 I, 
In
te
st
in
e.
mortality. The authors concluded that SDD produced a significant reduction of the 
colonisation rate with Gram-negative bacteria and yeasts in critically ill paediatric 
patients following cardiac surgery and needing intensive care for more than 3 days. 
SDD also significantly reduces the Gram-negative infection rate of the respiratory 
system. However, it did not alter ICU length of stay or mortality rate.
Smith and colleagues undertook the first prospective RCT of short-term SDD in 
children having orthotopic liver transplantation. Oral and nasogastric SDD, in 
addition to routine parenteral antibiotics, was given to 18 children having transplants 
and only routine parenteral antibiotics to the control group of 18. There was no 
difference in the group’s demographics, intensive care or hospital length of stay. 
During the study, 14 Gram-negative infections (intra-abdominal abscess 7, 
septicemia 5, pneumonia 1, urinary tract 1) developed in the 36 patients studied. 
Mortality was not significantly different in the two groups. There were significantly 
fewer patients with Gram-negative infections in the SDD group: 3/18 patients (11%) 
vs. 11/18 patients (50%) in the control group (p< 0.001). There was also significant 
reduction in aerobic Gram-negative flora in the stool and pharynx. The authors 
concluded that short-term postoperative SDD significantly reduces Gram-negative 
infections in children having orthotopic liver transplantation.
In a prospective, randomized, non-blinded and controlled trial Ruza et al studied 
children aged 1 month to 14 years old, who had any manipulation or instrumentation 
such as mechanical ventilation, vascular cannulation, monitoring of intracranial 
pressure, thoracic or abdominal drainage, bladder catheterization, peritoneal 
dialysis, and/or presented a neurological coma during a greater than 3 day stay in a 
tertiary PICU (Ruza F). Over a 2 year period 226 children were included in the study, 
the treatment group comprised 116 patients and the control group, 110 patients. The 
treatment group was given colimicin, tobramycin and nystatin administered orally or 
via nasogastric tube. Using univariate analysis SDD did not significantly reduce the 
incidence of nosocomial infection, the length of stay, or mortality. However, using 
multivariate analysis SDD decreased the incidence of respiratory and urinary tract 
infections, reducing the risk of such infections to 1/5 and 1/3, respectively. Ruza and 
colleagues concluded that SDD was effective in controlling respiratory and urinary 
tract infections in children admitted to the PICU, but it did not reduce the incidence of
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other types of nosocomial infection.
Finally, Barret et al studied 23 children with severe burns (Barret JR) (Table 4.1). 
Following randomisation SDD was given in a double-blinded manner to 11 children 
and 12 received placebo. Both groups received parenteral antibiotics, the SDD 
group also received oral and nasogastric enteral antibiotics including polymyxin E, 
tobramycin and amphotericin B. Demographics, hospital course, microbiology 
results, complications, infectious episodes, and serum levels of lL-1beta, IL-6, IL-10, 
and TNF-alpha were compared. There was a similar incidence of colonization rates 
to the wound, sputum, nasogastric aspirates, and faeces. The incidence of 
pneumonia, sepsis and other complications was also similar in both groups as were 
serum levels of all cytokines studied. The authors noted a significantly higher 
incidence of diarrhoea (p=0.003) in the children who received SDD. They concluded 
that SDD is not effective in decreasing bacterial colonisation and infectious episodes 
in severely burned paediatric patients.
Pneumonia
All four RCTs included 335 patients in total (Figure 4.2). Pneumonia occurred in 5 of 
170 patients (2.9%) of those who received SDD and in 16 of 165 patients (9.7%) in 
the control group. This was a significant reduction in the incidence of pneumonia 
with SDD (OR 0.31; 95% Cl, 0.11-0.87; p = 0.027). Heterogeneity was not observed 
(X2 = 2.51, p = 0.47, /2 = 0) (Table 4.2 and 4.3).
Infection
In three RCTs, including 109 children, infections of various origins were confirmed in 
10 of 54 (13%) children on SDD and in 24 of 55 (15.9%) children in the control 
group. SDD had no impact on general infection rates, with no overall difference 
between the groups (OR, 0.34; 95% Cl 0.05-2.18; p = 0.25) (Table 4.2 and 4.3).
Mortality
The impact of SDD on mortality was analysed in all four studies. Overall mortality for 
those who received SDD versus those who did not was 13 of 170 (6.7%) and 11 of 
163 (7.6%), respectively, demonstrating a non-significant reduction in the odds of 
death (OR 1.18; 95% Cl 0.50-2.76; p = 0.70) (Table 4.2 and 4.3).
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Subgroup analysis
Subgroup analyses of type of SDD regimen, randomisation, and blinding are shown 
in Table 4.4. A significant impact on infections and pneumonia was found with the 
use of the full protocol of parenteral and enteral antimicrobials rather than solely 
enteral antimicrobials. A significant impact on pneumonia and overall infection was 
demonstrated when randomisation was adequate and in unblinded studies. The 
subgroup analyses for mortality were consistent with previous pooled results 
whether the intervention was parenteral/ enteral or enteral, whether the design was 
blinded or not, whether the randomisation process was adequate or not. The Q and 
I2 tests for heterogeneity yielded non-significant results in all comparisons.
Discussion
There are very few paedaitric studies on the use of SDD in critically ill children. 
Although there has been a systematic review of the four studies (Leclerc F), this is the 
first meta-analysis of the currently available RCTs. The numbers of children included 
are relatively small which probably accounts for the lack of significant effect on 
mortality or overall infection. However, even with relatively few numbers there is still a 
significant reduction in pneumonia rates. Using a recognised assessment tool for 
quality of studies included in meta-analyses the four studies resulted in a very 
acceptable median value for quality of studies. Previous studies have demonstrated 
that the infection rate using SDD is very low over a five year period (Sarginson RE).
The finding of this meta analysis in paediatrics is that SDD does not significantly 
reduce overall infections, nor mortality. However, there is a significant impact of SDD 
on reduction of the incidence of pneumonia in critically ill children (OR 0.34 p=0.027). 
Previous reports have demonstrated that the infection rate in children using SDD is 
very low over a four year period (Sarginson RE). Furthermore, on subgroup analysis, 
when the full SDD protocol of enteral plus parenteral antibiotics is used there is 
significant reduction in overall infections (OR 0.13 (0.04-0.40; p<0.001). However, this 
subgroup analysis has to be taken with considerable caution as it involves small 
numbers of patients. The enteral component of SDD when used alone does not have 
an impact.
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All four paediatric RCTs used non-invasive techniques to diagnose pneumonia 
consisting of tracheal aspirate and/or sputum. Invasive diagnosis of pneumonia with 
protected specimen brush or brancheoalveolar lavage following bronchoscopy is 
associated with halving the diagnosis of pneumonia (Cook D). However, invasive 
management does not impact upon mortality (Muscedere J). So using non-invasive 
techniques in paediatric is a good surrogate measure of diagnosing pneumonia.
We raised the question fifteen years ago whether mortality or morbidity was the goal to 
measure quality outcomes against (Petros AJ). Debate has ensued and morbidity is 
certainly now recognised as a valuable endpoint, particularly when it improves quality 
of care for the patient. Given this acknowledgement, the question has to be asked 
whether withholding SDD from critically ill children is now ethically questionable given 
the extensive adult literature (Zandstra DF CC 2010) and now the beginnings of a 
paediatric evidence base albeit limited. The answer must surely be yes. If there is a 
technique or treatment that convincingly demonstrates a reduction in morbidity is it 
unethical to not use it ?
Demonstrating an overall survival benefit with SDD may be very hard to achieve in 
pediatrics as the numbers needed to treat are potentially very large given the low 
mortality rate in pediatric intensive care. A simple sample size calculation assuming a 
5% mortality in the control group looking for a 15% reduction in mortality to 4.25% with 
a 10% Type 1 error or false positive rate and a 10% Type 2 false negative rate, would 
require a sample size in the order of 27,390 children.
Mechanical ventilation can be seen as a measure of disease severity, defining the 
need for complex intensive care. The recent control of hyperglycaemia in paediatric 
intensive care trial (CHiP) (Control of hyperglycaemia in paediaitric intensive care) 
used as the primary outcome the number of days alive and free from mechanical 
ventilation within the 30 days after trial entry. The concept of ventilator free days 
(Vedas) brings together these two outcomes. Schoenfeld et al (Schoenfeld DA) define 
ventilator free days (VFDs) as: VFD=0 if the child dies before 30 days; VDF=(30-x) if 
the child is successfully weaned from ventilator within 30 days (where x is the number 
of days on ventilator) or VFD=0 if the child is ventilated for 30 days or more. The use 
of organ failure free days to determine patient-related morbidity surrogate end-points in
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paediatric trials has been supported by influential paediatric trialists in the current low 
mortality paediatric critical care environment (Curley M). Even for this surrogate 
marker 1,500 children were needed just to be adequately powered to demonstrate a 
difference of two ventilator free days. Death was considered an important outcome but 
the study was not powered to detect a difference in mortality.
Extrapolating from adult data into paediatric practice is generally considered 
inadvisable. However, even if the significant reduction in mortality in adults given SDD 
is to be ignored, the reduction in pneumonia, which parallels the adult observations, 
tantalizingly hints at the possibility of a potential reduction in mortality in paediatrics, if 
studies were to be carried out which were powered adequately with large enough total 
number of children. As this is unlikely to happen the potential benefit of a proven 
maneuver in adults is lost to the paediatric world rendering the paediatric population 
again therapeutic orphans. Until this happens the potential benefit of a proven 
maneuver in adults is lost to the pediatric world rendering the pediatric population 
again therapeutic orphans. It took almost six years from the early suggestions of using 
of inhaled nitric oxide (Bigatello LM) until to a number of RCTs characterized its 
benefits (Roberts JD Jr, Clark RH).
Although disparate and small, the four limited studies performed in children, allow a 
meta-analysis which clearly demonstrates a significant reduction in pneumonia rates. 
SDD significantly reduces the number of children who develop pneumonia. Barret et al 
could not demonstrate any treatment benefit from SDD in children with severe burns 
so at this stage SDD cannot be advocated in this patient population. Furthermore, 
there was no overall reduction in mortality, nor a reduction in overall infection rates, 
probably because of the small sample size.
However, on the evidence presented it may be worth considering the use of SDD in 
certain groups of vulnerable children, such as those with a high risk of mortality score 
or those undergoing solid organ transplantation, whilst awaiting evidence of any 
survival benefit from large multi centre randomized control trials ?
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Table 4.3
Data extracted from four randomized controlled trials of selective digestive 
decontamination in the paediatric population.
Author Patients Patients with
infection
Patients with
pneumonia
Mortality
SDD C SDD C SDD C SDD C
Zobel 25 25 2 10 1 6 3 2
Smith 18 18 3 11* 0 2 2 3
Ruza 116 110 NA NA 3 8 6 5
Barret 11 12 5 3 1 0 2 1
RCTs, randomized controlled trials; OR, odds ratio; Cl, confidence interval; SDD, 
selective digestive decontamination; C control.; NA, not available 
*patients with Gram- negative infections.
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Table 4.4
Meta-analysis of the impact of selective digestive decontamination on secondary 
endpoints.
Outcome RCTs N° of patients N° of patients with
outcome
OR (95 Cl) P ?
SDD C SDD C
Pneumonia 4 170 165 5 16 0.31 (0.11-0.87) 0.027 0%
Infection 3 54 55 10 24 0.34 (0.05-2.18) 0.25 4.7%
Mortality 4 170 165 13 11 1.18 (0.50-2.76) 0.70 0%
RCTs, randomized controlled trials; OR, odds ratio; Cl, confidence interval; SDD, 
selective digestive decontamination; C control. OR less than the unit favors treatment; 
OR above the unit favours controls. I2 test for heterogeneity.
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Figure 4.1
Selection procedure for studies meeting the inclusion criteria.
Potentially relevant studies 
identified and screened for 
retrieval (n=152)
>
Randomized controlled trials 
retrieved for more detailed 
evaluation (n-88)
Potentially appropriate 
randomized controlled trials 
for inclusion (n=64)
Inappropriate design, non-randomized (n=64)
Duplicate publication (n=21)
Both study arms received polymyxin, 
tobramycin and antifungal but evaluated 
another drug (n=3)
Randomized controlled trials not performed in 
children (n=60)
Randomized controlled trials 
included in the systematic 
review (n=4)
Trials withdrawn from specific outcomes only 
when data not available from publication
Randomized controlled trials with usable information by outcome:
- Pneumonia (n=4)
- Overall infections (n=3)
- Mortality (n=4)
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Figure 4.2
Effect of selective decontamination of the digestive tract on pneumonia in children.
T+ T-
Barret
Ruza
Smith
Zobel
Total
Odds ratio
3/116 8/110
5/170 16/165>=0.027
Events/Sizes
100 700
Odds ratio <1 favours treatment; odds ratio > 1 favours control 
T+, selective decontamination group; T-, control group
97
Chapter 5
MORTALITY RATES AND ADMISSION DIAGNOSES FOR CHILDREN ADMITTED 
TO PAEDIATRIC INTENSIVE CARE: A 5-YEAR DATASET
Magnitude of the problem
In this chapter the magnitude of the problem of mortality in PICU is explored. Using 
the PICANet database for admission between 2005-2009 various demographics and 
outcomes have been analysed and are presented, mortality rates are described and 
other relevant variables.
Sarginson reports that the overall mortality rate at AH was 5% for the year 2004. 
However, in a subset of 300 patients requiring PICU for >4 days the mortality 
increased to 10%. Brierley et al reports a mortality rate of 2/30 (6.6%) in PICU rising 
to 5/30 (16.6%) in hospital in severely septic children at GOSH. Sands reports a 
mortality rate of 5% overall over a 10 year period in their PICU. Overall morality rate 
in GOSH in 2007 was reported as 5.5% (Ramnarayan P)
Mortality rates vary according to disease condition. Watson suggests mortality from 
sepsis is 7% - our estimate of severe sepsis-associated deaths represents 7% of all 
deaths in children in 1995.
So mortality rates are higher for specific pathologies. Markovitz BP et al found in a 
group of 6693 children aged 0-17 years with severe sepsis, an overall mortality of 
24% (Markovitz BP). They identified that age, hematologic-oncologic diagnosis, 
case volume, and use of steroids remained independent predictors of mortality in 
multivariable analysis.
Thorburn reported that his group found the mortality from pneumococcal sepsis was 
greater than that form meningococcal sepsis (Thorburn K). Eight (4.3%) children 
died from meningococcal sepsis. The study included 22 children with invasive 
pneumococcal disease (IPD), median age 14 months (interquartile range 3-52),
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median Paediatric Index of Mortality (PIM) 0.051 (0.028-0.066), median length of 
PICU stay 8.5 days (4-13). Four patients died, three (13.5%) attributable to IPD.
Naghib et al also identified the relationship between illness severity and survival in 
children on PICU (Naghib S). The longer children stayed in PICU the higher their 
risk of mortality irrespective of initial cause. In their PICU, 4.4% of the children 
(116/2,607, equal gender, mean age 29 days) had a prolonged stay. Median (range) 
stay was 56 (28-546) days. These children accounted for 3% of total admissions 
and occupied 63% of total admission days. Mortality during admission for this group 
was five times higher (22%) than the average PICU mortality rate of 4.6%. 
Withdrawal or limitation of therapy preceded 70% of deaths.
The aim of this chapter is to explore the incidence of mortality in children requiring 
intensive care. The purpose of this is to determine whether any manoeuvre 
designed to reduce mortality could actually have a significant impact. If mortality 
rates are very low then it may not be possible to demonstrate an impact.
Methods
Data was obtained from the PICANet resource for the years 2004-2008 on all cause 
mortality. All twenty three PICUs in the UK report to PICANet on an annual basis. 
The data is anonymised and an annual report is produced by the Leeds group. 
Following formal request to the PICANet office, the data was sent in an excel 
spreadsheet (Microsoft Office 2007) and analysis of the demographic data and 
statistical analysis performed.
The PICANet data was interrogated and demographic data was extracted (Table 
5.1). Admission and diagnostic data are presented as Read Codes (Table 5.2). 
Read codes are diagnoses coding system used in General Practice in the United 
Kingdom. It supports detailed clinical encoding of multiple patient phenomena 
including: occupation; social circumstances; ethnicity and religion; clinical signs, 
symptoms and observations; laboratory tests and results; diagnoses; diagnostic, 
therapeutic or surgical procedures performed and a variety of administrative items. It 
therefore includes but goes significantly beyond the bounds of a diagnosis coding
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system. These diagnoses were sifted using Microsoft Access and the most frequent 
diagnoses for the major systems are presented in Table 5.3.
Results
Over the five year period 2004-2008, 83,863 children were admitted to 23 PICUs in 
the UK. Boys were more frequently admitted (56.5%) compared to girls (43,3%). 
The average age was 45.8 months (range 0-227). Not surprisingly, there was a 
seasonal variation in admission rates with highest numbers of admissions occurring 
between October and January. The average length of stay was 5.51 days (range 0- 
588) and 72.4% of all admission required mechanical ventilation. There were 
number of routes of admission to the PICU. The most common route of admission 
was an unplanned admission as an emergency from outside the Trust and 
accounted for 54.1% of all admissions; only 54% of those children were intubated 
on admission. Planned admission following elective surgery accounted for 33.6% 
admissions and of those 66.6% were intubated and needed mechanical ventilation.
Within the Read codes, which are defined as A-Z there are numerous sub 
classifications defining virtually every medical diagnosis known. Table 5.4 broadly 
describes the distribution of cases for the major codes. In certain common 
conditions the individual code has been identified and highlighted with the relevant 
clinical diagnosis. For example, in category H the code H0615 for acute bronchiolitis 
due to respiratory syncitial virus reports 1692 incidences during the five year period. 
There were of course more cases than this but they will have been reported 
differently, perhaps as pneumonia or just bronchiolitis with no cause and they will 
have been allocated a different code, for instance the code XSDOK reports just 
bronchiolitis. Similarly, there are no reports of any diseases which fall into category 
O of the Read coding. Code P describes the cardiovascular system and hence there 
are a number of reports.
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Table 5.1 Demographic data of admission 2004-2008.
Total number of admissions 83,863
Gender distribution
Male 47,424 56.5%
Female 36,379 43.4%
Unrecorded/unknown 60 0.07%
Average Age 45.8 months (SD 60.4m) min 0- max 227 months
Annual distribution of admissions
Jan Feb Mar Apr May Jun Jul Aug Sept Oct Nov Dec
7188 6585 7071 6714 6868 6753 6805 6555 6623 7356 7705 7640
Average length of stay 5.51 days (SD 14.98) Min 0 - Max 588
Reasons for admission and intubation rate
Intubation NO YES %
Planned -following surgery 28192 4925 18775 66.6
Unplanned -following surgery 4156 893 1932 46.5
Unplanned other 45358 11214 24545 54.1
Planned other 5997 1669 2485 41.4
Unknown 94 25 32 34.0
Rate of Mechanical ventilation 60742 (72.4%)
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Table 5.2
Most commonly returned Read Codes for primary reason for admission 2004-2008. Every 
medical diagnostic condition has been given a Read code (Bentley T).
Read Code Incidence Sub-category Incidence Description
A 1678 A362 1031
B 839 B640 232
C 976 C101 424
D 351 D1062 106
D113 109
E 25
F 2106 F001 249
F2512 287
G 1364 G55 250
H 6625 H47 496
H0615 1692 Acute bronchiolitis due to respiratory syncytial virus
H061 1154
H33 547
I 0 -
J 1166 J500 161
K 328 K04 177
L 7
M 79
N 360 N373z 245
O 1
P 16539 P51 1643 Discordant ventriculoarterial connection
P510 513 Total great vessel transposition
P511 555 Double outlet right ventricle
P52 1931 Tetralogy of Fallot
P54 2479 Ventricular septal defect
P67 1333 Hypoplastic left heart syndrome
P70 1024 Patent ductus arteriosus
P71 1271 Interrupted aortic arch
Q 1401 Q464 613 Neonatal necrotising enteroco itis
R 45
S 900
T 9
U 64
V 0
W 0
X 48097 XSDOK 1312 Bronchiolitis
XM09V 1985 Respiratory failure
X007B 1731 Status epilepticus
X100E 1236 Pneumonia
X70D3 1007 Acquired scoliosis
X70VZ 1497 Sepsis
X77wc 1352
X77vY 1127 Atrial septal defect
XA003 1169 Injury of head region
Y 38
Z 54
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Table 5.3
Most commonly returned Read Codes for primary reason for admission 2004-2008. Every 
medical diagnostic condition has been given a Read code (Bentley T).
Read
Code Incidence
Sub­
category Incidence Description
A 1678 A362 1031
B 839 B640 232
C 976 C101 424
D 351 D1062 106
D113 109
E 25
F 2106 F001 249
F2512 287
G 1364 G55 250
H 6625 H47 496
H0615 1692 Acute bronchiolitis due to respiraton/ syncytial virus
H061 1154
H33 547
I 0 -
J 1166 J500 161
K 328 K04 177
L 7
M 79
N 360 N373z 245
O 1
P 16539 P51 1643 Discordant ventriculoarterial connection
P510 513 Total great vessel transposition
P511 555 Double outlet right ventricle
P52 1931 Tetralogy of Fallot
P54 2479 Ventricular septal defect
P67 1333 Hypoplastic left heart syndrome
P70 1024 Patent ductus arteriosus
P71 1271 Interrupted aortic arch
Q 1401 Q464 613 Neonatal necrotising enterocolitis
R 45
S 900
T 9
U 64
V 0
w 0
X 48097 XSDOK 1312 Bronchiolitis
XM09V 1985 Respiratory failure
X007B 1731 Status epllepticus
X100E 1236 Pneumonia
X70D3 1007 Acquired scoliosis
X70VZ 1497 Sepsis
X77wc 1352
X77vY 1127 Atrial septal defect
XA003 1169 Injury of head region
Y 38
z 54
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Table 5.3
Top diagnoses for admission for major specialities over the 5 year period.
Surgery
Sepsis
Neurology
Respiratory
Cardiac
0 5 10 15 20 25 30
% Total Admissions
Sifting the PICANet database reveals the systems which present with illness and the 
most common diagnoses within these groups. Table 5.4 shows the twenty most 
common reasons for admission to PICU. The most common reason for admission is 
cardiac and repair of ventricular septal defect the most common cardiac defect. The 
next most common reason for admission is due to respiratory failure, then neurology 
and sepsis with surgery contributing only a small percentage of admissions. Looking 
at individual systems the most frequent diagnoses for admission are listed in Table 
5.5.
Mortality Rates
Mortality rates in the UK for the five year period 2004-2008 were 5.3%, 4.9%, 5.3%, 
4.8% and 4.4% respectively and are shown in Table 6.1. It can be seen that for this 
period the average rate is 4.85%. The average PIM score (see page 132) was
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0.0579 and the average SMR (see page 125) for the whole country was 0.84. As the 
PIM score increases the mortality does too. Those who survived had a SMR of 0.99 
and those who died had an SMR of 0.24. With a PIM of <0.05 the average national 
mortality rate (Table 6.3b) was 2.048%; PIM 0.5-1.0 it was 7.85%; PIM 1.0-15 it was 
9.2%; PIM 1.5-2.0 it was 13.11%; PIM 2.0-2.5 19%; PIM 2.5-3.0 20.4%; 3.0-4.0 
26.0% and greater than 4.0 it was 58% (Table 6.3).
The mortality rates and SMRs (see page 133) for Liverpool and the National 
average were not significantly different for any of the PIM ranges except for PIM 3.0- 
4.0 when significant difference is seen both in mortality rate and SMR for the 5 year 
period. Krueger found, in a post-hoc analysis, a similar effect in adults for mid-range 
Acute Physiology and Chronic Health Evaluation (APACHE)-il scores between 20- 
29 on admission (Kruger WA).
Conclusions
The use of SDD in the whole paediatric ICU population is unlikely to have any 
significant effect on mortality of 5%. It may be more beneficial to target the higher 
risk groups. Those children with high PIM2 scores, or specific pathology groups i.e. 
haematologic-oncologic, those who require steroids, those with severe sepsis. Even 
targeting these heterogeneous groups may not demonstrate a positive effect as the 
numbers needed to show significance may still be too large.
The other option to reducing mortality is to try and influence morbidity. The most 
obvious area to try and influence is that of resistance. Using SDD may reduce the 
resistance profile and may reduce the requirement for long-term antibiotic usage or 
broad spectrum antibiotics. Also by controlling overgrowth other features of super 
infection may be avoided such as line infection and ventilator associated 
pneumonias. All these morbidities have certainly been impacted by SDD in the adult 
world.
There is an impact on mortality using SDD in paediatric intensive care but only in the 
mid-range SMR, and not overall. Extremes of scores are not sensitive enough to 
detect a survival benefit by any intervention. Those with low scores are likely to
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survive anyway and would need large sample size for any trail to show any benefit. 
And those with very high scores are almost invariably going to die whatever 
intervention is used.
Table 5.4
Incidence of top 20 most common primary diagnoses requiring admission to PICU.
Total
Number %
Ventricular septal defect 2479 3.0
Respiratory failure 1985 2.4
Tetralogy of Fallot 1931 2.3
Status epilepticus 1731 2.1
Acute bronchiolitis due to respiratory syncytial virus 1692 2.0
Discordant ventriculoarterial connection 1643 2.0
Sepsis 1497 1.8
Atrioventricular septal defect & common atriovent junction 1352 1.6
Hypoplastic left heart syndrome 1333 1.6
Bronchiolitis 1312 1.6
Aortic coarctation 1251 1.5
Pneumonia 1236 1.5
Injury of head region 1169 1.4
Acute bronchiolitis 1154 1.4
Atrial septal defect 1127 1.3
Meningococcal septicaemia 1031 1.2
Patent ductus arteriosus 1024 1.2
Acquired scoliosis 1007 1.2
Acute lower respiratory tract infection 843 1.0
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Table 5.5
Most frequent diagnoses within individual systems, requiring PICU admission.
Cardiac Incidence % of total
Ventricular septal defect 2479 3.0
Tetralogy of Fallot 1931 2.3
Discordant ventriculoarterial connection 1643 2.0
Atrioventricular septal defect & common atriovent junction 1352 1.6
Hypoplastic left heart syndrome 1333 1.6
Aortic coarctation 1251 1.5
Atrial septal defect 1127 1.3
Patent ductus arteriosus 1024 1.2
Congenital heart disease 567 0.7
Double outlet right ventricle 555 0.7
Total great vessel transposition 513 0.6
Aortic stenosis 493 0.6
Pulmonary atresia with ventricular septal defect 483 0.6
Persistent truncus arteriosus 338 0.4
Subaortic stenosis 284 0.3
Pulmonary valve stenosis 279 0.3
Tricuspid atresia 268 0.3
Cyanotic congenital heart disease NOS 262 0.3
Coarctation of aorta NOS 260 0.3
Cardiomyopathy 250 0.3
Respiratory Incidence % of total
Respiratory failure 1985 2.4
Acute bronchiolitis due to respiratory syncytial virus 1692 2.0
Bronchiolitis 1312 1.6
Pneumonia 1236 1.5
Acute bronchiolitis 1154 1.4
Acute lower respiratory tract infection 843 1.0
Respiratory distress 690 0.8
Asthma 547 0.7
Status asthmaticus 516 0.6
Aspiration pneumonitis 496 0.6
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Neurology Incidence % of total
Status epilepticus 1731 2.1
Injury of head region 1169 1.4
Febrile convulsion 568 0.7
intracranial tumour 555 0.7
Head injury NOS 445 0.5
Seizure 397 0.5
Meningitis 358 0.4
Hydrocephalus 342 0.4
Isolated seizures 316 0.4
Epileptic seizures - clonic 287 0.3
Surgery Incidence % of total
Neonatal necrotising enterocolitis 613 0.7
Gastroschisis 597 0.7
Gastro-oesophageal reflux disease 563 0.7
Kyphoscoliosis or scoliosis NOS 245 0.3
Obstruction of intestine 240 0.3
Hirschsprung's disease 233 0.3
Oesophageal atresia with tracheo-oesophageal fistula 230 0.3
Tracheo-oesophageal fistula 209 0.3
Cleft palate 204 0.2
Idiopathic scoliosis 202 0.2
Diaphragmatic hernia 189 0.2
Adolescent idiopathic scoliosis 171 0.2
Intussusception 161 0.2
Malrotation of intestine 155 0.2
Duodenal atresia 152 0.2
Congenital omphalocele 142 0.2
Imperforate anus 123 0.1
Oesophageal atresia 123 0.1
Nephroblastoma 113 0.1
Sepsis Incidence % of total
Sepsis 1497 1.8
Meningococcal septicaemia 1031 1.2
Septic shock 296 0.4
Septicaemia 170 0.20
Meningococcal meningitis with meningococcal septicaemia 37 0.04
Sepsis syndrome 34 0.04
Gp A streptococcal septicaemia 26 0.03
Meningococcal infection 22 0.03
Necrotising fasciitis 22 0.03
Bacterial endocarditis 14 0.02
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Chapter 6
MORTALITY RATES AT ALDER HEY CHILDREN’S HOSPITAL VERSUS THE 
OVERALL UK PICU RATE AS REPORTED TO THE PAEDAITRIC INTENSIVE 
CARE NETWORK.
The Royal Liverpool Children's Hospital has been using SDD on their PICU since 
1992. The mortality rate reported in 2005 by Sarginson was relatively low at 5%. One 
might expect the use of SDD to affect the mortality rates reported to PICANet for 
Alder Hey compared to the UK average.
Methods
Using the PICANet database the mortality rate for 5 years from 2004-2008 was 
analysed to see if there were any differences in mortality rates between Alder Hey 
and the rest of the UK. Simple statistical analyses were used, including comparison 
of averages and ANOVAs.
The Paediatric Index of Mortality was designed to provide a predicted mortality for a 
patient by following a well-defined algorithm. Predicted mortalities are good when 
dealing with several patients, because the average predicted mortality for a group of 
patients is an indicator for the morbidity of these patients (Slater A). So PIM is a 
scoring system for rating the severity of medical illness for children. PIM2 was 
subsequently described as a refinement on PIM and provides a good way to 
benchmark different sets of patients.
The standardised mortality ratio (SMR) is the ratio of observed deaths to expected 
deaths, where expected deaths are calculated from PIM or PIM2 for a typical sub-set 
with the same age and gender mix by looking at the death rates for different ages 
and genders in the larger population. The SMR may be quoted as either a ratio or a 
percentage. If the SMR is quoted as a ratio and is equal to 1.0, then this means the
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number of observed deaths equals that of expected cases. If higher than 1.0, then 
there is a higher number of deaths than is expected.
Results
83,863 children were admitted during the 5-year period between 2004 and 2008 
throughout the UK with an overall mortality rate of 4.85 % (Table 6.1). The severity of 
illness as measured by the RIM score was 0.0579. At Alder Hey 5369 children were 
admitted during this period with a mortality of 5.34% and a RIM score of 0.0532. The 
standardised mortality rate (SMR) derived from RIM for the UK was 0.8376 and for 
Alder Hey 1.0049. A more detailed look into the annual rates revealed a similar 
trend. From 2006 onwards P1M2 was introduced and reported. As described above 
SMR is calculated by dividing the expected mortality rate by the observed mortality 
rate. The expected rate is derived from the RIM and PIM2 scores.
As would be expected those children who survive in AH had on average a 
statistically significant lower RIM score 0.0463 compared to those who do not survive 
0.170 (p=0.009) and SMR of 1.165 vs. 0.33 (p=0.008) (Table 6.2). The PIM2 score 
for those children who survive was 0.042 vs. 0.217 for those who died. The SMR for 
the former was 1.156 vs. 0.225 or a 75% risk of mortality. A similar pattern is seen 
nationally (Table 6.2).
In those children with a risk of mortality of 5% or less, the point has already been 
made that no therapy is likely to reduce the mortality rate significantly. To explore the 
possibility that SDD is more effective in the higher risk groups the overall data was 
stratified into different RIM groups (Table 6.3). Ranges used were <0.05; 0.05-1.0; 
1.0-1.5; 1.5-2.0; 2.0-3.0; 3.0-4.0; >4.0.
There was no significant difference between the UK population and the AH subset in 
all but the 3-4.0 RIM risk group (p=0.04, n=191 vs. 12) (Table 6.4). Again the number 
of patients in each group are relatively small for the AH subset and to detect a 
difference a larger sample size would be needed.
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Conclusions
The simplest conclusion that can be drawn from the data is that SDD does not have 
a significant impact on reducing mortality in critically ill children. However, this may 
be too simplistic. Other factors have to be taken into consideration. Sample size in 
particular. With the overall PICANet dataset it was not possible to extract any 
information on morbidity or infection rates, so other reported beneficial aspects of 
SDD could not be considered.
Although the number of children admitted to AH was 5369 the death rate was still on 
average 5.34%. The mortality rate for the PIM > 4 group was 0.735 or a 73.5% risk 
of death. However the numbers in this group was only n=34.
Similarly the only statistically significant difference observed was in the PIM 3-4 
group which had the lowest number of patients and statistical testing is really not 
very useful.
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Table 6.4 Mortality rates and SMRs for various RIM ranges with significance levels. 
There was no significant difference between the UK population and the AH subset in all 
but the 3-4.0 RIM risk group (p=0.04, n=191 vs. 12).
Mortality
Rates
RIM
<0.5
RIM
0.5-1
RIM
1.0-1.5
RIM
1.5-2
RIM
2.0-3.0
RIM
3.0-4.0
RIM
>4.0
Liverpool 2.3 7.2 14.1 11.5 19.0 42.9 63.0
GOSH 2.8 8.6 11.4 17.6 23.9 31.8 59.2
National 2.0 7.9 9.2 13.1 20.4 26.0 58.0
P 0.09 0.68 0.18 0.48 0.91 0.05 0.58
SMRs
RIM
<0.5
RIM
0.5-1
RIM
1.0-1.5
RIM
1.5-2
RIM
2-3.0
RIM
3.0-4.0
RIM
>4.0
Liverpool 0.78 1.04 1.14 0.66 0.79 1.25 0.90
GOSH 1.00 1.18 0.76 1.02 0.99 0.92 0.84
National 0.73 1.07 0.74 0.76 0.85 0.76 0.79
P 0.45 0.82 0.19 0.47 0.93 0.04 0.57
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Chapter 7
CONCLUSIONS
Can SDD reduce infection morbidity in paediatric intensive care?
The major difference between paediatric and adult intensive care is the mortality 
rate. Adults have in the past had a mortality rate approaching 30%. In the early days 
of adult ICU the rate for sepsis was as high as 80%. More recently, the overall rate 
has decreased to around 20%. This is still much higher than for paediatrics. The 
overall mortality rate as reported to PICANet is around 5.0% nationwide when 
adjusted for severity of illness the risk of mortality is very low compared to adults.
The causes for death also are different from those in adults. There are a larger 
proportion of deaths as a result of withdrawal of therapy as a consequence of 
incurable background pathology (Sands R). A recent retrospective study reported the 
characteristics of death in a single PICU over a 10 year period (Sands R). The 
morality rate was 5.1% and comprised of 204 children. The authors found that the 
most common cause of death in that particular tertiary unit was managed withdrawal 
of life-sustaining medical therapy. This mode of death was attributed to 54.9% of all 
deaths over the 10 year period.
The data presented by Sands and colleagues is useful in that it is the result of a 
single centre in which patient notes can by checked for accuracy of diagnosis of 
death. The numbers were sufficiently small enough to allow this validation. Only 204 
case notes would have to have been reviewed. However, it is not clear whether this 
single center study reflects the pattern of death throughout the country.
The causes of death are described in the UK for children admitted to PICU to be able 
to compare them with those in adults. There are very few reports describing the 
causes of death of children on PICU. The difficulty of obtaining the cause of death is 
that it is often influenced by decisions to withdraw treatment in a number of non-
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viable cardiac or metabolic conditions. Also the reliability of the description of the 
cause of death can be questioned. Admission data however is collected according to 
recognised coding systems and it could be argued is more useful in giving an idea of 
the distribution of diseases within organ systems, particularly in the paediatric world 
since the introduction of the PICANet database.
Consequently, the impact of SDD on the all cause mortality is limited as the illness 
profile for children and adults is different. If mortality does not result from a 
pneumonic or septic process in equal proportion to adult the SDD is unlikely to 
produce a similar reduction in either as seen in the adult ICU world.
However, other measures of effectiveness and reduction of morbidity may confirm 
SDD’s usefulness. Recently, the use of antibiotics on neonates have been shown to 
result in multiresistant Enterobacteriaceae strains which were found at high 
frequency in the infants during their stay in the NICU and persisted in a proportion of 
infants (Millar LM). By reducing the amount of parenteral antibiotics used SDD may 
have an impact on this increasing incidence of resistance.
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Selective decontamination of the digestive tract in critically ill 
children: Systematic review and meta-analysis
Andy Petros, FRCP; Luciano Silvestri, MD; Rachelle Booth, FPharm; Nia Taylor;
Hendrick van Saene, MD, PhD
Objective: We examined the impact of selective decontamina­
tion of the digestive tract on morbidity and mortality in critically 
III children.
Data Sources: We searched MEDLINE, EMBASE, the Cochrane 
Register of-Controlled Trials, and previous meta-analyses.
Study Selection: We included all randomized controlled trials 
comparing administration of enteral antimicrobials in selective 
decontamination of the digestive tract with or without a paren­
teral component with placebo or standard therapy used in the 
controls.
Data Extraction: The primary end point was the number of 
acquired pneumonias. Secondary end points were number of 
infections and overall mortality. Odds ratios were pooled with the 
random effect model. .
Data Synthesis: Four randomized controlled trials including 
335 patients were identified. Pneumonia was diagnosed in five of
170 patients (2.9%) for selective decontamination of the digestive 
tract and 16 of 165 patients (9,7%) for controls (odds ratio [OR], 
0.31; 95% confidence interval [Cl], 0.11-'0.87; p - .027). Overall 
mortality for selective decontamination of the digestive tract was 
13 of 170 (7.6%) vs, control, 11 of 165 (6.7%) (OR, 1.18; 95% Cl, 
0.50-2.76; p = .70). In three studies (n = 109), infection occurred 
in ten of 54 (18,5%) patients on selective decontamination of the 
digestive tract and 24 of 55 (43.6%) in the controls (OR, 0.34; 95% 
Cl, 0.05-2.18; p = .25).
Conclusions: In the four available pediatric randomized con­
trolled trials, selective decontamination of the digestive tract 
significantly reduced the number of children who developed 
pneumonia, (Pediatr Grit Care Med 2012; 13:000-000)
Key Words; critically ill children; Infection; mortality; pediatric; 
pneumonia; randomized controlled trial (ROT); selective decon­
tamination of the digestive tract (SDD)
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S
ince the recent randomized 
controlled trial (RCT) on selec­
tive decontamination of the di­
gestive tract (SDD) demon­
strated a significant reduction in mortality 
In critically ill adults in intensive care (1), 
there has been a resurgence of interest in 
tire value of SDD.
Nosocomial infection is associated with 
changes in the gut flora and critical illness 
profoundly changes body flora, both quali­
tatively and quantitatively (2), and pro­
motes a shift from 1) normal (3) to abnor­
mal carriage (4, 5) and 2) low- to high- 
grade carriage or gut overgrowth (6).
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There are now 65 RCTs and 11 meta­
analyses demonstrating a significant reduc­
tion in nosocomial pneumonia morbidity 
and more importantly mortality in adult 
venti ated patients in intensive care.
We reviewed all RCTs performed in 
children to determine whether SDD is 
also effective in children. The use of SDD 
in pediatrics has been very limited in 
contrast to the adult experience. This is 
in part the result of the low rates of 
infection and mortality in the general pe­
diatric population. The overall mortality 
rate in pediatric intensive care varies be­
tween 5% and 10% (7). Total inhouse 
mortality (3.74%) can differ a little from 
outside admissions mortality (3.94%) (8). 
Crude mortality rates from the Australian 
and New Zealand 2009 census reported a 
rate of 2.9% (9). These are low rates com­
pared with the 20% to 30% in adults. 
There are of course subgroups of children 
who are at greater risk of infections and 
also death that might benefit from the 
use of SDD.
The participants in this systematic re­
view and meta-analysis include children 
up to the age of 16 yrs who received 
selective decontamination of the diges­
tive tract. The reason for undertaking the
meta-analysis was to assess the four pe­
diatric trials with respect to the primary 
end point of pneumonia, the secondary 
end point of overall infection, and finally 
overall mortality from the available RCTs,
Data Sources
Search Strategy. RCTs were ob­
tained by searching electronic databases 
EMBASE and MEDLINE with no restric­
tion on language or gender. Search key 
words were SDD, selective decontamina­
tion of the digestive tract, selective bowel 
decontamination, and gut decontamina­
tion. In addition, the authors searched 
their personal archives and published 
meta-analyses on SDD.
Inclusion and Exclusion Criteria, We 
established inclusion and exclusion crite­
ria before reviewing abstracts and arti­
cles. We included all RCTs comparing 
enteral administration of the SDD antibi­
otics (oropharyngeal, intestinal, or both) 
with or without a parenteral component 
with no treatment or placebo in the con­
trols. RCTs with usable information by 
outcome were finally included in the 
meta-analysis. Studies were excluded for 
the following reasons: 1) nonrandomized 
studies or studies with an inappropriate
Pediatr Grit Care Med 2012 Voi. 13, No. 5
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design; 2) double publications or studies 
including data extracted from main pub­
lication; 3) both study arms received 
SDD; and 4) studies including neutro­
penic, stem cell, and bone marrow trans­
plant patients.
Data Extraction of Outcome 
Measures
Three investigators (AP, LS, HvS) in­
dependently retrieved the published find­
ings from each study and compared the 
sets of data. Any disagreement was re­
solved by discussion. The following data 
were sought for each study and recorded 
on standard collection sheets: specific an­
timicrobials used and routes; number of 
patients in each arm; number of patients 
with pneumonia and infection; and num­
ber of deaths.
Quality Assessment
The quality of each study was assessed 
with reference to a predefined list of seven 
criteria in a scoring system of 0-14 re­
ported originally by Heyland et al (10) and 
modified by Brazzi et al (11) and Silvestri et 
al (12). The criteria used here included ran­
domization, study blinding, patient selec­
tion, population description, reproducibil­
ity, definitions of infection, and carriage 
(12). The assessment was made by three 
investigators, (AP, LS, HvS).
Definitions
Pneumonia was defined based on the 
individual clinical and laboratory criteria 
used by the authors of the selected RCTs, 
i.e., fever, increased volume and puru- 
lence of lower airway secretions, a cul­
ture positive for potential pathogens in 
high concentrations (sdO5 quantitatively 
or S2+ semiquantitatively), and the 
presence of a new or evolving pulmonary 
infiltrate on the chest radiograph (13).
All other infections were defined ac­
cording to Centers for Disease Control 
and Prevention criteria (13).
Statistical Analysis
The primary end point was the num­
ber of children developing pneumonia 
during treatment with SDD. Secondary 
end points were overall infection and 
mortality, We planned a priori the follow­
ing subgroup analysis of the three end 
points: 1) type of regimen used (parenteral 
plus enteral or enteral only); 2) randomiza­
tion procedures (adequate or inadequate);
and 3) blinding of patients and caregivers to 
allocated treatment (blinded or unblinded). 
We hypothesized that the treatment effect 
would be lower with enteral only regimen, 
in adequate randomization, and in blinded 
studies. Randomization was adequate when 
patients were randomized by telephone or a 
centra] office. A study was blinded when 
both caregivers and outcome assessors 
were blinded.
Checking for heterogeneity across 
studies and random-effects meta-analysis 
were undertaken (14). Results are pre­
sented as odds ratio (ORs) with 95% confi­
dence intervals (CIs) using the random ef­
fects model. The Cochran Q statistic for 
heterogeneity was used both for the out­
come measures and through subgroup 
analyses; we considered heterogeneity to be 
significant if the p value was <,10. f was 
also evaluated using the formula 100% X 
{Q~df)/Q where Q is Cochran Q and df the 
degree of freedom (number of studies-1). 
Negative values of i2 are equal to 0%. i2 
<30% indicates mild heterogeneity and 
30% to 50% moderate and >50% severe 
heterogeneity. Computations were per­
formed using EasyMA software (15).
Data Synthesis
Search Findings and Characteristics 
of the Studies. The preliminary search
Randomized controlled trials 
included in the systematic 
review
Potentially appropriate 
randomized controlled trials 
for Inclusion (n=t>-l)
Potentially relevant studies 
idoniiiied and screened for 
retrieval (n=152|
Randomized controlled trials 
relrloved for more detailed 
evaluation (n-88)
identified 153 potentially relevant studies 
(Fig. 1). Of these studies, 88 were ex­
cluded: 64 studies were not randomized, 
21 RCTs were double publications, and 
three RCTs used SDD in both arms. We 
identified 65 potentially appropriate RCTs 
of whom 61 were excluded because they 
were not performed in children. A final 
sample of only four RCTs, which enrolled 
a total of 335 patients (170 SDD, 165 
controls), was the basis for the systematic 
review and meta-analysis. One of the four 
studies was in burn patients only and two 
of the others were also special popula­
tions, cardiac, and liver transplant. How­
ever, these are the only four from which 
some impression of efficacy may be 
gained (Table 1).
Leclerc and Noizet (16) undertook a 
systematic review of the four pediatric 
studies in 2004 but did not undertake a 
meta analysis of the data they described. 
We go further and describe the four RCTs 
(17-20) in terms of quality on a previ­
ously devised score. The trials include a 
varied population ranging from severely 
burned pediatric patients, to children in 
pediatric intensive care units, to children 
undergoing liver transplantation. Quality 
assessment for all trials using the meth­
ods described by Heyland (9), Brazzi (10), 
and Silvestri (11) resulted in a median
I Inappropriate design, noit-rendomizedfii^Sri)
Duplicate puMcslion or data extracted and 
complemented min publication (0=21)
Belli study arms received polymixin. 
tobramycin and anlilungal but evaluated 
onother drug (rm3)
Randomized controlled trials not performed in 
children (n=60)
Trials wilhdrawn from specllic outcomes only 
whon data not available from publication
Randomized controlled trials with usable information by outcome:
- Pneumonia (n=4)
- Overall Infections (n=3)
- Mortality ln=4)
Figure 1. Selection procedure for studies meeting the inclusion criteria.
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Table 1. General characteristics of randomized controlled trials of selective decontamination undertaken in children
Outcome
Selective Aerobic
Decontamination Regimen Gram-
Author First End of the Digestive Enteral Negative
(Reference) Year Country No. Blinding Randomization Point Traci vs. Control Population Parenteral Bacilli Yeasts Site
Zobel 
et al (17)
1991 Austria 50 No Adequate Colonization 
Infection rates
0% vs. 52%
8% vs. 36%
Cardiac surgery Cefotaxime P, T A 0,1
Smith 
et al (18)
1993 United
States
36 No Adequate Infection rates 
Length of stay 
Mortality
11% vs. 50%
7 days vs. 8 days 
vs. 23%
Liver transplants Cefotaxime/
ampieilliin
2 arms
P, T A 0,1
Ruza 
el al (19)
1998 Spain 226 No Inadequate infection rates 
Length of stay 
Mortality
39% vs. 38%
10.4 days vs. 9.G days 
4.5% vs. 5.2%
Invasive
instrumentation 
on intensive 
care unit
None Col.T Ny -,I
Barrel 
et al (20)
2001 United
States
23 Yes Inadequate Infection rates 
Mortality
25 vs. 45%
8% vs. 18%
Severe burns Vancomycin,
amikacin,
piperacillin
P, T A I
P, polymyxin; T, tobramycin; Col, colistin; A, amphotericin; Ny, nystatin; 0, oropharynx; I, intestine.
score of 9.2 (range, 8.4-9.9), This com­
pares well with previous quality assess­
ment of all the SDD meta-analyses of 
adult and pediatric data, which resulted 
in a median score of 9.0 (interquartile 
range, 8-11) (11). Zobel et al (17) re­
ceived a score of 10.3, Smith et al 9,7 
(18), Ruza et al (19) 7.3, and Barret et al 
(20) achieved a score of 8.7.
Zobel and colleagues (17) studied 50 
children in a cardiac pediatric intensive 
care unit. All patients were endotracheally 
intubated and mechanically ventilated. 
SDD was given to 25 children in a prospec­
tive RCT after cardiac surgery in addition to 
the routine antibiotic regimen and 25 chil­
dren were controls. During the study, col­
onization with Gram-negative micro­
organisms and yeasts in the oropharynx 
and digestive and respiratory tracts in­
creased up to 52% in the control group. 
There was no colonization with these mi­
cro-organisms in the treatment group. The 
rates of acquired secondary infections in 
the control and treatment groups were 
36% and 8%, respectively ip < .025), There 
were no differences in length of intensive 
care or mortality. The authors concluded 
that SDD produced a significant reduction 
of the colonization rate with Gram-nega­
tive bacteria and yeasts in critically ill pe­
diatric patients after cardiac surgery and 
needing intensive care for >3 days, SDD 
also significantly reduces the Gram-nega­
tive infection rate of the respiratory system, 
However, it did not alter intensive care unit 
length of stay or mortality rate.
Smith and colleagues (18) undertook 
the first prospective RCT of short-term 
SDD in children having ortho topic liver 
transplantation. Although not specifically
documenting that all the children were 
ventilated, because the patients were liver 
transplants admitted to the intensive care 
unit postoperatively, it was assumed both 
groups were ventilated. Oral and nasogas­
tric SDD, in addition to routine paren­
teral antibiotics, was given to 18 children 
having transplants and only routine par­
enteral antibiotics to the control group of 
18. There was no difference in the group’s 
demographics, intensive care, or hospital 
length of stay. During the study, 14 
Gram-negative infections (intra-abdomi­
nal abscess, seven; septicemia, five; pneu­
monia, one; urinary tract, one) developed 
in the 36 patients studied. Mortality was 
not significantly different in the two 
groups. There were significantly fewer 
patients with Gram-negative infections in 
the SDD group: three of 18 patients 
(11%) vs. 11 of 18 patients (50%) in the 
control group {p < .001), There was also 
significant reduction in aerobic Gram­
negative flora in the stool and pharynx. 
The authors concluded that short-term 
postoperative SDD significantly reduces 
Gram-negative infections in children 
having orthotopic liver transplantation.
In a prospective, randomized, non- 
blinded and controlled trial, Ruza et al
(18) studied children aged 1 month to 14 
yrs who had any manipulation or instru­
mentation such as mechanical ventila­
tion, vascular cannulation, monitoring of 
intracranial pressure, thoracic or abdom­
inal drainage, bladder catheterization, 
peritoneal dialysis, and/or presented a 
neurologic coma during a >3-day stay in 
a tertiary pediatric intensive care unit
(19) . Over a 2-yr period, 226 children 
were included in the study, the treatment
group comprised 116 patients and the 
control group 110 patients. A total of 164 
(73%) children were ventilated, 91 
(55.5%) receiving SDD and 73 (44.5%) in 
the control group ip < .05). The treat­
ment group was given colimycin, tobra­
mycin, and nystatin administered orally 
or through a nasogastric tube, whereas 
no oropharyngeal decontamination was 
implemented. Using univariate analysis, 
SDD did not significantly reduce the in­
cidence of nosocomial infection, the 
length of stay, or mortality. However, us­
ing multivariate analysis, SDD decreased 
the incidence of respiratory and urinary 
tract infections, reducing the risk of such 
infections to one of five and one of three, 
respectively. Ruza and colleagues (19) 
concluded that SDD was effective in con­
trolling respiratory and urinary tract in­
fections in children admitted to the pedi­
atric intensive care unit, but it did not 
reduce the incidence of other types of 
nosocomial infection.
Finally, Barret et al (20) studied 23 
children with severe burns (Table 1). Af­
ter randomization, SDD was given in a 
double-blind manner to 11 children and 
12 received placebo, The control group 
received mechanical ventilation for 8 ± 2 
days and the SDD group for 14 ± 5 days 
with no significant difference. Both 
groups received parenteral antibiotics; 
the SDD group also received oral and 
nasogastric enteral antibiotics including 
polymyxin E, tobramycin, and amphoter­
icin B. Demographics, hospital course, 
microbiology results, complications, in­
fectious episodes, and serum levels of in­
terleukin-1 p, interleukin-6, interleukin- 
10, and tumor necrosis factor-a were
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compared. There was a similar incidence 
of colonization rates to the wound, spu^ 
turn, nasogastric aspirates, and feces. The 
incidence of pneumonia, sepsis, and 
other complications was also similar in 
both groups as were serum levels of all 
cytokines studied. The authors noted a 
significantly higher incidence of diarrhea 
(p — .003) in the children who received 
SDD. They concluded that SDD is not 
effective in decreasing bacterial coloniza­
tion and infectious episodes in severely 
burned pediatric patients.
Pneumonia
All four RCTs included 335 patients in 
total (Fig, 2). Pneumonia occurred in five 
of 170 patients (2.9%) of those who re­
ceived SDD and in 16 of 165 patients 
(9.7%) in the control group. This was a 
significant reduction in the incidence of 
pneumonia with SDD (OR, 0.31; 95% Cl, 
0.11-0.87; p = .027). Heterogeneity was 
not observed (chi square = 2.51, p = .47, 
/3 = 0) (Tables 2 and 3).
infection
In three RCTs, including 109 children, 
infections of various origins were con-, 
firmed in ten of 54 (18.5%) children on 
SDD and in 24 of 55 (43.6%) children in 
the control group. SDD had no impact on 
general infection rates with no overall dif­
ference between the groups (OR, 0.34; 95% 
Cl, 0.05-2.18; p = .25) (Tables 2 and 3).
Mortality
The impact of SDD on mortality was 
analyzed in all four studies. Overall mor­
tality for those who received SDD vs. 
those who did not was 13 of 170 (7.6%) 
and 11 of 165 (6.7%), respectively, dem­
onstrating no reduction in the odds of 
death (OR, 1.18; 95% Cl, 0.50-2.76; p = 
.70) (Tables 2 and 3).
Subgroup Analysis
Subgroup analyses of type of SDD reg­
imen, randomization, and blinding are 
shown in Table 4. A significant impact on 
infections and pneumonia was found with 
the use of the full protocol of parenteral 
and enteral antimicrobials rather than 
solely enteral antimicrobials. A signifi­
cant impact on pneumonia and overall 
infection was demonstrated when ran­
domization was adequate and in un- 
blinded studies. The subgroup analyses 
for mortality were consistent with previ­
T+ T-
Smlift
Odds ratio 100 700
Figure 2, Effect of selective decontamination of the digestive tract on pneumonia.
Table 2. Data extracted from four randomized controlled trials of selective digestive decontamination 
in pediatric population
Author
Patients
Patients With 
Infection
Patients With 
Pneumonia Mortality
SDD C SDD C SDD C SDD C
Zobel 25 25 2 10 1 6 3 2
Smith 18 18 3 ir 0 2 2 3
Ruza 116 110 NA NA 3 8 6 5
Barret 11 12 5 3 1 0 2 1
SDD, selective digestive decontamination; C, control; NA, not available. 
“Patients with Gram-negative infections.
ous pooled results whether the interven­
tion was parenteral/enteral or enteral, 
whether the design was blinded or not, 
and whether the randomization process 
was adequate or not. The Q and i2 tests 
for heterogeneity yielded nonsignificant 
results in all comparisons.
DISCUSSION
There are very few pediatric studies on 
the use of SDD in critically ill children. 
Although there has been a systematic re­
view of the four studies (16), this is the 
first meta-analysis of these currently 
available RCTs. The numbers of children 
included are relatively small, which prob­
ably accounts for the lack of significant 
effect on mortality or overall infection. 
However, even with relatively few num­
bers, there is still a significant reduction 
in pneumonia rates. Using a recognized 
assessment tool for quality of studies in­
cluded in meta-analyses, the four studies 
resulted in a very acceptable median 
value for quality of the studies.
The new finding of this meta-analysis 
in pediatrics is that SDD does not signif­
icantly reduce overall infections nor mor­
tality. However, there is a significant im­
pact of SDD on reduction of the incidence 
of pneumonia in critically ill children 
(OR, 0.34; p = .027). Previous reports 
have demonstrated that the infection rate 
in children using SDD is very low over a 
4-yr period (21).
Furthermore, on subgroup analysis, 
when the full SDD protocol of enteral 
plus parenteral antibiotics is used, there 
is significant reduction in overall infec­
tions (OR, 0.13 [0.04-0.40]; p < .001). 
However, this subgroup analysis has to be 
taken with considerable caution because 
it involves small numbers of patients. The 
enteral component of SDD when used 
alone does not have an impact.
Because invasive mechanical ventilation 
is a major risk factor for nosocomial pneu­
monia, it is important to note that in the 
Zobel et al (17), Smith etal (18), and Barret 
et al (20) studies, all patients were venti­
lated and in the Ruza et al (19) study, 73% 
of the study was ventilated equally distrib­
uted. All four pediatric RCTs used noninva- 
sive techniques to diagnose pneumonia 
consisting of tracheal aspirate and/or spu­
tum. Invasive diagnosis of pneumonia with 
a protected specimen brush or bronchoaf- 
veoiar lavage after bronchoscopy is associ-
4 Pediatr Grit Care Med 2012 Vol. 13, No. 5
balt5/zK8-pcc/zR8-pccfck899911/ZK84138-12z | xppws S~1 12/6/11 12:31 Art: 201136 [ Input-lh
Table 3. Meta-analysis of the impact of selective digestive decontamination on secondary end points
No. of Patients
No. of Patients With Outcome
Outcome
Randomized 
Controlled Trials
Selective Digestive 
Decontamination Control
Selective Digestive 
Decontamination Control
Odds Ratio 
{95% Confidence 
Interval) > P
Pneumonia 4 170 165 5 16 0.31 (0,11-0.87) .027 0%
Infection 3 54 55 10 24 0.34 (0.05-2.18) .25 4.7%
Mortality 4 170 165 13 11 1.18 (0.50-2.76) .70 0%
Odds ratio less than the unit favors treatment; odds ratio above the unit favors controls.
Table 4. Subgroup analysis of the impact of selective digestive decontamination on the end points of pneumonia, infection, and mortality
No. of Patients No. of Events
Odds Ratio 
(95% Confidence 
Interval)End Points
No. of Randomized 
Controlled Trials
Selective Digestive 
Decontamination Control
Selective Digestive 
Decontamination Control P
Pneumonia
Parenteral plus enteral 2 43 43 1 8 0.14 (0,02-0.89) .037
Enteral only 2 127 122 4 8 0.65 (0,07-6.34) .71
Randomization adequate 2 43 43 1 8 0.14 (0.02-0.89) .037
Randomization inadequate 2 127 122 4 8 0.65 (0.07-6.34) .71
Blinded 1 11 12 1 0 5.97 (0.07-471.43) NE
Not blinded 3 159 153 4 16 0,26 (0,09-0.76) .013
Infections
Parenteral plus enteral 2 43 43 5 21 0.13 (0.04-0.40) <.001
Enteral only 1 11 12 5 3 2.50 (0,43-14.61) NE
Randomization adequate 2 43 43 5 21 0.13 (0.04-0-40) <.001
Randomization inadequate 1 11 12 5 3 2,50 (0.43-14.61) NE
Blinded 1 11 12 5 3 2.50 (0.43-14.61) NE
Not blinded 2 43 43 5 21 0.13 (0.04-0.40) <.001
Mortality
Parenteral plus enteral 2 43 43 5 5 1 (0.26-3.84) 1
Enteral only 2 127 122 8 6 1.32 (0.44-3.95) .62
Randomization adequate 2 43 43 5 5 1 (0.26-3.84) 1
Randomization inadequate 2 127 122 8 6 1.32 (0.44-3.95) .62
Blinded I 11 12 2 1 2.44 (0.19-31-54) NE
Not blinded 3 159 153 11 10 1.08 (0.44-2.66) .87
NE, not evaluated as only one study was included.
The Q and P tests for heterogeneity were not significant in all comparisons. Odds ratio <1 favors treatment; odds ratio >1 favors controls.
ated with halving the diagnosis of pneumo­
nia (22). However, invasive management 
does not impact on mortality (23). So using 
noninvasive techniques in pediatric is a 
good surrogate measure of diagnosing 
pneumonia.
We raised the question 15 yrs ago 
whether mortality or morbidity was the 
goal to measure quality outcomes against 
(24). Debate has ensued and morbidity is 
certainly now recognized as a valuable 
end point, particularly when it improves 
quality of care for the patient, Given this 
acknowledgment, the question has to be 
asked whether withholding SDD from 
critically ill children is now justifiable 
given the extensive adult literature (25) 
and now the beginnings of a pediatric 
evidence base, albeit limited? A recent 
French Consensus Conference recom­
mended SDD as pneumonia prophylaxis in 
critically ill children (26). Unfortunately,
this recommendation lias not been imple­
mented. There is still antipathy to SDD 
from various sectors. Microbiologists and 
some intensivists dislike the use of such 
broad-spectrum oral antibiotics and con­
tinue to have concerns over emerging re­
sistance. Perhaps more importantly, SDD 
uses readily available antibiotics and conse­
quently has never been marketed commer­
cially by a large pharmaceutical company 
and so has not benefited from the persua­
sive professional marketing techniques 
available to these agencies. However, if 
there is a technique or treatment that con­
vincingly demonstrates a reduction in mor­
bidity, should we not use it?
In terms of costs of implementing 
SDD, a study by Garcia-San Vicente (27) 
compared two periods of 1 yr: before and 
after using SDD in the adult intensive 
care unit. Surveillance cultures did not 
significantly increase the workload nor
the cost of processing the samples. The 
explanation provided by the authors was 
that the increase in surveillance samples 
was offset by the decrease in diagnostic 
samples such as blood samples, bronchio- 
alveolar lavage, and urine. During the 
SDD period, they reported an increase in 
Pseudomonas aeruginosa resistance to 
imipenem, tobramycin, and ciprofloxacin, 
However, the changes in resistance do not 
refer to the two periods of study, The au­
thor described changes in resistance be­
tween 1996 and 2007. The studied periods 
were 2001-2002 pre-SDD and 2002-2003 
post-SDD (28). The authors recognized 
that their conclusion about P. aeruginosa 
resistance was not well supported (29).
Also the costs during SDD may have 
been overestimated because surveillance 
of tracheal and gastric aspirate is not nec­
essary. Costs adjusted for length of stay also 
confirm that surveillance during SDD is
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not associated with increased expenditure 
(26). Although the cost-effectiveness of 
SDD has not yet been formally calculated, 
the daily cost of using SDD was estimated 
at approximately 12 Euros (1).
A study by Oostdijk and colleagues (30) 
report the emergence of multidrug-resis­
tant bacterial organisms. They conclude 
that SDD and also selective oral decontam­
ination have marked effects on the bacterial 
ecology in the intensive care unit with in­
creasing ceftazidime resistance prevalence 
rates in tire respiratory tract and a consid­
erable rebound effect of ceftazidime resis­
tance in the intestinal tract after stopping 
SDD. However, an alternate explanation 
was offered for these findings. It was 
pointed out that in Oostdijk's analysis of 
resistance all patients, study and nonstudy 
were included. Abnormal carriage was re­
ported as 5% before, increasing to 15% 
during and after the trial. However, approx­
imately 70% of the admissions were not 
actually in the Dutch study conducted by 
de Smet (31). In contrast, de Smet analyzed 
surveillance data from only study patients 
and found the opposite; the proportion of 
patients with resistant aerobic Gram- 
negative bacilli to the marker antibiotics, 
including ceftazidime, was lower with SDD.
A study by Ochoa-Ardila (32) have also 
recently demonstrated that the long-term 
use of SDD over a 5-yr period in an adult 
intensive care unit setting docs not in­
crease antibiotic resistance.
SDD using parenteral cefotaxime, en­
teral amphotericin B, polymyxin, and to­
bramycin does not cover intrinsically resis­
tant methicillin-resistant Staphylococcus 
aureus, There have been frequent concerns 
raised about emergence of methicillin- 
resistant 5. aureus as a result of using SDD. 
Enteral vancomycin has been added to the 
traditional SDD protocol in case of ende- 
micity of methicillin-resistant 5. aureus 
(33), There are concerns that enteral van­
comycin promotes vancomycin-resistant 
enterococci (34; however, none of the RCTs 
and long-term studies using enteral vanco­
mycin have ever reported vancomycin- 
resistant enterococci outbreaks (35-41). 
This can be explained by the high fecal 
vancomycin levels between 3000 and 
24,000 mg/L after a 2-g enteral dose. In 
contrast, studies have shown that 2 g par­
enteral antibiotic that disregards the hu­
man ecology and which are excreted by bile 
in concentrations <3-95 mg/L of feces pro­
mote the emergence of vancomycin- 
resistant enterococci (42).
Demonstrating an overall survival ben­
efit with SDD may be very hard to achieve
in pediatrics because the numbers needed 
to treat are potentially very large given the 
low mortality rate in pediatric intensive 
care. A simple sample size calculation as­
suming a 5% mortality in the control 
group looking for a 15% reduction in mor­
tality to 4.25% with a 10% type 1 error or 
false-positive rate and a 10% type 2 false­
negative rate would require a sample size 
on the order of 27,390 children.
Mechanical ventilation can be seen as 
a measure of disease severity, defining 
the need for complex intensive care. The 
recent Control of Hyperglycemia in Pedi­
atric intensive care trial (CHiP) (43) used 
as the primary outcome the number of 
days alive and free from mechanical ven­
tilation within the 30 days after trial en­
try. The concept of ventilator-free days 
(VFDs) brings together these two out­
comes. A study by Schoenfeld et al (44) 
define VFDs as: VFD = 0 if the child dies 
before 30 days; VDF = (30-x) if the child 
is successfully weaned from ventilator 
within 30 days (where x is the number of 
days on the ventilator); or VFD = 0 if the 
child is ventilated for >30 days. The use 
of organ failure free days to determine 
patient-related morbidity surrogate end 
points in pediatric trials has been sup­
ported by influential pediatric trialists in 
the current low mortality pediatric criti­
cal care environment (45). Even for this 
surrogate marker, 1500 children were 
needed just to be adequately powered to 
demonstrate a difference of two VFDs. 
Death was considered an important out­
come, but the study was not powered to 
detect a difference in mortality.
Extrapolating from adult data into pe­
diatric practice is generally considered 
inadvisable. However, even if the signifi­
cant reduction in mortality in adults 
given SDD is to be ignored, the reduction 
in pneumonia, which parallels the adult 
observations, tantalizingly hints at the 
possibility of a potential reduction in 
mortality in pediatrics, if studies were to 
be carried out, which were powered ade­
quately with a large enough total number 
of children. Until this happens, the poten­
tial benefit of a proven maneuver in adults 
is lost to the pediatric world rendering the 
pediatric population again therapeutic or­
phans. It took almost 6 yrs from the early 
suggestions of using of inhaled nitric oxide 
(46) until a number of RCTs characterized 
its benefits (47,48).
Although disparate and small, the four 
limited studies performed in children al­
low a meta-analysis, which demonstrates 
a significant reduction in pneumonia
rates. SDD significantly reduces the 
number of children who develop pneu­
monia. The study by Barret et al (20) 
could not demonstrate any treatment 
benefit from SDD in children with severe 
burns so at this stage, SDD cannot be 
advocated in this patient population. Fur­
thermore, there was no overall reduction 
in mortality nor a reduction in overall 
infection rates, probably because of the 
small sample size.
However, on the evidence presented, 
is it not at least worth considering the 
use of SDD in certain groups of vulnera­
ble children such as those with a high 
risk of mortality score or those undergo­
ing solid organ transplantation while 
awaiting evidence of any survival benefit 
from large multicentered RCTs?
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LETTERS
MANAGING PERIOPERATIVE RISK
Selective decontamination of the digestive tract may 
reduce perioperative risk in elective surgery
Andy Petros consultant intensivist\ Daphne Roos consultant surgeon2, Hendrick van Saene reader 
in microbiology3, Nia Taylor research assistant3, Hans Rommes consultant intensivist4, Luciano 
Silvestri consultant intensivist5
'Great Ormond Street Hospital, London WC1N 3JH, UK; 2OLVG, Amsterdam, Netherlands; 3University of Liverpool, Liverpool, UK; 4Gelre Hospitals, 
Apeldoor, Netherlands; 5Gorizia Hospital, Italy
Pearse and colleagues review numerous medical interventions 
for their potential in reducing perioperative morbidity and 
mortality, all of which they admit lack serious evidence base.1 
Surprisingly, they did not review selective decontamination of 
the digestive tract, an effective evidence based prophylaxis 
against pneumonia in patients requiring treatment in intensive 
care.
Selective decontamination of the digestive tract is well 
established and has been assessed in 65 randomised controlled 
trials and 12 meta-analyses including around 15 000 patients.2 
It is an essential component of critical care for patients 
undergoing major non-cardiac surgery as it improves survival 
by preventing pneumonia.' Patients may also derive as much 
diagnostic benefit from preoperative surveillance cultures of 
throat and rectum as from cardiopulmonary exercise testing, 
discussed in detail by Pearse and colleagues. If surveillance 
samples give positive results for abnormal micro-organisms, 
such as aerobic Gram negative bacilli, selective decontamination 
of the digestive tract should be started preoperatively.4
Pearse and colleagues recommend admission to intensive care
as part of the multimodal approach to elective perioperative
care to improve survival. Therefore selective decontamination
of the digestive tract must be included.
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Worlds Apart: Proof that SDD Works
We read with interest Wunderink’s editorial “Welkommen to 
our world” (1) accompanying Oostdijk and colleagues’ analysis 
of resistance patterns during selective digestive decontamina­
tion (SDD) (2) in the multicenter randomized controlled trial 
(RCT) by de Smet and coworkers (3). We disagree with 
Wunderink that SDD leads to antibiotic resistance. Rather we 
interpret the original RCT (3) and subsequent analysis (2) as 
providing strong evidence that SDD reduces infection and 
mortality without causing the resistance reported.
Resistance can be caused by three mechanisms: (7) import, 
(2) acquisition from transmission, or (3) de novo development 
(4). de Smet and colleagues’ RCT of SDD focuses on bacterial 
acquisition and de novo development in individual patients 
using surveillance samples. Oostdijk and coworkers analyzed 
abnormal carriage of aerobic gram-negative bacilli (AGNB) 
producing extended spectrum (Tlactamse (ESBL) at import and 
point prevalence on the ICU once a month. All patients, study 
and nonstudy, were included; about 70% of admissions were not 
actually in the Dutch study (2). Abnormal carriage was 5% 
before, increasing to 15% during and after the trial. In contrast, 
de Smet and colleagues analyzed surveillance data from only 
study patients and found the opposite: the proportion of 
patients with resistant AGNB to the marker antibiotics, in­
cluding ceftazidime, was lower with SDD.
Homogeneity in antibiotic prescription is a recognized cause 
of ecology shift with increased resistance (5). A balanced use of 
antimicrobials with heterogeneity or diversity reduces the 
selective pressure that aids development of resistance. The 
study by Oostdijk and coworkers reaffirms that blanket use of 
homogenous antibiotics (i.e., SDD with cefotaxime) will result 
in a shift in unit ecology toward increased cefotaxime-resistant 
AGNBs. However, Wunderink erroneously concludes that this 
increased use of cephalosporin leads to increased resistance. 
This causal link has not been established, is conjecture, and can 
only be proven with a proper control group.
The ecology in intensive care changes continuously under 
the influence of many factors, involving patients, staff, and other 
antibiotics (6), so to attribute the development of ESBL to SDD 
alone is not good science.
SDD using cefotaxime does result in an ecological shift 
toward a higher abnormal carriage rate of resistant AGNB. 
However, using surveillance samples, the evidence clearly 
shows that it also prevents transmission and de novo develop­
ment of resistance because of the actions of polymyxin and
tobramycin (3). More importantly, for 1 in 12 patients receiving 
SDD, it also reduces mortality.
There is one good point in Wunderink’s editorial: that the 
study by Oostdijk and colleagues may be an aberration of the 
original RCT.
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Dear Editor-in-Chief,
We read the case discussion by Dr. 
M. J. Smit et al. [1] reporting accu­
mulation of oral antibiotics as an 
adverse effect of selective decon­
tamination of the digestive tract. The 
article disappointed us as it did not 
describe in detail the composition of 
the paste or suspension nor did the 
authors estimate the incidence of their 
reported SDD side-effect. How can 
your readers assess what actually 
caused the observed problem if the 
constituents of the paste are not 
reported, in particular the percentage 
of the sticky compound carboxy- 
methylcellulose (CMC) in the paste.
The eradication of abnormal flora 
including aerobic Gram-negative 
bacilli (AGNB) and methicillin- 
resistant Staphylococcus aureus 
(MRSA) from the oropharynx, i.e. 
oropharyngeal decontamination, is 
difficult. In 1981, Gerald Bodey 
wrote that ‘antibiotic prophylaxis was 
less effective against the flora of the 
throat, probably because of the short 
contact of antibiotic with the oral 
mucosa’ [2]. The solution came from 
the experience in dentistry where 
pastes and gels are commonly used
for their prolonged contact time 
between salivary micro-organisms 
and metronidazole mixed with pastes 
and gels [3]. Stoutenbeek [4] was the 
first to decontaminate the oropharynx 
of ventilated patients using orabase 
paste mixed with 2% of polymyxin E, 
tobramycin and amphotericin B [4]. 
At the SDD meeting in Jersey in 
1988, Crome recommended a gel 
containing 3% of CMC rather than a 
paste preparation for oropharyngeal 
decontamination, the main reason 
being that the paste is so adherent to 
the mucosa that removal is difficult 
and it has a drying effect on the 
mucosa [5]. In contrast, the gel has 
good adhesion to the mucosa with 
prolonged release of drugs but is easy 
to use.
We have abandoned the paste and 
replaced it with a gel. The side effect 
described by Dr. Smit et al. has never 
been reported during the use of the 
3% CMC gel over 20 years. The 
higher concentration of the CMC in 
the paste compared with the gel 
inhibits proper oral care allowing the 
patient to swallow residual buccally 
applied SDD paste sticking around 
the nasogastric tube in the 
oesophagus.
Unfortunately, Smit et al. have not 
described the nasogastric tubes or 
intravenous cannulae they used nor 
their enteral feeding policies. We in 
Amsterdam change plastic devices in 
every patient every 7 days, and have 
never experienced ‘glued’ gastric 
tubes over the last 20 years during 
which time 14,000 patients received 
SDD. We believe that enteral feed is a 
significant cause of obstruction of the 
esophagus due to solidification of 
tube feeding [6].
As the total amount of paste used is 
too small to create the type of solid 
mass reported by Smit et al., we 
suggest that a more credible reason 
for the obstruction observed is that 
the amphotericin B suspension reacts 
with the gastric compounds and leads 
to the formation of a bezoar-type of
mass in the upper gastro-intestinal 
tract following reflux.
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clinical investigations in critical care
Systemic Antibiotics Fail to Clear 
Multidrug-Resistant Klebsiella from a 
Pediatric ICU*
Audi) J. Petros, MD; Marie O’Connell, RSCN; Clare Roberts, BSc; 
Pant Wade, BSc; and Hendrick K. F. van Saene, MD
Study objectives: To determine the magnitude of infection rate and antimicrobial resistance in a 
pediatric ICU (PICU), and to evaluate the efficacy of using broad-spectrum antibiotics.
Design: A 3-month, prospective, observational cohort audit.
Setting: A 12-bed tertiary, referral PICU.
Patients or participants: All children admitted to the PICU for > 72 h.
Interventions: Surveillance cultures of throat and rectum on admission and once weekly thereafter. 
Measurements and results: Of the 150 admissions during the 3-month period, a total of 52 patients (24 
girls and 28 boys) requiring mechanical ventilation for a minimum of 3 days were enrolled in the 
audit. The median age and interquartile range (IQR) was 17 months (IQK, 5.8 to 63); length of stav, 
6.5 days (IQK, 4 to 13); ventilation days, 5 (IQK, 3 to 11); pediatric risk of mortality score, 14 (IQK, 
9 to 19); and risk of mortality, 0.03 (IQK, 0.014 to 0.087). Fifteen patients (29%) developed 21 
infections, mainly lower-airway infections and septicemias. Of the 52 children, 7 children carried 
multidrug-resistant bacteria and 3 patients progressed to develop four infections with those resistant 
bacteria. Of the seven carriers, six patients carried gentamicin-resistant Klebsiella. Methicillin- 
resistant Staphylococcus aureus, penicillin-resistant Streptococcus pneumoniae and gentamicin- 
resistant Pseudomonas aeruginosa each were carried by one child. Six of those nine resistant isolates 
were present in the admission flora. Despite the potent combination of piperacillin/tazobactam and 
amikacin, three children acquired the multidrug-resistant Klebsiella while in the PICU and became 
nosocomial carriers.
Conclusions: Only surveillance cultures allow the distinction between import of multidrug-resistance 
and resistant bacteria acquired while in PICU. In this study, two thirds of the resistant isolates were 
imported. The introduction of newer potent systemic antibiotic combinations failed to control the 
endemic reservoir of multidrug-resistant Klebsiella and suggests that such policies have little impact.
(CHEST 2001; 119:862-866)
Key words: antibiotic resistance; carriage; gentamicin; nosocomial infection; pediatric ICU
Abbreviations: IQK = interquartile range; MRSA = methicillin-resistant Staplujlococcwi aumis; PICU = pediatric ICU; 
PPM = potentially pathogenic microorganisms; PRISM = pediatric risk of mortality
T n 1992, a hospital-wide outbreak of a multidrug- 
resistant Klebsiella occurred in our institution. Tra­
ditional measures were implemented to clear this en­
demic strain.1 These included re-enforcement of strict
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attention to hand washing, isolation, and introduction 
of a potent antibiotic combination of piperacillin/ta­
zobactam and amikacin as a first-line therapy to cover 
the endemic resistant strain. To evaluate the efficacy of 
using these broad-spectrum antibiotics, a 3-month pro­
spective, observational cohort audit was canned out to 
detennine the magnitude of both infection rate and 
antimicrobial resistance in our pediatric ICU (PICU).
Materials and Methods
All patients requiring mechanical ventilation for at least 3 days 
were enrolled in this prospective audit between September 1.
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1997, and November 11, 1997. Age, sex, diagnosis, length of stay, 
and duration of ventilation were recorded. Severity of illness was 
quantitated using the pediatric risk of mortality (PRISM) score.2 
The onset of both imported and nosocomial infections was 
recorded. The first-line antibiotic policy consisted of piperacillin/ 
tazobactam and amikacin. This combination was started on 
suspicion of infection. Therapy was adjusted depending on 
microbiological results.
The end points of this audit were to quantitate the overall 
infection rate and the nosocomial infection rate. The traditional 
time cutoff of 48 h was compared with the criterion of the carrier 
state as defined below. We also quantitated the carriage and 
infection rate of multidrug-resistant microorganisms.
Infection was defined in this study as a microbiological!)' 
proven clinical diagnosis of local and or generalized inflamma­
tion, This necessitated having a diagnostic sample with the 
highest growth density from the specimen using the three- 
segment technique as defined below. In addition, a minimum of 
a moderate number of leukocytes was required, on a semiquan- 
titative scale of + = few, ++ = moderate, +-M- = many leu­
kocytes.
Carriage of resistant microorganism was defined in this study 
as the isolation from throat and/or gut of a gentamicin-resistant, 
aerobic Gram-negative bacillus, methidllin-resistant Staphylo­
coccus aurmis (MRSA), or penicillin-resistant Streptococcus 
pneumoniae.
Diagnostic samples of tracheal aspirate, blood, urine, and pus 
were obtained on clinical indication only. Diagnostic samples 
were processed using standard microbiological techniques.3 The 
growth density of potentially pathogenic microorganisms (PPMs) 
isolated from diagnostic samples was estimated using the three- 
segment technique: low (1+), moderate (2+), and high (3+). 
Colonies were pure cultured and identified using standard 
techniques. Isolates were tested for susceptibility to appropriate 
ranges of antibiotics by disk diffusion using the rotation Stokes 
technique.
Surveillance samples of throat (swab) and gut (fecal specimen) 
were taken on admission and thereafter once weekly on Wednes­
day.'1 The aim of this surveillance program was to distinguish PPM 
carried by patients on entry to the PICU (“import”) from PPM 
acquired and subsequently carried during their PICU slay (“noso­
comial"). Each fecal specimen was screened for antibiotic-resistant 
microorganisms by incubation overnight at 37°C on MacConkey 
agar, onto which 8 mg/L of gentamicin discs were put.3
The organisms' were identified by antibiotyping, using extend­
ed-sensitivity patterns (enterobacteria), phage- (S aureus), sero- 
(S pneumoniae) and pyocine- (Pseudomonas aeruginosa) typing.
Nosocomial or PICU-acquired infection was defined as an 
infection episode occurring > 48 h after admission to PICU.3 
The carrier-state criterion allows us to distinguish the endoge­
nous infection, ie, preceded by carriage from the exogenous 
infection due to a microorganism not carried by the patient at all.7 
A primary endogenous infection is an infection caused by PPM 
imported by the patient into the PICU in the admission flora, 
while a secondary endogenous infection is due to an ICU- 
associated PPM, not carried on admission but acquired in the 
unit, followed by carriage and subsequent superinfection. Only 
exogenous and secondary endogenous infections are “true” nos­
ocomial infections according to the carrier-state criterion.'11
Results
Of 150 admissions during the 3-month period, a 
total of 52 patients received mechanical ventilation 
for > 3 days. The data from this group were ana-
Table 1—Demographics of At-Risk Group
Variables Median IQR
Age, mo 17 5.8-63
Sex, male/female 24/28
Length of stay, cl 6.5 4-13
Duration of ventilation, cl 5 3-11
PRISM score 14 9-19
Risk of mortality 0.03 0.014-0.087
lyzed. The demographics are given in Table 1. In this 
at-risk group, 15 of 52 patients (29%) developed a 
total of 21 infectious episodes (Table 2). These 
infections occurred at a median of 4 days (interquar­
tile [IQR] range, 1 to 28 days). Ten of the infections 
involved the lower airways, and 7 were from blood 
cultures. Community bacteria including S pneu­
moniae, H influenzae, and S aureus caused seven 
infections, particularly of the lower airways. Another 
seven infections were due to hospital bacteria, in­
cluding Enterobacter cloacae, Proteus mirabilis, and 
P aeruginosa. Four infections were caused by mul­
tidrug-resistant microorganisms. Gentamicin-resis­
tant Klebsiella was responsible for one case of 
pneumonia and one ease of septicemia at day 16 and 
day 28, respectively. MRSA caused one wound in­
fection and one case of pneumonia in the same 
patient at day 2 and day 22, respectively.
Of 52 patients, 7 patients carried a multidrug- 
resistant PPM; 3 patients developed four infections 
due to those multidrug-resistant PPMs (Table 3). 
The carriage profile of the seven patients included 
gentamicin-resistant Klebsiella carried by six of 
seven patients, MRSA in one of seven patients, 
penicillin-resistant S pneumoniae in one of seven 
patients, and gentamicin-resistant V aeruginosa in 
one of seven patients. Six of these nine resistant 
strains were imported by the patient into the unit. 
Nosocomial carriage occurred in three children and 
was invariably due to gentamicin-resistant Klebsiella. 
Those three cases of nosocomial carriage reflected 
the transmission rate in the PICU. In obtaining 
surveillance samples, there was a 80% compliance 
rate for the first sample and 70% for the second 
sample.
Discussion
Although there were 150 admissions to our unit 
during this study, we were more interested in those 
who required mechanical ventilation for > 3 days. 
Thus, we focused on analyzing 52 patients. We feel 
this group reflects our sickest patients and those at 
greatest risk of nosocomial carriage and infection.
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Table 2—Details of Infections and Carriage of Similar Microorganisms*
Patient ICU Nosocomial
No. Infection Site Day Organism Import Carriage Carringef Pathogenesis
1 Lower airways 2
2 Lower airways 2
Septicemia 3
3 Digestive tract 10
4 Lower airways 2
5 Lower aiiways 6
Septicemia 7
Lower airways 16
6 Lower aiiways 2
7 Septicemia 1
8 Stomatitis 4
9 Gastrostomy wound 2
Neck wound 5
Lower airways 22
10 Septicemia 22
Septicemia 22
11 Lower airways 3
12 Septicemia 7
13 Septicemia 28
14 Lower airways 2
15 Lower aiiways 2
S aureus
P aeruginosa
P mirabilis
Ascaris lumbricoides
Haemophilus influenzae
S aureus
CNS
Klebsiella (gentamicin resistant)
H influenzae
CNS
Candida albicans 
MRS A 
P aeruginosa 
MRS A 
CNS
P aeniginosa/CNS 
E cloacae 
C albicans/Cm 
Klebsiella (gentamicin 
tesistant)/Es6'7ieric/z;i7 colt 
S pneumoniae 
S aureus
S aureus
P aeruginosa
P mirabilis
Ascaris lumbricoides
Haemoph ilus influenzae
S aureus
Not investigated
Klebsiella (gentamicin resistant)
H influenzae
Not investigated
Candida albicans
MRS A
Negative
MRS A
Not investigated 
Negative 
E cloacae 
C albicans 
Negative
S pneumoniae 
S aureus
Primary endogenous 
Primary' endogenous 
Primary endogenous 
Primaiy endogenous 
Primary endogenous 
Primary endogenous
Primaiy endogenous 
Primaiy endogenous
Primaiy endogenous 
Primaiy endogenous 
Exogenous 
Primaiy endogenous
20 Secondary endogenous
Primaiy endogenous 
Primaiy endogenous 
26 Secondary endogenous
Primaiy endogenous 
Primary endogenous
*All but three CNS infections were evaluable for analysis by the carrier-state criterion. Eighty-five percent (15 of IS) of infections were of primaiy 
endogenous development, while only 3 infections, 2 of secondaiy endogenous and 1 of exogenous pathogenesis, were true nosocomial infections 
and due to microorganisms acquired in the unit.
tNosocomial carriage = ICU day on which the microorganism was detected by surveillance culture.
The use of a population size of 150 as a denominator 
would minimize the problem and would not allow 
any room for improvement.
Three findings emerged from this study. Firstly, 
the overall infection rate in the sickest patients was 
29%. Using the traditional 48-h cutoff, nosocomial
Table 3—Carriage and Subsequent Infections Due to 
Resistant Micro organ isms
Microorganisms/
Patient Carriage Infection
Gentamicin-resistant
Klebsiella
Patient 5 Import Lower airways
Patient 9 Nosocomial —
Patient 13 Nosocomial Septicemia
Patient 14 Nosocomial —
Patient A* Import —
Patient B* Import —
MRSA
Patient 9 Import Wound: gastrostomy.
Penicillin-resistant
S pneumoniae 
Patient C* Import
Lower airways
Gentamicin-resistant
P aeruginosa 
Patient 9 Import
* Patients A, B and C were only carriers, with no evidence of infection.
864
infection occurred in 17.3% of patients (9 of 52); 
therefore, it would appear that 61% (1.5 of 21) of all 
infectious episodes were due to microorganisms 
acquired on the PICU, Using the criterion of the 
carrier state, nosocomial infection occurred in 6% (3 
of 53) and 15% (3 of 21) of all infections were caused 
by nosocomial PICU microorganisms.
Secondly, of die 52 children studied, 7 children 
carried resistant strains that were imported by four 
patients. Therefore, three children acquired the 
resistant strains during their PICU stay, suggesting 
transmission via hands.
Thirdly, despite using die combination of pipera- 
eillin/tazobactam and amikacin in all 52 children, it 
was only justified in 3 patients who carried the 
gentamicin-resistant Klebsiella on admission. Thus 
this potent antibiotic combination failed to prevent 
transmission, acquisition, and carriage to these three 
children, one of whom went on to develop a second­
ary endogenous Klebsiella infection.
Our nosocomial infection rate of 17.3% is compa­
rable to rates reported by other PlCUs.9-11 There is 
consensus that the single most important factor 
responsible for infection in PICU is illness severity 
and related immunoparalysis.12'13 This figure of 
17.3%, using the 48-h cutoff, was identified in a 
subset of children with a median PRISM score of 14, 
and who required a median stay of 6.5 days and 5
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days of ventilation. The nosocomial infection inci­
dence was 5%, and 15% of all infections were due to 
PICU microorganisms, according to the carriage 
criterion. We prefer the carrier-state classification, 
because this concept enables us to usefully reclassify 
a substantial number of infections considered tradi­
tionally to be PICU acquired into the imported 
group. Thus, based on our carrier-state classification, 
we transferred nine infections (50%) from die tradi­
tional nosocomial group to the import group. By 
identifying the 85% of all infections imported by the 
patients in their admission flora, we could accurately 
detect the 15% of true nosocomial infections, reveal­
ing the magnitude of the cross-infection problem 
due to transmission. The two major advantages of the 
carriage criterion are as follows: first, the population 
with primary endogenous infections can be identi­
fied, thereby explaining all infections after 48 h; 
second, knowledge of carriage on admission and 
throughout the PICU stay prevents fruitless investi­
gation of apparent cross-infection episodes. Finally, 
without surveillance samples, exogenous infec­
tion,7’14 which can occur at any time due to breaches 
of hygiene, are impossible to recognize at least at an 
early stage, when only diagnostic samples such as 
tracheal aspirate, urine, and blood have been tested.
Resistant PPMs were carried by 13.5% of all 
patients studied. Surveillance samples of throat and 
gut revealed that > 50% of the children imported 
the resistant strain onto the PICU. Our findings are 
similar to those of two studies15'16 that examined the 
carrier state of resistant PPM in pediatric patients. In 
those two studies, respectively, 30% and 50% of 
patients carrying resistant PPM were detected within 
24 h of admission, using surveillance techniques. In 
our study, four different resistant strains—penicillin- 
resistant S pneumoniae, MRSA, gentamicin-resistant 
P aeruginosa, and Klebsiella—were detected in the 
52 patients over 3 months. Surprisingly, transmission 
of only the resistant Klebsiella occurred. Three 
children acquired and subsequently developed the 
secondary carrier state of resistant Klebsiella. One 
child (patient 13 in Table 2) developed secondary 
endogenous septicemia with the nosocomial Kleb­
siella strain.
The knowledge of carriage of resistant microor­
ganisms both imported and acquired is beneficial for 
the individual patient. A patient who only carries 
normal flora and does not cany opportunistic resis­
tant PPMs in throat and gut is at low risk of 
infection.16~1S This type of patient does not require 
new potent and expensive antimicrobials such as 
[3-lactams, combined with (3-lactamase inhibitors, 
fluoroquinolones, and carbapenems. In this study, all 
children received “blind” therapy with piperacillin/ 
tazobactam and amikacin. Surveillance cultures showed
that this blind combination was justified in three 
children only, who carried the resistant Klebsiella 
strain on admission to the PICU. But more impor­
tant, the particular systemic antibiotic combination 
used failed to prevent the development of carriage of 
the resistant Klebsiella in three children who re­
quired long-term mechanical ventilation. Our study 
suggests that a strict antibiotic policy using a potent 
parenteral antibiotic combination does not influence 
the carrier state of resistant PPM, both imported and 
subsequently acquired. This important observation 
may be explained by the fact that systemic antibiotics 
only rarely reach lethal salivary and fecal concentra­
tions following excretion via saliva, bile, and mucus 
into throat and gut. Most parenteral antibiotics fail to 
clear carriage of resistant PPM.U) Our experience is 
consistent with data20 from Cleveland Children’s 
Hospital, where the introduction of a identical anti­
biotic policy failed to reduce a similar resistance 
problem. To decrease the reservoir of carriers of 
resistant strains in the PICU, antibiotic policies will 
need to be coupled with other strategies. Routine 
surveillance samples on the subset of long-stay chil­
dren together with oral nonabsorbable antimicrobi­
als as the most important part of selective digestive 
decontamination will likely be necessary components 
of this effort,21 barrier precautions being an exam­
ple.22 Adjustment of blind therapy at an early stage is 
only possible if the surveillance cultures are an 
integral part of the infection control policy. Selective 
digestive decontamination using oral nonabsorbable 
antibiotics polymyxin E and tobramycin has been 
shown to be very effective in prevention and, if 
present on admission, eradication of the abnormal 
carrier state of resistant Klebsiella.21-23-26
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Should morbidity replace mortality as an endpoint for clinical 
trials in intensive care?
A J Petros, J C Marshall, H K F van Saene
Intensive care medicine has recently seen the rejection of 
several promising new treatments: monoclonal antibodies 
to endotoxin, to tumour necrosis factor, and to cytokine 
modulators such as interleukin-1 receptor antagonist were 
developed, tested, and rejected within the space of a few 
years on the grounds that they did not lessen mortality. 1 
But was this ever a realistic objective?
Mediator-directed measures are not the only forms of 
intensive care unit (ICU) treatment to fail this litmus test 
of ICU-based clinical trials. Indeed there are few, if any, 
interventions currently in use in the ICU that have been 
demonstrated unequivocally to reduce mortality, and ICU 
mortality rates have remained unchanged at 30-50% over 
the past 30 years.2 ICU funding accounts for up to 20% 
of inpatient hospital costs3 and the financial impact of 
interventions that lack efficacy will be considerable. 
However, we risk discarding treatments that may by other 
criteria prove beneficial.
Department of Anaesthesia and Intensive Care,
Royal Brompton Hospital and National Heart Hospital,
Sydney Street, London SW3 6NP, UK (A J Petros mrcp); 
Department of Critical Care Surgery, Toronto General Hospital, 
Toronto, Ontario, Canada (J C Marshall frcsc);
Department of Microbiology, Royal Liverpool Children’s NHS Trust, 
Liverpool, UK (H K F van Saene md)
Correspondence to: Dr A J Petros
Is a reduction in ICU mortality achievable?
Why do ICU patients die? Do they die of an inability to 
control overwhelming infection or do they die because of 
an overactive host response? Do they die because 
treatment cannot support failing organ function or 
because the act of supporting the failing organ causes 
further injury? Or do they die because we decide we can 
go no further and limit or withdraw support. If we know 
the cause of death for a particular condition and if 
treatment alters the pathological process leading to death, 
then mortality is an appropriate study endpoint. However, 
it is unproven that patients die because of an inadequate 
antibody response to aerobic gram-negative bacilli or 
because of overproduction of tumour necrosis factor or 
interleukin-1. Thus we should not assume that an 
intervention which targets these will lead to a reduction in 
ICU mortality.
Mortality is a useful endpoint to evaluate the 
pathophysiological mechanism of disease in animal 
models-1 and such studies can provide insights relevant to 
management of human disease) for example, 
demonstration that the effects of manipulation of a 
cytokine such as interleukin-10 can be diametrically 
opposite depending on the model used5 has raised the 
possibility that attempts to completely antagonise the 
cytokine response to sepsis may inappropriately switch off 
defence mechanism of benefit in the containment of
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infection. But it is a naive leap of faith to assume that a 
single intervention that can alter mortality in the 
controlled and homogeneous context of an animal study 
will have a similar benefit in the clinical arena where the 
diseases to be treated are complex, patients are 
heterogeneous, and the nature of the threat to survival is 
ill-defined.
Even if the disease process is so well characterised that 
response to treatment can reliably be predicted, large 
sample sizes are needed to show a reduction in mortality. 
The use of mortality as an endpoint assumes a 
homogeneous patient population. ICU patients, even 
those with defined physiological abnormalities such as 
sepsis syndrome, do not comprise such a homogeneous 
group. Moreover, even in studies of myocardial infarction 
where populations are homogeneous and die relation 
between intervention and mortality is clear, large sample 
sizes are required to show statistical significance. Lau 
calculated that, for a treatment that reduced mortality due 
to myocardial infarction by 5%, 10 000 patients were 
needed to show a statistically significant effect.6 The small 
number of patients admitted to an ICU does not permit 
trials of this magnitude.
Large sample sizes in ICU-based trials are required, in 
part, because for a given diagnosis patients face a 
spectrum of risk based on the severity of physiological 
derangement at the time treatment is started.1 Some 
patients will improve irrespective of treatment while 
others will die despite effective treatment; the cohort of 
patients in an intermediate risk range, where therapeutic 
benefit might be seen, is substantially smaller than the 
total patient population.
What manoeuvres currently used in ICUs have actually 
been shown to improve survival? Ventilation is obviously 
life saving in apnoea, although no particular mode of 
ventilation has been proved to reduce overall ICU 
mortality. Total parenteral nutrition may prolong life for 
patients with short-gut syndrome, but its role in critical 
illness is undefined. A review of 5 randomised studies, 
involving 500 patients, concerning the effect of enteral 
nutrition versus parenteral feeding on infection suggests 
advantages for early enteral feeding. Neither mode 
seemed to alter mortality,8 Inotrope support is a mainstay 
of ICU care. A prospective study of dobutamine in 
adequately hydrated patients was abandoned as survival in 
the treatment group was actually lower.9 No controlled 
trial has demonstrated improved clinical outcome 
associated with low-dose dopamine for renal protection.10 
The annual costs of pulmonary artery flotation catheters 
in the USA approach 2 billion dollars,11 yet this device has 
never been shown to improve overall survival. Nor have 
infection control methods such as hand washing and mask 
wearing been proved to alter mortality although they may 
reduce infection transmission.12
The lack of a demonstrable effect on mortality does not 
signify that a treatment is worthless and we are concerned 
that potentially useful interventions may be abandoned 
because of the limitations of trial methodology. Although 
corticosteroids failed to improve survival in a 
heterogeneous group of ICU patients with sepsis 
syndrome,13 we know that high-dose dexamethasone is 
beneficial in chloramphenicol-treated patients with severe 
Salmonella typhi septicaemia.14 Similarly, it is possible that 
monoclonal antibodies and cytokine modulators will 
prove useful in certain patient subsets, or in combined 
therapy. Antibodies to TNF can moderate the
inflammatory response in Crohn’s disease15 and may 
reduce pyrexial swings in malaria.16
The current standard endpoint for ICU-based clinical 
trials is 28-day all-cause mortality. Patients who die later 
are considered treatment successes, even if their death is 
directly related to the disease treated in the ICU. 
Conversely, critically ill patients may die early because of 
intercurrent conditions unrelated to their primary illness. 
Estimation of cause-specific mortality introduces potential 
for bias and will fail to detect mortality related to the 
adverse effects of treatment. Survival curves provide 
useful information on the effects of treatment, but is 
prolonged survival desirable if the patient will never leave 
the ICU? For patients who eventually return to an 
independent existence, the duration of their subsequent 
survival may be little affected by treatment received 
during the ICU stay.
Reducing morbidity: an achievable endpoint
If overall ICU mortality has remained the same for 30 
years and if new treatments have not reduced mortality, 
should we not shift our focus to reducing morbidity? 
Disease-specific measures of quality of life are increasingly 
used in disease processes such as rheumatoid arthritis17 or 
inflammatory bowel disease18 for which mortality is clearly 
an inappropriate endpoint. In the ICU setting, measures 
reflecting ICU-specific morbidity such as severity of 
multiple organ dysfunction syndrome, nosocomial 
infection, and length of stay are more relevant endpoints.
A reduction of morbidity is an accepted endpoint in 
many other realms of investigation. Antimicrobial 
prophylaxis given before colon surgery for carcinoma 
reduces postoperative infection rates from 30% to less 
than 10%.19 Survival benefit has never been the primary 
endpoint of this prophylaxis; indeed overall mortality 
from colon carcinoma has not changed. Similarly, 
endocarditis prophylaxis is designed to avoid valvular 
damage and reduce morbidity20 but has not reduced 
overall death rates.
In measuring morbidity we are interested in measures 
that either improve the quality of life or reduce costs. 
Reduction in haemodynamic and respiratory instability 
during ICU admission will lessen morbidity. The 
prevention of pneumonia or systemic inflammatory 
response avoids the need for increased ventilation 
pressures, reduces the risk of barotrauma and oxygen 
toxicity, and shortens the time to extubation. Although 
subject tp a great deal of variation from one unit to the 
next, and influenced by extraneous pressures such as the 
availability of ward beds, length of stay is a useful measure 
of both ICU morbidity and ICU costs. Overall morbidity 
may be measurable with an aggregate variable such as an 
organ dysfunction score. Similarly, analyses based on the 
costs of therapy may prove more relevant in decision 
making.21
It has been suggested that as few as 15% of medical 
interventions have been adequately validated.22 In a 
setting where the potential to do harm and generate 
unnecessary costs is exceptionally high, intensive care 
physicians have a responsibility to question dogma. 
Regulatory agencies such as the USA Food and Drug 
Administration have recently begun to doubt the primacy 
of all-cause mortality as an endpoint for ICU-based 
clinical trial (Roberts R. Letter to participants at the 
roundtable symposium on the design of clinical trial in 
sepsis). Intensive care physicians should be taking the
370 Vol 345 ♦ February 11, 1995
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initiative in developing and validating more appropriate 
instruments to determine the efficacy of our 
interventions.
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Raising Lazarus
Robert Pensack and Dwight Williams. New York: G P Putnam’s Sons. 
1994. Pp 317. $22.95. ISBN 0-399140018.
Raising Lazarus is the story of Robert 
Pensack’s nearly life-long struggle 
with a mortal illness, idiopathic 
hypertrophic subaortic stenosis 
(IHSS). The author, a psychiatrist in 
Colorado, collaborated with the 
writer Dwight Williams to produce 
this remarkable and often disturbing 
story of Pensack’s battle with his 
flawed heart. Pensack’s medical histo­
ry is typical for IHSS patients, but his 
personal story is written through the 
lens of a physician, imparting a 
unique perspective of physician- 
author as patient. The main theme 
explored in Raising Lazarus is that 
facing a chronic and potentially fatal 
illness is a personal war, complete 
with the horrors of battle and the 
ever-present risk of defeat, as well as 
the occasional taste of victory.
The author’s battle with his illness 
begins at the age of 4 when his 
mother dies of IHSS. Pensack and his 
older brother inherit from her the 
mutated gene that will doom them to 
heart failure at an early age. By age 
17 the author is experiencing palpita­
tions and syncope and begins to suf­
fer the anxiety and depression that 
will plague him relentlessly. Fascinat­
ed by his genetic illness, he enters 
medical school, in part to learn more 
about the process already weakening 
his myocardium. As a medical stu­
dent he becomes elated that self- 
knowledge of his own condition “is 
evidence that I can master this dis­
ease, come to know it so intimately 
that I will be able to survive with it. I 
am a spy in the house of my heart”. 
But his medical studies are soon 
interrupted by congestive heart fail­
ure, and he travels to the National 
Institutes of Health in Maryland for 
an attempt at corrective surgery. Dur­
ing recovery from his open heart 
operation, Pensack suffers a cardiac 
arrest. He undergoes a typical out-of- 
body experience, floating up and 
away from his body, able to look 
down calmly at himself on the bed, 
his cardiologist working frantically to 
restore a heartbeat. As he observes 
his own near death, the 25-year-old 
patient accepts for the first time that 
he is slowly dying. As he awakens 
from this brush with death, he per­
ceives a new reality “the unbearable 
terror of this world, the immense 
burden of being alive”.
After he recovers from surgery and
BOOKSHELF
re-enters medical school, the author 
considers a career in surgery—per­
haps another effort to gain control of 
his illness. However, the rigours of a 
surgical internship are more than his 
heart can bear, and he decides to 
train in psychiatry. But even this less 
physically demanding specialty 
becomes too much for him, and Pen- 
sack is compelled to face the ultimate 
terror—a heart transplant. Cardiac 
transplantation at age 42 is the major 
battle in Pensack’s private war, and 
although he ultimately survives, the 
cost is high. He suffers enormous 
anxiety during the long wait for a 
suitable donor, and is reduced to 
combing the television channels for 
news of a young accident or suicide 
victim whose heart might become his. 
The 13-hour operation is described 
in harrowing detail by Dwight 
Williams, who met Pensack before 
the operation and who wimessed the 
transplant. During the prolonged 
recovery Pensack’s enormous physi­
cal discomfort and constant fear of 
death are compounded by a deepen­
ing guilt that his survival was possible 
only because the donor’s accidental 
death made a heart available.
Raising Lazarus, as the title 
implies, is about the conquest of 
death and return to life. On a deeper 
level the book explores the frighten­
ing dilemma that doctors face when
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